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ABSTRACT 
 
Background:  Microglial cells can be regarded as the macrophages of the 
central nervous system. Their activation has protective functions in the 
destruction of pathogens, removal of debris and release of neurotrophic 
factors, but excessive activation can exacerbate the effects of inflammation 
contributing to neurodegenerative conditions such as Alzheimers disease. 
The cannabinoids have a variety of anti-inflammatory properties and the 
main aim of this project is to determine the role of cannabinoids in 
modulation of microglial cell function using in vitro approaches, and to 
investigate the molecular mechanisms underlying such modulation. 
 
Methods: BV-2 murine microglial and primary murine microglial cells were 
activated using bacterial lipopolysaccharide (LPS). Nitric oxide (NO) was 
determined with a Griess assay.  Western blotting was used to measure the 
expression of 1)ǉ%S,NǃĮLQGXFLEOHQLWULFR[LGHV\QWKDVHL126&2;-
2, and total and phosphorylated forms of the MAP kinases, p38, JNK1/2 
and ERK1/2; blots were analysed with an Odyssey imaging system (Li-Cor 
Bioscience), Expression of GPR55 mRNA was determined by RT-PCR. 
Phagocytosis was assessed in BV-2, HAPI and primary murine microglial 
cells and in RAW 264.7 monocyte/macrophages using fluorescent latex 
beads and the cells viewed by confocal microscopy. Fluorescent bead 
accumulation was quantified on consecutive image and rate phagocytic was 
calculated by normalizing the number of beads to the number of cells in 
each field. 
Western blotting was used to measure the expression of the receptor 
channels TRPV2 and TRPV1 and AKT. Immunocytochemistry was used to 
investigate the translocation of TRPV2, and the involvement of MLC11, 
PLCȖ 3.&Į İ LQ SKDJRF\WRVLV Fura-2-based Ca2+ imaging of microglia 
was undertaken and mLJUDWLRQ ZDV DVVHVVHG XVLQJ D QRYHO ³&RPSDVV´
device. 
 
Result: BV-2 cells did not express CB1 or CB2 receptor mRNA; however, 
the cannabinoid receptor agonist CP55-940, the CB1 antagonist AM251and 
the non-psychoactive cannabinoid cannabidiol (CBD) all at 10ǋM produced 
significant inhibitions of lipopolysaccharide (LPS; 100ng/ml)-stimulated 
nitric oxide (NO) formation. The putative GPR55 receptor agonists VSN16R 
and O1916 (were without effect, as was the endogenous GPR55 agonist 
V 
 
lysophosphatidylinositol (LPI). A number of other cannabinoid receptor 
agonists and antagonists and the phytocannabinoids (CBG, CBDV, THCV, 
CBDA and CBGA (Pertwee, 2008) (all 10 µM) were without. 
 Cannabidiol inhibited LPS-enhancement of both iNOS and COX-2 
expression. LPS significantly induced phosphorylation of the MAP kinases 
ERK 1/2, p38 and JNK and CBD inhibited both LPS-induced p38 and JNK 
phosphorylation but was without effect on phosphorylation of ERK1/2. The 
p38 inhibitor SB203580 (10 µM) also significantly reduced iNOS expression 
after 24 hours of LPS stimulation. LPS increased NF-KB p65 expression and 
this was significantly attenuated by CBD. LPS also stimulated NF-KB p65 
translocation to the nucleus whereas CBD inhibited the effect. 
 CBD-induced phagocytosis of BSA latex beads was similarly induced in 
HAPI, RAW264.7 and primary murine microglial cells. Inhibitors of Rho 
kinase (Y27632) and PI (3)kinase (wortmannin) inhibited basal but not 
CBD-enhanced phagocytosis. CBD increased intracellular calcium in BV-2 
cells and the TRP channel blocker ruthenium red reversed CBD-induced 
phagocytosis. 
CBD increased expression of TRPV2 protein and mRNA and caused a 
translocation to the cell membrane. This was abolished in presence of 
cycloheximide and PI3K inhibitor. Other cannabinoids and 
phytocannabinoids (CBG, CBDV, THCV, CBDA and CBGA) were without 
effect. CBD also increased BV-2 cell migration. 
 
Conclusion: The data presented demonstrate that CBD, despite inhibiting 
NO formation, mediated by reduction of NF-Nǃ P38 MAPK, JNK and ROS 
activity, enhances microglial migration and phagocytosis. 
The mechanism of action appears to involve TRPV2 channel activation 
accompanied by increased protein synthesis and translocation to the cell 
membrane. Therefore, CBD might be developed as a useful treatment for 
neurodegenerative disease. 
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1 General introduction  
 
       1.1 Origin of the microglia  
Excluding the vasculature, the central nervous system (CNS) is 
populated by two main types of cells; neurons and glial cells. Glial 
cells include astrocytes, oligdendrocytes and microglia, with the 
microglia forming 10% of the total glial cell population (Perry, 1998). 
They were first described by Nissl in 1899 and were named 
Stäbchenzellen (rod cells), due to their rod-shaped nuclei, and they 
were classified as reactive neuroglia.  
De Rio-Hertega (1932) later recognised that microglia were distinct 
from other glia and neurons (Pivneva, 2008). The origin of microglia 
is controversial; they might be derived from (1) neuroectoderm, (2) 
vascular adventitia (3) an intrinsic population of hematopoietic stem 
cells resident within the nervous system, (4) peripheral 
mesodermal/mesenchymal or (5) from circulating blood monocytes. 
It has also been suggested that the microglia originate from myeloid 
cells that enter the brain during early life before the blood brain 
barrier develops (Chan et al., 2007). These parenchymal cells 
originate from the same monocyte lineage as other tissue 
macrophages (Facchinetti et al., 2003; Rock et al., 2004; Vilhardt, 
2005). 
1.2 Microglial functions and cytotoxicity  
The main function of the immune system is to protect the host, 
including the central nervous system (CNS) against infection by 
pathogens (Owens and Babcock, 2002).  The immune system¶s 
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essential function, including both the innate and adaptive immune 
systems, is to protect the body through layered defenses of 
increasing specificity from infection. Pathogens, such as viruses and 
bacteria, are prevented from invading the organism first by physical 
barriers; however, if pathogens overcome these barriers, a non-
specific but immediate, short-term response will be provided by the 
innate immune system. This is usually started by identification of the 
pathogen by pattern recognition receptors, or when injured, damaged 
or stressed cells release alarm signals (Litman et al., 2005). 
 A third layer of defense, the adaptive immune system, becomes 
active if the innate response is overcome allowing for antigen-
specific, stronger immune responses as well as immunological 
memory, where each pathogen is remembered. This response 
requires the identification of specific ³QRQ-VHOI´ DQWLJHQV GXULQJ D
process called antigen presentation (Becher et al., 2000).  The 
LPPXQH V\VWHP¶V HIIHFWRU PHFKDQLVPV LQFOXGH DQWLERGLHV DQG RWKHU
immunity-related molecules (Hickey et al., 1991). Under physiological 
circumstances, only activated T-lymphocytes are able to pass the BBB 
and get into the brain (Hickey et al., 1991). They depart the brain if 
they do not encounter antigen presentation (Finsen et al., 1991). In 
situations of acute or chronic brain damage or disease, activated 
leukocytes can enter the brain in large numbers even when the BBB 
is not opened (Brown 2001). The processes underlying this effect are 
still not clear. Next to blood-derived activated leukocytes, the brain-
resident astrocytes, and microglia are also present at the site of brain 
injury but only the microglial cells posses complete competence for 
immunological functions (Gehrmann et al. 1995).  
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In the central nervous system, microglia play a major role in the 
inflammatory process (Nakamura, 2002). Microglia not only share 
surface molecules with peripheral macrophages but are also capable 
of antigen presentation, phagocytosis and secretion of cytokines, 
chemokines and cytotoxins (Nakajima et al., 2001; Town et al., 
2005).  
Microglial cells can be divided into three types according to their 
activation status: resting microglia, activated microglia and amoeboid 
phagocytic microglia (Cabral et al., 2008). In the CNS, ramified 
resting microglia constitute 5-20% of the neuroglial population, are 
more prevalent in grey matter than in white matter and they adopt 
their morphology and expression of cell surface antigens according to 
their microenvironment (Kim and de Vellis, 2005).  
 Microglial cells with ramified morphology and sparse expression of 
molecules associated with macrophage function are found in healthy 
nervous tissue and have been associated with a resting phenotype. 
Resting microglia are not, however, inactive but are characterized by 
a lack of endocytic and phagocytic activity and low expression of the 
leukocyte common antigen CD45 (David and Kroner, 2011). They 
express low levels of membrane ligands and receptors that are 
important for mediating or inducing typical macrophage functions 
including major histocompatibility complex (MHC) class II molecules 
typical of professional antigen-presenting cells (Aloisi, 2001).  
Furthermore, resting microglia may secrete low levels of growth 
factors to support the viability of the surrounding neurons and other 
glia. Kim and Joh (2006) have claimed that the neurons play a role in 
maintaining resting microglia phenotype through CD200 and 
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glycoprotein expressed on the surface of neurons linked with the 
microglia and involved in the regulation of phagocytic activity (Wright 
et al., 2000). In transgenic mice in which CD200 has been deleted, 
microglia are spontaneously stimulated and express high levels of 
CD45 and CD11b (Hoek et al., 2000).  
Under normal conditions during adult life, resting microglia numbers 
remain relatively constant with a slow turnover (Chew et al., 2006). 
Responding to chemical signals and directing the responses for tissue 
repair and induction of protective immune responses is one of the 
most important characteristics of microglia. To carry out these 
different functions, microglia need to be activated (Aloisi, 2001; 
Hanisch, 2002). There are two different types of activated microglia 
according to their phagocytic activity; one sort is hypertrophic with 
increased expression of the surface marker molecules but these are 
not phagocytic. They are found mainly in areas of secondary reaction, 
for example, as a result of nerve transection. The other type is fully 
phagocytic microglia, found in areas of primary trauma, infection or 
neural necrosis but also in the developing brain (Gehrmann et al., 
1995).  
Microglia appear to have a spectrum of activation states; minor 
changes in morphology and functional state can even be observed in 
the process of preparing cultured microglia cells which have been 
found to express CD14, a marker not present in ramified microglia 
(Wright et al., 1990). At the extreme end of the activity spectrum, 
stimulation with lipopolysaccharide (LPS) to simulate infection, leads 
to marked alterations in function (Hayakawa et al., 1997). Fully 
activated microglia are present in the foetal brain where they act as 
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scavengers of pruned cell materials during the remodeling stages of 
development (Voyvodic, 1996; Watnab et al., 1997). 
Microglial activation is characterized by proliferation and migration to 
the site of injury which requires a change in morphology to one 
different from resting cells; their processes retract into the soma 
giving an amoeboid shape and they develop a generally more 
rounded appearance (Vilhardt, 2005) as shown in Figure 1.1.  In 
addition to morphological modifications during this multi-step 
activation process, microglia also undergo differential gene 
H[SUHVVLRQRIDKRVWRIVXUIDFHUHFHSWRUVLQFOXGLQJ)FUHFHSWRUV)FǄ-
RI, RII and RIII); CD14 receptors; Toll-like receptors (TLR); 
chemokine receptors (CCR2, CCR3, CCR5, CXCR4, CX3CRI), 
interferon-gamma receptors (IFN-Į ǃ Ǆ WXPRU QHFURVLV IDFWRU-
alpha (TNF-Į UHFHSWRUV 71)5, 71)5,, DQG WUDQVIRUPLQJ JURZWK
factor-beta (TGF-ǃ UHFHSWRUV 7*)ǃ-RI, RII and RIII) (Qin et al., 
2005; Rock et al., 2004) in addition to other antigens including, MHC 
class II, CD45, CD11b (Kim and Joh, 2006).  
Microglia detect pathogens by means of pattern recognition receptors 
(PRRs) on the cell surface which recognize pathogen-associated 
molecular patterns (PAMPs), molecular structures associated with 
host cells (Medzhitov and Janeway, 2000). Most PRRs are expressed 
only at low levels on ramified microglia, if at all, and are upregulated 
upon microglial activation (Aloisi, 2001). Previous studies have 
postulated that microglia have the dual, contrasting functions of 
mediating both neurotoxicity and neuroprotection, because they 
stimulate neuronal cell death, by releasing neurotoxic factors such as 
nitric oxide, glutamate, or unknown neurotoxins, as well as 
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supporting the survival of neurones, by releasing neurotrophic factors 
(Streit, 2005; Takahashi 2005; Chao et al., 1992). 
 
 Figure 1.1 Diagrammatic representations of the stages of microglia cell 
during activation, adapted from Sterit, (1999). 
Microglia polarization is routinely classified into classical (M1) and 
alternative (M2) activation. Although this calssification might be an 
over simplification, microglia can be polarized into an activation state 
that is intermediate between a neuro-harmful and a protective state. 
Lipopolysaccharide (LPS) is known as a representative M1 polarization 
inducer, and these are highly aggressive against bacteria and produce 
large amounts of lymphokines (Murray and Wynn, 2011). M1 
microglia express proinflammatory molecules that include tumor 
necrosis factor-Į (TNF-Į), interleukin-1ǃ (IL-1ǃ), interferon-Ǆ (IFN-
Ǆ), and nitric oxide (NO) as well as cell surface markers, CD86 and 
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CD68. On the other hand, IL-4 induces M2 polarization (Liao et al., 
2012; Kigerl et al., 2009; Meissner et al., 2012). M2 microglia 
express different molecules, such as IL-4, arignase1, Ym1, CD206, 
and IL-10, and show neuroprotective effects (Liao et al., 2012; Kigerl 
et al., 2009; David and Kroner, 2011; Ponomarev et al., 2007). 
Microglial activation has protective functions in the destruction of 
pathogens, such as microorganisms, neoplastic cells, removal of 
debris and enhancement of tissue repair and release of neurotrophic 
factors.  However, excessive activation can be damaging and can 
exacerbate the effects of inflammation leading to neurodegenerative 
disease (Banati et al., 1993). Microglial activation has been 
LPSOLFDWHG LQ $O]KHLPHU¶V GLVHDVH PXOWLSOH VFOHURVLV FKURQLF SDLQ
3DUNLQVRQ¶V GLVHDVH DQG LQ WKH DQLPDl model experimental allergic 
encephalomyelitis (EAE), and numerous other disorders, including 
3LFN¶VDQG+XQWLQJWRQ¶VGLVHDVHVDP\RWURSKLFODWHUDOVFOHURVLV6K\-
Drager syndrome (Banati et al., 2004; McGeer et al., 1988);  post-
traumatic injury and aging also involve activated microglia (Figure 
1.1). In fact, activation of microglia may be a common feature of all 
neurological damage. This activation could contribute further insult 
through immune-mediated cellular damage (Fontana et al., 1987) 
and this will be discussed in more detail later in a separate section.  
1.2.1 Microglia migration 
Movement of microglia can be the result of a random, non-vectorial 
motility (chemokinesis), or a directed migration that depends from a 
chemical gradient to organize the movement (chemotaxis), or both 
(Devreotes and Janetopoulos, 2003; Miller and Stella, 2009).  Cell 
migration can be triggered by a diverse array of chemoattractants. 
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Consistent with their role in the immune response in the CNS, 
microglia express an array of receptor for chemokines which are 
involved in the intercellular communication in brain and contribute to 
intracerebral recruitment of immune cells (Aloisi, 2001; Hanisch, 
2002; Kim and de Vellis, 2005). Fractalkine, as mentioned in the 
previous section, is a chemokine that can exist in two different forms, 
membrane-anchored or as a soluble glycoprotein (Harrison et al., 
1998). Under normal conditions, CX3CL1 is constitutively associated 
to the neuronal membrane, stimulating higher intracellular calcium 
mobilization in responding cells. This process is apparently needed for 
adhesion properties. However, after an excitotoxic stimulus, the 
chemokine undergoes a cleavage by matrix metalloproteinases 
(MMPs) triggered by the NMDA (N-methyl-D-aspartate) receptor 
pathway (Chapman et al., 2000).  
The soluble glycoprotein can then interact with its receptor expressed 
on microglia inducing their chemotaxis (Harrison et al., 1998). Thus, 
the release of this molecule is an early event in the inflammatory 
response leading to neuronal death after an excitotoxic injury 
(Chapman et al., 2000). Moreover, microglial migration is also 
induced, among others, by the lymphoid chemokine CCL21, which 
involves chloride channels (Rappert et al., 2002), and by secondary 
lymphoid-tissue (Biber et al., 2001), both expressed by damaged 
neurons and acting on CXCR3 receptor expressed by microglia.  
Microglial cells also migrate towards neurotrophic factors such as the 
epidermal growth factor (Nolte et al., 1997) and nerve growth factor 
(De Simone et al., 2007), corroborating the role of microglia in brain 
development. Pathological protein aggregates, such as amyloid-been 
shown to induce microglial migration (Gyoneva et al., 2009).  
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Purines that are released from injured tissue in higher levels into the 
extracellular space by neurotransmission, lead to microglia 
chemotaxis (Parkhurst and Gan, 2010). Indeed, the baseline motility 
of microglial processes in the intact brain is modulated by some of 
the ATP signaling mechanisms mediating injury-induced microglial 
responses (Davalos et al., 2005).  
ATP G protein-coupled purine receptors (P2YR) (Honda et al., 2001; 
Haynes et al., 2006), In fact, microglial cells from mice lacking 
P2Y12R receptor are unable to polarize, migrate or extend processes 
towards nucleotides, either  in vitro or in vivo (Haynes et al., 2006). 
Besides P2YR, ATP acts on ionotropic P2X receptors (P2XR) and 
P2X4R which are also involved in microglial chemotaxis as 
demonstrated by Ohsawa and his colleagues (2007). Furthermore, 
microglial cells themselves can release ATP so that a positive 
feedback mechanism may exist to perpetuate migration.  
Intriguingly, Duan et al., (2009), and more recently Samuels and his 
colleagues (2010), claim that nitric oxide (NO) is the true responsible 
for directing the movement of microglia after nerve injury in leech. 
According to these studies, ATP released by damaged cells activates 
microglia and induces their initial movement, whereas NO directs 
migration of the cells to CNS lesions. In fact, NO mediates microglial 
response to acute spinal cord injury in vivo, but this process is under 
the control of ATP (Dibaj et al., 2010). Nucleotide uridine diphosphate 
(UDP) is released by dying neurons and recognized by P2Y6 receptor 
(P2Y6R), specifically expressed on microglia.  
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1.3 Mechanisms of microglial activation 
Many molecules and conditions can trigger a transformation of resting 
to activate microglia. Activation can result from damage to brain 
parenchyma or imbalances in ion homeostasis. Microglia do respond 
to neuronal depolarization and associated increased potassium fluxes 
across membranes in the absence of neuronal damage (Gehrmann et 
al., 1993). Furthermore, ATP and other P2 receptor agonists change 
the electrophysiological properties of microglia, by facilitating 
depolarization, and ATP can be released as a co-transmitter by 
several cell types during injury.  
 Several molecules stimulate microglial cells such as the gram-
negative bacterial endotoxin lipopolysaccharide (LPS), interferon-Ǆ
(IFN-ǄDP\Ooid-ǃSHSWLGH$ǃ&' OLJDQG&'/ FKHPRNLQHV
neurotransmitters and gangliosides, thrombin, tissue plasminogen 
activator (tPA) and matrix metalloproteinase-3 (MMP-3). Some 
activators can be derived from pathogens, or from neurons, for 
instance ATP, and also from the microglia themselves, such as TNF-Į
plasminogen and NO (Abd-el-Basset and Fedoroff, 1995; Vogel and 
Noelle, 1998). 
The most commonly used compound to stimulate microglial activation 
experimentally in vitro and in vivo is the bacterial endotoxin 
lipopolysaccharide (LPS), the major mediator of shock induced by 
gram-negative bacteria (Rietsehel et al., 1994). This, therefore, 
mimics gram-negative bacterial infection of the brain, which is 
prevented under normal circumstances by the BBB. The pattern 
recognition receptor (PRR) Toll-like receptor 4 (TLR4) (Kalis et al., 
2003) and cluster of differentiation (CD 14) are expressed by 
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microglia and other cells of the monocyte/macrophages lineage; this 
is a GPI-anchored glycoprotein which reacts with LPS to form LPS-
binding protein in serum (Wright et al., 1990). LPS also activates 
microglia through CD4, CD11c, CD18. 
 Myeloid differentiation primary response gene 88 (MyD88) is the 
primary TLR4 signalling mechanism (Figure 1.2); the interaction of 
MyD88 with TLR recruits IL-1 receptor (IL-1R) -associated kinase 4 
,5$. WR GHDWK GRPDLQV RI ERWK 0\' DQG 7/5 2¶1HLOO et al., 
2003; Hacker et al., 2006). The interaction of IRAK4 with the death 
domains acts to facilitate the phosphorylation of IRAK1, the activated 
IRAK1 then binds to the tumour necrosis factor receptor associated 
factor 6 (TRAF6) (Kobayashi et al., 2002). Two distinct pathways are 
activated by TRAF6. The first pathway activated is transforming 
JURZWKIDFWRUǃ-activated kinase (TAK1) pathway. The other pathway 
activated by TRAF6 is the Nuclear Factor KappaB (NF-ǉB) and 
activator protein-1 (AP-1) system (Kobayashi et al., 2002).  
Both of these pathways lead to transcription factors like NF-ǉ%EHLQJ
up-regulated and an increase in the activation of mitogen-activated 
protein (MAP) kinases (Akira and Takeda, 2004). Protein tyrosine 
kinases, MAP kinases, protein kinase C, small G proteins and 
ceramide-activated protein kinase are all intracellular signalling 
molecules for LPS-mediated monocyte, macrophage and also 
microglial activation. LPS activates transcription factors, including NF-
IL6, C/EBP and activated PKCs may facilitate Fos/ Jun families and 
cytokine genes (Sweet and Hume, 1996; Koistinaho and Koistinaho, 
2000; Fiebich et al., 1998). As a consequence of pro-inflammatory 
activation, ramified microglia morphologically transform into an 
amoeboid shape and migrate towards the lesion spot. 
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 Figure 1.2: Diagrammatic representation of the LPS/TLR4 signalling LPS 
recognition is assisted by LBP and CD14, and is mediated by TLR4/My88 
receptor. TRAF6, which mediate the activation of pro-inflammatory cytokine 
(Adapted from Takeda and Akira, 2004). 
Activated microglia express increased levels of chemokine (C-C) motif 
ligand 2 (CCL2), a modulator of microglial migration and proliferation 
(Hinojosa et al. 2011), building a chemoattractant gradient at the 
lesion spot to attract further cells and shield the adjacent tissue 
environment from neurotoxic substances (Ambrosini and Aloisi 2004). 
Activated microglia sequester effector cytokines like interleukin-6 (IL-
6) and interleukin-1ǃ (IL-1ǃ leading to paracrine activation of 
migrating microglia (Ferreira et al. 2010). 
Other PRRs expressed by microglia include TLR2, TLR9 and other 
mannose receptors. In addition, microglial receptors exist allowing 
detection and phagocytosis of other pathogens which have been 
opsonised (coated) by soluble components of the immune system 
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(Aloisi, 2001). The receptors expressed by microglia which allow 
detection of pathogens are discussed in detail in Chapter three. 
1.3.1 Microglial effector molecules 
Different receptors and signaling pathways are involved in the 
detection of and response to different molecules which activate 
microglia (Pocock and Liddle, 2001). It is, therefore, likely that 
different microglial activators cause the up-regulation of specific 
genes and lead to slightly different activated phenotypes. Microglial 
activation may lead to the release of reactive oxygen and nitrogen 
species (ROS and RNS), proteolytic enzymes, prostanoids and 
glutamate. Microglia can also release glutamate through increased 
expression or activity of the cystine/glutamate antiporter Xc or the 
reversal of excitatory amino acid transporters. 
The release of ROS and RNS by activated microglia represents a 
cytotoxic attack mechanism against invading pathogen. Microglial 
activation may induce the rapid generation of superoxide by reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase known 
as the respiratory burst (Sankarapandi et al., 1998). Either 
superoxide may be cytotoxic alone; alternatively they may combine 
together to form the highly reactive species peroxynitrite (Noack et 
al., 1999). ROS and RNS have the potential to cause cell damage and 
death by reacting with proteins, nucleic acid and lipids of neighboring 
cells (Volko et al., 2007). Peroxynitrite causes the dysregulation of 
mitochondrial respiration (Bolaños et al., 1997). However, in some 
cells peroxynitrite may be protective through the up-regulation of the 
pentose phosphate pathway, leading to stimulation of NADPH levels 
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to regenerate the reduced form of the antioxidant glutathione 
(Almeida et al., 2005).  
Activated microglia may also express inducible nitric oxide synthase 
(iNOS) allowing the production of the inflammatory mediators,  nitric 
oxide (NO) (Brown and Bal-Price, 2003; Michelucci et al. 2009), 
tumour necrosis factor (TNF)-Į LQWHUOXNLQV ,/ ,/-ǃ ,/-6, 
transforming growth factor-ǃ 7*)-ǃ PDFURSKDJH-colony 
stimulating factors (M-CSF) (Sgeng et al., 2005), brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neural growth 
factor (NGF). Moreover, activated microglia secrete proteinases, for 
instance, cathepsin B/L and plasminogen activator, which could be 
involved in neuronal remodeling during repair (Gehrmann et al., 
1995; Merrill, 1992). 
Activated brain microglial cells release NO which has protective 
activity in the central nervous system by keeping iNOS expression 
suppressed via preventing NF-ǉ% DFWLYDWLRQ RU DOWHUQDWLYHO\12 PD\
cause up-regulation of glycolysis leading to compensatory ATP 
production and maintenance of the mitochondrial membrane potential 
(Almeida et al., 2005). Moreover, NO may act as an antimicrobial 
defense (Chao et al., 1992). By contrast, excessive release of NO has 
been found to cause brain injury and to mediate neurodegenerative 
inflammatory processes (Cabral, 2001; Colasanti et al., 1995). 
There are three isoforms of nitric oxide synthase (NOS) that have 
been cloned, two of them are constitutively active; endothelial NOS 
(eNOS) and neuronal NOS (nNOS), which are responsible for the 
production of transient, low level bursts of NO and both are 
calcium/calmodulin-dependent. The third type is inducible by 
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inflammation, endotoxin, cytokines and oxidative stress, but not by 
calcium, and its expression is induced in many cell types including 
macrophages (Brown, 1997).  Under normal conditions, the release of 
NO from microglial cells is insignificant, but when it is released, it can 
pass from the cell of origin into surrounding tissue to act on other 
cells because it is small and without charge (Brown, 1997). However, 
upon stimulation with LPS or cytokines such as TNF-Į DQG ,)1-Ǆ
inhibition of NO release has been found to increase microglial cell 
survival in several models (Gibbons and Dragunow, 2006). The 
modulation of NO release from microglia by cannabinoids will be 
addressed in Chapter Two. 
 1.4 Microglial receptors  
Microglial cells express a variety of cytokine and chemokine 
receptors, as discussed previously.  They also contain receptors for 
the major excitatory neurotransmitter glutamate including 
metabotropic glutamate receptors, which can be neuroprotective 
through group III mGlus (mGlu4, mGlu6 and mGlu8 receptors) or 
neurotoxic via group II mGlus (mGlu2 and mGlu3) (Taylor et al., 
2002; Taylor et al., 2003; Taylor et al., 2005). Receptors for the 
main inhibitory transmitter, gamma-amino butyric acid (GABA), 
GABAA and GABAB receptors, are also expressed in microglia. 
Activation of GABAB receptors inhibits the LPS-induced release of IL-
6, IL-12 and p40 (Kuhn et al., 2004; Lee et al., 2011).  
Dopamine receptors have been found in rat and mouse microglia in 
culture and in brain slices (Farber et al., 2005). D1 and D2 receptors 
generate the inhibition of the constitutive potassium inward rectifier 
currents and stimulated potassium outward currents in a 
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subpopulation of microglia. Chronic dopamine receptor stimulation 
increases migratory activity and attenuates the LPS-induced NO 
release (Farber et al., 2005). 
Microglia H[SUHVVǃ1 DQGǃ2-adrenoceptors which, upon activation with 
noradrenaline or adrenaline, both increase the level of cAMP 
production and IL-ǃ P51$ 6HOHFWLYH ǃ2±adrenoceptor agonists 
inhibit LPS-induced release of IL-12, p40 and cAMP (Prinz et al., 
2001). Moreover, microglia contain endothelin (ETB) receptors which, 
when stimulated, lead to increased intracellular Ca2+ release from 
cytoplasmic stores (Moller et al., 1997). Cultured rat microglia also 
express mRNA for Ca2+-mobilizing bradykinin type 2 (B2) receptors 
(Noda et al., 2003); bradykinin increases microglial motility and 
induces the release of NO and PGE2 (Noda et al., 2006). 
A2A adenosine receptor-mediated neuroprotective effects might be a 
result of the release of neurotrophic factors including nerve growth 
factor (NGF). Activation of A2A receptors also induces cyclooxygenase-
2 (COX-2 mRNA) expression (Fiebich et al., 1996). Moreover, 
activation of microglial adenosine A3 receptors inhibits LPS-induced 
TNF-ĮIRUPDWLRQ/HHet al., 2006). 
Microglia express the P2 receptors P2X and P2Y in both resting and 
activated states, leading to increases in cytosolic calcium upon 
stimulation.  Activation of P2X7 receptors by high concentrations of 
ATP induces the release of IL-ǃDQGSODVPLQRJHQDVZHOODVUHGXFing 
the LPS-mediated production of IL-6, IL-12, TNF-ĮDQGPDFURSKDJH
inflammatory protein 1-alpha (MIP1-Į 3< UHFHSWRUV FDQ EH
stimulated by ATP or ADP leading to alterations in microglial 
chemotaxis (Honda and Kohsaka, 2001). 
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Microglia also expresses glucocorticoid (GR) and mineralocorticoid 
(MR) receptors in primary cultures from the forebrain of newborn 
rats. Stimulation of GR inhibited proliferation of cultured microglia 
and enhanced lysosomal formation (Tanaka et al., 1997). 
Furthermore, the vasoactive intestinal polypeptide (VIP) acts via the 
VPAC (VIP/pituitary adenylyl cyclase activating peptide) G protein-
coupled receptors. VPAC1 receptors are found in rat microglia, and 
stimulation of these receptors with VIP (0.1 µM) or with its 
functional/structural analogue pituitary adenylyl cyclase-activating 
polypeptide leads to inhibition of TNF-Į SURGXFWLRQ LQ /36-activated 
cultured rat microglia (Kim et al., 2000).  
 1.5 Cannabinoid signalling system. 
  Microglia are reported to express cannabinoid CB1 and CB2 receptors 
which play an important role in microglial activation states and have 
been linked to cannabinoid modulation of chemokine and cytokine 
action. 
1.5.1 CB1/CB2 receptors 
The CB1 receptor was identified in 1988 by Devane et al., 1992 and 
cloned in 1990; since then it has been cloned from mouse and human 
tissues and there is 97-99% sequence identity between them. In 
humans, the CB1 receptor is expressed extensively throughout the 
central nervous system (CNS) particularly in the hippocampus, basal 
ganglia, hypothalamus and amygadala (Herkenham et al., 1990; 
Mechoulam et al., 2012). CB1 receptors have also been recognized 
peripherally in tonsils, spleen, sympathetic nerve terminals, and in 
preparations such as the guinea-pig small intestine (Pertwee et al., 
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1996), the mouse urinary bladder, the mouse vas deferens, hamster 
smooth muscle cells (Filipeanu et al., 1997) and cat vascular smooth 
muscle cells (Gebremedhin et al., 1999). 
The CB1 receptor is considered to be the most highly expressed GPCR 
in the brain (Maccarrone et al., 2011). Regional expression density 
correlates well with the observed acute central effects of 
cannabinoids, such as impairment in cognition, memory, learning and 
motor coordination (Huffman et al., 2005; Patel and Hillard, 2006). In 
URGHQWV FDQQDELQRLG GUXJV SURGXFH D ³FDQQDELQRLG WHWUDG´ RI
characteristic pharmacological effects: antinociception, hypothermia, 
a decrease in general mobility (sedation), and catalepsy, the 
combination of which has achieved acceptability as a screening 
procedure (Martin et al., 1991). In addition, CB1 receptor activation 
for minutes to hours changes gene expression inducing 
neuroprotective proteins, for example BDNF, to reduce cell damage 
(Stella, 2004). 
CB2 receptors were cloned from human promyelocytic leukaemia (HL-
60) cells (Munro et al., 1993). This receptor shares with the CB1 
receptor the structural features typified by seven transmembrane-
spanning domains and coupling to G proteins. The human CB2 
receptor has 68% amino acid sequence homology to the CB1 receptor 
within the transmembrane domains, but only 44% homology 
throughout the total protein (Begg et al., 2005; Fernandez-Ruiz et 
al., 2007). Both CB1 and CB2 receptors belong to the group of 
rhodopsin-like G protein-coupled receptors (GPCRs) which comprise 
one subdivision of the GPCR superfamily (Pertwee et al., 2010). CB1 
and CB2 receptors both signal through the Gi/o class of heterotrimeric 
G proteins (Bosier et al., 2010; Pertwee et al., 2010). 
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Activation of CB1 or CB2 receptors via binding of endogenous or 
V\QWKHWLFDJRQLVWVFDXVHVGLVVRFLDWLRQRIWKH*ĮVXEXQLWIURPWKH*ǃǄ
subunits and the consequent initiation of a number of intracellular 
signaling cascades.  Both CB1 and CB2 activation result in inhibition of 
adenylyl cyclase and the associated inactivation of protein kinase A 
WKURXJK WKH*ĮVXEXQLWDQGDFWLYDWLRQRI HOHPHQWVRI WKHPLWRJHQ-
DFWLYDWHGSURWHLQNLQDVH0$3.VLJQDOLQJPHGLDWHGE\*ǃǄ%RVLHUet 
al., 2010; Pertwee et al., 2010).  
Furthermore, in addition to the Gi/o  subtype of G alpha, the CB1 
UHFHSWRU LV DOVR UHSRUWHG WR VLJQDO WKURXJK *V DQG *Į VXEXQLWV WR
stimulate a rise in intracellular Ca2+ (Bosier et al., 2010). CB1 
receptor activation is linked to the modulation of ion channel 
signaling pathways including activation of inwardly rectifying K+ 
channels (Demuth and Molleman, 2006).  
CB2 receptor expression has traditionally only been associated with 
cells of the immune system, although in recent years, evidence has 
emerged for its presence on neurons (Mechoulam et al., 2012; den 
Boon et al., 2012; Viscomi et al., 2009). Munro et al (1993) 
suggested that CB2 receptors are absent in healthy brain. They are 
also present on glial cells where their roles include modulation of 
cytokine release and immune cell migration, especially activated 
microglial cells (Waksman et al., 1999; Walter et al., 2003). 
Little is known about CB2 homomers or heteromers although a recent 
study demonstrated the formation of functional CB1/CB2 heteromers 
in transfected neuronal cells and in brain tissue (Callen et al. 2012).  
Of particular interest was their observation of bidirectional cross-
antagonism in the heteromers with CB1 antagonists able to block the 
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effects of CB2 agonists and vice versa. CB1 receptors are located 
both pre- and post-synaptically, whereas CB2 receptors are thought 
to display a preferentially post-synaptic distribution (Callen et al. 
2012; Brusco et al. 2008).  CB1 but not CB2 receptor distribution is 
also affected by membrane cholesterol content, with lower cholesterol 
levels resulting in increased CB1 signalling (Maccarone et al. 2011; 
Bari et al. 2005).    
The CB2 receptor is implicated in the neuroprotective activity of 
cannabinoids, mainly through a series of glia-dependent anti-
inflammatory actions (Pertwee, 2006; Fernandez-Ruiz et al., 2007). 
Activation of CB2 receptors contributes to an inhibtion of pro-
inflammatory responses in vitro and the most relevant pro-
inflammatory agents that seem to be under control of CB2 receptors 
are TNF-Į,/-1 and IL-6 (Ashton et al., 2006; Fernandez-Ruiz et al., 
2007).  
1.5.2 Non-CB1/CB2 receptors 
Reports of the existence of additional cannabinoid receptors continue 
to accumulate, and these are based on investigations using CB1 
knockout or CB1/CB2 double-knockout mice which demonstrate that 
some pharmacological responses to endogenous, exogenous and 
synthetic cannabinoids are exerted through mechanisms independent 
of CB1 and CB2 (Breivogel et al., 2001; Alexander, 2012).   
Previous reports have proposed that the orphan GPR55 receptor and 
the transient receptor potential vanilloid 1 (TRPV1) may potentially be 
novel cannabinoid receptors. In addition, McHugh et al., (2012) found 
that two cannabinoid receptor agonists, anandamide (AEA) and 
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tetrahydrocannabinol (THC), are full agonists and the non-
psychoactive phytocannabinoid cannabidiol (CBD) is a weak partial 
agonist at the GPR18 receptor.   
N-arachldonoylglycine (NAGLY; an endogenous fatty acid) is a full 
agonist at GPR18 (McHugh et al., 2012). GPR18 expression is 
reported in human lymphoid cells (Kohno et al., 2006), BV-2 
microglial cells, HEC-IB human endometrial cells (McHugh et al., 
2012) and metastatic melanoma (Qin et al., 2011). Several reports 
have suggested that there is sufficient evidence for GPR18 to be 
considered as a third cannabinoid receptor (Pertwee et al., 2010). 
1.5.2.1 GPR55 receptor 
Some recent studies indicate that GPR55, an orphan G protein-
coupled receptor, could also be considered as a novel cannabinoid 
receptor. GPR55 pharmacology is a controversial issue and the 
inconsistencies in the literature are likely attributed to the differences 
in assay protocols and /or cellular backgrounds employed by different 
workers (Henstridge et al., 2010). 
GPR55 belongs to the class A family of GPCRs and has been found to 
be activated by endogenous, synthetic and phytocannabinoids 
(Sawzdargo et al., 1999). However, a clear classification of GPR55 as 
a cannabinoid receptor is not well supported. Some cannabinoid 
receptor agonists such as CP-55,940, as well as endocannabinoids 
and endocannabinoid-like molecules including anandamide, 
virodhamine and palmitoylethanolamine activate [35S]-GTP-Ǆ-S 
binding via this receptor with nanomolar potency. On the other hand, 
Kapur and colleagues (2009) have reported that CP-55,940 is an 
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antagonist of the GPR55 receptor in common with abnormal 
cannabidiol, O-1602, HU 210, JWH 015 and AM 251 (Baker, 2006; 
Johns et al., 2007). GPR55 is also reported to be antagonized by 
cannabidiol (CBD), independent of CB1 or CB2 activity (Ryberg et al., 
2007). Kapur and colleagues (2009) have found that the CB1 
antagonist rimonabant (SR141716A) activated GPR55 at a 
concentration of 10 µM (Johns et al., 2007; Ryberg et al., 2007).  
Several reports concerning the pharmacology of GPR55 are 
controversial and divergent and some groups have also reported that 
cannabinoids that have been previously described as ligands for 
GPR55 may not actually have affinity for the receptor (Ross, 2009; 
Oka et al., 2009; Henstridge et al., 2009).  Lauckner and his 
colleagues (2008) observed a significant intracellular calcium rise in 
human GPR55-expressing HEK293 cells and in large dorsal root 
ganglion (DRG) cells when GPR55 was stimulated by the classical 
cannabinoid THC, JWH015, AEA, myristoylethanolamine (MEA) and 
lysophosphatidylinositol (LPI) requiring GĮT, PLC, GĮ and RhoA, 
whereas, there was less calcium release in non-transfected HEK cells 
(Edeeb et al., 2009). GPR55 pharmacology will be discussed in 
greater detail in Chapter Two. 
The latter agents described appear to have more potency at GRP55 
than CB1 and CB2 cannabinoid receptors (Pertwee, 2007). Ryberg and 
colleagues (2007) have claimed that GPR55 is activated by 
endocannabinoid-related ligands, especially PEA and OEA. However, 
other studies have reported that GPR55 is not activated by 
endocannabinoid-like ligands (Yin et al., 2009). GPR55 is thus 
unlikely to be reclassified as a cannabinoid receptor in the near future 
and more recent evidence has suggested that it may be a receptor for 
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endogenous phospholipids with the arachidonic acid containing 
species 2-arachidonoyl-sn-glycero-3-phosphinositol (LPI), having the 
highest affinity (Oka et al., 2010). 
1.5.2.2   PPARs  
The peroxisome proliferator-activated receptors (PPARs) belong to a 
family of nuclear receptors. Three PPAR isoforms are known to date: 
ĮǃįDQGǄZKLFKKDYHGLIIHUHQWH[SUHVVLRQSDWWHUQV :DKOL et al., 
 33$5Į LVSUHGRPLQDQWO\H[SUHVVHG LQ WLVVXHVFDWDEROLVLQJD
high volume of fatty acids, such as liver, heart and kidney (Wahli et 
al 2¶6XOOLYDQet al   33$5ǃį displays the broadest 
expression pattern with levels in certain tissues determined by cell 
proliferation and differentiation (Michalik et al 33$5ǃį LV
found in the skin, gut, adipose tissue, brain, skeletal and heart 
muscle amongst others (Wahli et al   33$5ǄKDV WZR VSOLFH
YDULDQWV Ǆ LV IRXQG LQ WKH EUDLQ YDVFXODU LPPXQH DQG
LQIODPPDWRU\ FHOOV Ǆ LV H[SUHVVHG SUHGRPLQDQWO\ LQ DGLSRVH WLVVXH
(Berger  and Moller, 2002; Michalik et al., 2006). PPARs mediate a 
wide variety of biological processes such as regulation of lipid 
metabolism, inflammation, energy homeostasis and cell 
GLIIHUHQWLDWLRQ2¶6XOOLYDQ 
There are several studies reporting that PPARs can be activated by 
cannabinoids; Kozak and his colleagues (2002) found the first 
evidence of interaction between PPAR Į and cannabinoids by 
demonstrating increasing transcriptional activity of PPARs from 
stimulation by the endogenous cannabinoids 2-AG and OEA in 
concentrations of 0.1-10µM. Furthermore, Rockwell and Kaminski, 
(2004) found that AEA inhibited pro-inflammatory cytokines and this 
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ZDV UHYHUVHG E\ 33$5Ǆ DQWDJRQLVWV Other cannabinoids which 
DFWLYDWH WKH WUDQVFULSWLRQDO DFWLYLW\ RI 33$5Ǆ LQFOXGH :,1-2, 
CP-55,940, cannabidiol (1±20 ǋM) and HU-210 (100 nM) 2¶6XOOLYDQ
et al., 2006).  Studies focused on the cannabinoid mechanism of 
stimulation of PPARs, Yano et al. (2007) reported that cannabinoids 
activate the receptors at the cell surface, initiating intracellular 
signaling that may lead to PPAR activation, whereas another 
possibility demonstrated by Rockwell and Kaminski, (2004) might be 
that metabolites of cannabinoids are the active ligands of PPARs. 
2¶6XOOLYDQet al. (2005) identified that THC caused slowly developing 
vasorelaxation through activatLRQ RI 33$5Ǆ GHSHQGHQW RQ WKH
generation of hydrogen peroxide (H2O2), NO production and 
superoxide dismutase (SOD) activity (Kozak et al., 2002; O;Sullivan 
et al., 2005). 
1.5.2.3   Transient receptor potential channels 
Transient receptor potential channels type V1 (TRPV1 or vanilloid 
receptors) are ligand-gated ion channels that have a role in 
cannabinoid functions. TRPV1 are non-selective cation channels 
activated by both chemical (e.g. capsaicin, the active component of 
chili peppers) and physical (noxious heat and low pH) stimuli 
(Battista et al. 2012; De Petrocellis et al. 2010).They are not only 
found on sensory neurons, partly co-expressed with CB1 receptors 
(Ahluwalia et al., 2000), but are also found in several central nuclei 
including those in the hypothalamus and basal ganglia, hippocampus, 
cerebellum and striatum (Cristino et al., 2006).  
Di Marzo (1998) found that anandamide, which has some chemical 
similarities to capsaicin, activates the channel resulting in vasodilator 
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effects, production of pro-apoptotic kinases in neuronal and immune 
cells, increased mitochondrial uncoupling, release of cytochrome c 
and increased intracellular Ca2+, [Ca
2]i. The sensitivity to anandamide 
led to the proposal that TRPV1 may be considered to be a 
cannabinoid receptor (Ross, 2003; Battista et al., 2012). 
The transient receptor potential channel type V2 (TRPV2) protein, 
also known as vanilloid receptor-like 1 (VRL-1), is distributed in 
medium- to large-diameter Aǃmechanosensitive and thermosensitive 
sensory neurons in the rat dorsal root ganglion (DRG) (Caterina et 
al., 1999), the trigeminal ganglion (Ichikawa and Sugimoto, 2000), 
and the spinal cord (Lewinter et al., 2004). Moreover, TRPV2 is 
upregulated in rat DRG after nerve injury (Frederick et al., 2007) and 
inflammation (Shimosato et al., 2005). TRPV2 receptors can be 
activated by noxious heat, (with an activation threshold >52°C), 
swelling, and 2-aminoethoxydiphenylborate (Caterina et al., 1999; 
Muraki et al., 2003). The activation of this receptor leads to 
translocation of the protein from an intracellular compartment to the 
plasma membrane as result of stimulation by insulin-like growth 
factor-1, PDGF, or the neuropeptide (Boels et al., 2001) and PI3-
kinase signalling pathways (Penna et al., 2006).  
1.6 Cannabinoid receptor ligands 
 1.6.1 General information 
 For thousands of years, preparations of the marijuana plant 
Cannabis sativa (e.g. hashish) have been known to interact with the 
human body on many levels. In 1964, identification of the chemical 
structure RIWKHSULQFLSDOSV\FKRDFWLYHFRPSRXQGRIPDULMXDQD¨9 ±
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WHWUDK\URFDQQDELQRO ¨9±THC), by Gaoni and Mechoulam was made. 
It was previously thought that the effects of this and other highly 
lipophilic cannabinoid compounds were due to non-specific membrane 
perturbation but the radioligand binding studies of Devane et al.,  
(1988) clearly indicated the presence of a receptor protein in the 
plasma membrane that recognized cannabinoid ligands. 
6LQFH WKHGLVFRYHU\DQGHOXFLGDWLRQRI WKH FKHPLFDO VWUXFWXUHRIƩ9-
THC, many highly affinity, selective and non-selective cannabinoid 
receptor ligands have been synthesised and evaluated in animal 
models and in cell lines. This classification of cannabinoid receptor 
ligands is done according to their chemical classes and 
pharmacological activity. This has encouraged the classification of 
cannabinoids into five chemical groups; classical, non-classical, 
aminoalkylindol, eicosanoid and diarylpyrazole (Pertwee, 1997; 
Huffman, 2005; Pertwee, 2006).  
 1.6.2 Classical cannabinoids 
This group is represented by plant-GHULYHG FDQQDELQRLGV HJ Ʃ9-
7+& Ʃ8-THC) Figure1.3 A), cannabinol (CBN), cannabidiol (CBD) 
Figure 1.3 B], (low affinity for CB1 as well as for CB2) (Sharir and 
Abood, 2010).  In recent years, other phytocannabinoids have been 
isolated and characterized (see below). 
 Phytocannabinoids are synthesised in the cannabis plant by glandular 
trichomes as carboxylic acids from geranyl pyrophosphate and 
olivetolic acid to yield the parent phytocannabinoid compound, 
cannabigerolic acid (CBGA). Subsequent reactions involving different 
enzymes catalyze the transformation of CBGA into other 
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phytocannabinoids. The presence of these enzymes differs between 
various strains and species of cannabis, resulting in a different 
content of phytocannabinoids (Russo, 2007).  
          
            (A) THC                                               (B) CBD                                         
Figure 1. 3: structures of phytocannabinoids THC and CBD. 
               
(A) HU-210                                              (B) CP55,490 
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(D) JWH 015                                                (E) AM 251 
Figure 1.4: Structures of synthetic cannabinoids HU210, CP55,940, 
JWH015 and AM251. 
Further phytocannabinoids include CBDV (cannabidivarin), CBDVA 
(cannabidivaric acid), CBC (cannabichromene), CBG (cannabigerol), 
CBGV (cannabigerovarin), CBN (cannabinol), CBNV (cannabinovarin), 
THCA (tetrahydrocannabinolic acid) THCV (tetrahydrocannabivarin), 
and CBDA (cannabidiolic acid) (Gaoni and Mechoulam, 1966; Vollner 
et al., 1969; Gill et al., 1970). 
Synthetic analogs such as HU-210 and CP-55940 (Figure 1.4 A) have 
high affinity for CB1 and CB2 receptors and JWH-133, L-759633 and 
L-759656 are CB2 selective agonists, the main part of their structure 
contains a dibenzopyran ring (Kapur et al., 2009; Felder et al., 1995; 
Pertwee, 1997). 
 1.6.2.1 Cannabidiol (CBD)  
The phytocannabinoid cannabidiol (CBD) is a non-psychoactive 
substance (Ross et al., 2008) and is one of the major constituents, 
forming up to 40% of Cannabis sativa (marijuana) extract 
(Mechoulam et al., 2002). The action of CBD could involve other 
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cannabinoid receptors including an abnormal cannabidiol receptor, a 
non-CB1 and non-CB2 receptor (Franklin et al., 2003) and it was 
proposed to be a GPR55 receptor ligand; either an antagonist or 
agonist depending on the authors reporting the data (Oka et al., 
2007; Ryberg et al., 2007). Recent reports showed that CBD exerted 
analgesic effects and it is suggested that the analgesic effect of CBD 
is mediated, at least in part, by TRPV1 (McHugh et al., 2008). CBD 
has also been found to activate TRPV2 ion channels and to produce 
TRPV2-mediated elevation of [Ca2+]i and to cause the release of 
CGRP from sensory neurons (Bisogno et al., 2001; Qin et al., 2008). 
Furthermore, CBD inhibits serotonin reuptake and increases 
catecholamine activity in rat brain synaptosomes. It has been 
reported to activate serotonin (5-HT1A) receptors which might be 
involved in its proposed antidepressant, anxiolytic, and 
neuroprotective properties (Russo et al., 2005; Zanelati et al 2009; 
Resstel et al., 2009; Mishima et al 2005). It also inhibits adenosine 
uptake (Russo et al., 2005; Carrier et al., 2006) and can antagonise 
the SV\FKRWURSLF HIIHFWV RI ¨9-THC.  However, CBD displays all of 
these effects only at micromolar concentrations (Russo et al. 2005) 
and the molecular mechanisms underlying the effects are still unclear 
(Petit et al., 1998).  
CBD is suggested to produce different pharmacological effects 
including anti-inflammatory, anticonvulsant, hypnotic, anxiolytic, and 
antipsychotic effects via GPR55, whereas it has no activity at CB1 and 
CB2 receptors. Furthermore, CBD inhibits anandamide degradation 
and transport and was suggested to possess antioxidant capacities 
and neuroprotective actions (Mechoulam et al., 2002; Malfait et al., 
2000; Carlini et al., 1981) and CBD was reported to protect from 
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brain damage in gerbils caused by cerebral ischaemia (Braida et al., 
2003).  
Cannabidiol has also been shown to inhibit cancer cell growth, albeit 
with low potency. Although the inhibitory mechanism is not yet fully 
understood, Ligresti et al. (2006) suggested that CBD exerts its 
effects on these cells through multiple mechanisms that include either 
direct or indirect activation of CB2 and TRPV1 receptors, and induction 
of oxidative stress, all contributing to induce apoptosis. CBD has the 
ability to induce apoptosis in cultures of human HL-60 myeloblastic 
leukaemia cells and human U87 and U373 glioma cells (Gallily et al., 
2003) and recent reports have shown promise for controlling the 
spread of metastatic breast cancer by down-regulating the activity of 
the gene ID1 which is responsible for tumor metastasis (McAllister et 
al., 2007). 
Ryan et al., (2009) have found that CBD protect human 
neuroblastoma cell lines (SH-SY5Y) against mitochondrial toxins 
(FCCP, a mitochondria uncupler), oligomysin and hydrogen peroxide, 
moreover CBD may prove beneficial in preventing apoptotic signalling 
via a restoration of Ca2+homeostasis. 
 1.6.3 Non classical cannabinoids 
The group of bicyclic and tULF\FOLFDQDORJVRIƩ9±THC lacking a pyran 
ring was developed by Pfizer (Groton, CT, USA). It includes CP-
55,940 (Figure 1.4 B), a high affinity cannabinoid receptor agonist 
with a similar affinity for CB1 and CB2 receptors.  When radiolabelled, 
it is an important tool in determining the activity of compounds at the 
cannabinoid receptors and was used by Devane et al (1988) to 
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characterize the CB1 receptor. More recently synthesized compounds 
in this class are CP47497, CP55244 and HU-308 which have a higher 
affinity for CB2 than CB1 receptors (Felder et al., 1995). 
 1.6.4 Aminoalkylindoles (hybrid cannabinoids) 
These compounds differ structurally from the members of the first 
two groups and were developed by Sterling Winthrop (Collegeville, 
PA, USA). WIN55212-2 is the most widely investigated 
aminoalkylindole and it is high affinity agonist for CB1 and CB2 with a 
slight selectivity towards CB2 receptors (Felder et al, 1995). Since the 
synthesis of these aminoalkylindoles, several others have been 
developed, such as the CB2-selective ligands L768242 (GW405833) 
and JWH015 (Gallant et al., 1996; Howlett et al., 2002). 
        1.6.5 Eicosanoids  
The arachidonate-containing compounds in this class are the 
endocannabinoids, (discussed in section 1.8) but it also includes 
noladin ether, oleamide, virodhamine (VIR) and synthetic analogues 
of AEA, such as methanandamide, arachidonyl-¶-chloroethylamide 
(ACEA), arachidonylcyclo-propylamide (ACPA), 2-methylarachidonoyl-
(2-fluoroethyl)-amide (O-689) (potent CB1 agonists) and O-1812. 
Methanandamide (more potent at CB2 receptors) and O-1812 are 
more resistant to enzymatic hydrolysis than AEA, ACEA and ACPA 
(Hillard et al., 1999).  
1.6.6 Diarylpyrazoles  
The best characterized CB receptor antagonist is SR141716 
(rimonabant) discovered by Sanofi (Paris, France) which has high 
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selectivity for the CB1 receptor. It is an antagonist with nanomolar 
affinity for the CB1 and micromolar affinity for CB2 receptor, but it has 
been widely reported to have inverse agonist properties at CB1 
(Huestis et al., 2001). Other CB1 selective antagonists include LY 
320135, AM 251 (Figure 1.4 D) and AM 281; the latter two are 
synthetic analogues of SR141716. AM 251 also acts as a GPR55 
agonist. Selective CB2 antagonists/inverse agonists include SR144528 
and AM 630 (both having much higher affinity towards CB2 than to 
CB1 receptors) (Pertwee, 2005; Rinaldi-Carmona et al., 1994; Kapur 
et al., 2009; Barth and Rinaldi-Carmona, 1999). 
 1.7 Allosteric modulators  
In addition to the presence of the orthosteric (primary) binding site 
on the cannabinoid receptors with which agonists, antagonists and 
inverse agonists interact, studies have recently found evidence for an 
allosteric binding site on the CB1
 
receptor through which certain drugs 
interact and cause a conformational change in the receptor structure, 
modifying the affinity and/or intrinsic effectiveness of cannabinoids 
acting at the orthosteric binding site (Price et al., 2005; Ross, 2007). 
Recent reports suggest that CBD is a positive allosteric modulator at 
low micromolar concentrations for both strychnine-VHQVLWLYH Į1 and 
Į1ǃJO\FLQHUHFHSWRUV$KUHQVet al., 2009). 2AG is reported to be an 
allosteric modulator at other receptors such as the hA3 adenosine 
receptor (Lane et al., 2009). 
1.8 Endogenous cannabinoids 
The cloning of the cannabinoid receptors led to a search for 
endogenous cannabinoid receptor agonists (Pertwee, 2008). Several 
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fatty acid ligands of cannabinoid receptors (known as 
endocannabinoids) have been identified, of which N-arachidonoyl 
ethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG) are 
the best characterized (Pertwee et al, 2010). Endocannabinoids 
synthesis and release are thought to be in response to elevation of 
intracellular calcium concentrations and, in contrast to many other 
neurotransmitters, AEA and 2-AG are not stored in vesicles but they 
DUH ZLGHO\ EHOLHYHG WR EH UHOHDVHG RQ µ¶GHPDQG¶¶ ZKHQ DQG ZKHUH
they are needed (Piomelli et al., 2000) in response to cellular 
depolarization and influx of Ca2+ to act on cannabinoid receptors 
present in the cells surrounding the region of production to operate 
as neuromodulators and immunomodulators (Stella et al., 1997; 
Giuffrida et al., 2000). However, Sarmad et al., (2011) produced data 
which suggest that the dogma of calcium-driven endocannabinoid 
synthesis, at least in complex tissues, might not be universally true. 
One of the most well known functions of endocannabinoids is their 
role as retrograde messengers (Kano et al., 2009).  
Endocannabinoids released from the post-synaptic neurons traverse 
the synaptic cleft and bind to pre-synaptic CB1 receptors reducing 
Ca2+ and potassium (K+) conductance ultimately decreasing release 
of neurotransmitter (Ohno-Shosaku et al., 2001). The membrane 
phospholipid N±arachidonoyl phosphatidyl ethanolamine (NAPE) is the 
precursor for anandamide, whose formation is catalysed by N±
arachidonoyl phosphatidyl ethanolamine-selective phospholipase D 
(NAPE-PLD) whereas; 2-AG synthsis is derived from diacylglycerols 
catalysed by diacylglycerol lipase (DGL) (Stella and Piomelli, 2001). 
The levels of 2-AG in the brain are 170 times more than anandamide 
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and both are similar in their binding affinity for cannabinoid receptors 
(Mechoulam et al., 1995: Stella et al., 1997; Sugiura et al., 1996). 
Anandamide expresses typical pharmacological and biochemical 
effects of cannabinoid agonists at CB1 and CB2 receptors (Stella, 
2009) and inhibits adenylyl cyclase by binding to both receptors. The 
main mechanisms involved in termination of endocannabinoid 
signalling are transport across membranes into cells, intracellular 
hydrolysis and oxygenation (Mackie and Stella, 2006). 
Following cellular uptake, endocannabinoids are degraded by 
intracellular enzymes. Anandamide is predominately metabolised by 
fatty acid amide hydrolase (FAAH) (Cravatt et al., 2001; Kaczocha, 
2009) and also by N-Acylethanolamine-hydrolyzing Acid Amidase 
(NAAA), cyclooxygonese-2, lipoxygenase and some cytochromes 
P450. Whereas 2-AG is degraded by Monoacylglycerol Lipase (MGL) 
and also by FAAH (Cravatt et al., 2001). Furthermore, 
palmitoylethanolamide (PEA) and other fatty acid amides are also 
metabolized by fatty acid amide hydrolase (FAAH) and N-
acylethanolamine-hydrolyzing acid amidase (NAAA), the latter has 
more specificity toward PEA than other fatty acid amides (Tsuboi et 
al., 2007) as shown in Figure 1.5. Whilst PEA interacts with PPAR-Į
receptors and/or an unknown Gi/o protein-coupled receptor (Muccioli 
and Stella, 2008), it also appears to enhance the activation by AEA of 
cannabinoid receptors and TRPV1 channels (Petrosino et al., 2009).  
There are also other endocannabinoid-like agents including N-
dihomo-alpha-linolenoylethanolamine, N-
docosatetraenoylethanolamine, oleamide, N-arachidonoyl dopamine, 
N-oleoyl dopamine, oleoylethanolamide (OEA) and virodhamine which 
35 
 
have little or no affinity for CB receptors but can modify cannabinoid 
function  possibly via entourage effects (Pertwee, 2009).  
Microglia, which play an important role in modulating nociceptive 
responses, are capable of synthesising and catabolising 
endocannabinoids (Franklin et al., 2003, Guasti et al., 2009). 
Microglia, which play an important role in modulating nociceptive 
responses, are capable of synthesising and catabolising 
endocannabinoids (Franklin et al., 2003, Guasti et al., 2009). 
Recently, it has been demonstrated that mouse microglia produce a 
number of putative endocannabinoids (Walter et al., 2003). Carrier et 
al., 2004 have found that cultured microglial cells produce the 
endocannabinoid 2-arachidonylglycerol (2-AG) as well as anandamide 
in smaller quantities. 
 
Figure 1.5: Diagrammatic representation of the Main pathways of synthesis 
and degradation of the endocannabinoids anandamide and 2-
arachidonoylglycerol (2-AG) adapted from  El Manira  and  Kyriakatos  
(2010). 
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1.9 Cannabinoids and Neuroinflammation 
Since the 1970s, a few studies have suggested that marijuana use 
was associated with an increased incidence of viral infection and 
found that cannabinoids suppressed immune resistance to such 
microbes as Friend leukemia virus, herpes simplex viruses (HSV), 
Acanthamoeba, Listeria monocytogenes, Staphylococcus albus, 
Treponema pallidum and Legionella pneumophila (Cabral and Staab, 
2005; Morahan et al., 1979; Juel-Jensen, 1972; Cabral and Dove-
Pettit, 1998; Marciano-Cabral et al., 2001, Newton et al., 1994; Klein 
et al., 1998).  
Proteins which are up-regulated in neurological diseases 
characterized by an inflammatory component have been found to 
activate microglia in vitro. These include components of the blood 
such as albumin (Hooper et al., 2009) and thrombin (Choi et al., 
2003) which may be encountered at elevated concentrations by 
microglia following BBB damage. In addition, proteins present in the 
lesions characteristic of particular neurodegenerative diseases such 
as amyloid beta plaques, intracellular neurofibrillary tangles (NFTs) 
and prion proteins in spongiform encephalpathies (Fabriz et al., 2001) 
are associated with activated microglial and astrocytes (Campbell and 
Gowran., 2007; Meda et al., 1995; Ramírez et al., 2005). 
However, activated microglia have been cited as a direct cause of, or 
a contributor to, the progress of chronic neurodegenerative diseases 
that are characterized pathologically by an atypical production of pro-
inflammatory factors. Microglia in vivo tend to become progressively 
more activated with age (Streit et al., 1999); indeed an age-related 
microglia dystrophy have been reported in human brain (Streit et al., 
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2004) and microglia are activated after traumatic brain injury (d'Avila 
et al., 2012). 
Relase of pro-inflammatory and other neurotroxic factors from other 
cells in the CNS, such as astrocytes and perivascular macrophages, 
and from peripheral immune cells that have penetrated the BBB, 
contribute towards the pathology of neurodegenerative and 
neuroinflammatory diseases (Perry, 2004). 
Exogenous cannabinoids have been shown to suppress both cell-
mediated and humoral immune responses in a variety of immune 
FHOOV¨9-THC suppressed the antibody response of B-cells (Carayon 
et al., 1998; Kaminski et al., 1994), and diminished B and T cell 
proliferation in response to cell-specific mitogens (Carayon et al., 
1998; Derocq et al %RWK¨9-THC and CP-55,940 prevented 
macrophage cell contact-dependent cytolysis of tumor cells by 
macrophages and macrophage-like cells, to inhibit the processing of 
antigens by macrophages and to suppress proliferation of B 
lymphocytes (Wang et al., 1991; McCoy et alZKLOH¨9-THC 
suppresses the cell-killing activity of natural killer cells (Wang et al., 
 0RUHRYHU¨9-THC and CP-55,940 have been found to affect 
chemotaxis of immune cells to sites of infection and/or injury 
(Sacerdote et al., 2000). This modulatory affect was investigated in a 
mouse model of granulomatous amoebic encephalitis (GAE), where 
PLJUDWLRQ WR WKH VLWH RI LQIHFWLRQ ZDV GHFUHDVHG LQ ¨9-THC-exposed 
macrophages and macrophage-like cells (Marciano-Cabral et al., 
2001; Cabral and Marciano-Cabral, 2005).  
 There is a suggestion that, via their interactions with cannabinoid 
receptors, the immune modulatory effects of cannabinoids are down-
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stream consequences of the inhibition of adenylyl cyclase activity by 
a pertussis toxin-sensitive G protein-coupled mechanism (Kaminski et 
al., 1992; Kaminski., 1996).  A significant downstream effect of 
cannabinoid signaling is the modulation of gene expression of pro-
LQIODPPDWRU\ PHGLDWRUV  ¨9-THC has been shown to inhibit pro-
inflammatory cytokine (IL-Į ,/-ǃ ,/-6 and TNF-Į P51$
expression, as well as to ablate TNF-ĮUHOHDVH)HUQDQGH]-Ruiz et al., 
2007; Facchinetti et al., 2003).  
There is growing evidence that cannabinoids could be developed as 
therapeutic agents in neurological diseases, by attenuation of pro-
inflammatory factors from infiltrated peripheral immunocytes. 
Cannabinoids easily penetrate the blood brain barrier (BBB) and are 
not toxic to the brain (Cabral and Griffin-Thomas., 2008). Because 
cannabinoids can inhibit expression of pro-inflammatory mediators, 
and improve blood supply to injured brain, as a result of inhibiting 
endothelium-derived mediators, they have therapeutic potential for 
neuropathies characterized by chronic formation of pro-inflammatory 
factors (Chen et al., 2000).   
The therapeutic benefits of cannabinoids have been investigated both 
in vitro and in vivo models of multiplH VFOHURVLV 06 $O]KHLPHU¶V
disease (AD), HIV encephalitis (HIVE), amyotrophic lateral sclerosis 
(ALS), closed head injury (CHI) and granulomatous amoebic 
encephalitis (GAE) (Cabral and Griffin-Thomas., 2008; Ramírez et al., 
2005). Benefit has also been VKRZQ LQ 3DUNLQVRQ¶V GLVHDVH DQG
+XQWLQJWRQ¶VGLVHDVH7DQYHHUet al., 2012). This potential is largely 
based on the antioxidant, anti-inflammatory and anti-excitotoxic 
properties exhibited by these compounds that allow them to afford 
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neuroprotection in different neurodegenerative disorders (de Lago 
and Fernández-Ruiz, 2007). 
AD is a very common neurodegenerative disorder that leads to senile 
dementia as result of deposit beta-DP\ORLGSURWHLQǃ-A) (Mattiace et 
al., 1990). MS is a chronic inflammatory disease that is characterized 
by T-cell mediated demyelination of axonal myelin sheaths that 
protect axons. MS patients suffer from cognitive impairment, muscle 
weakness, and impaired coordination, balance, speech and sight 
(Mitrovic et al., 1994). HIVE, also known as Acquired Immune 
Deficiency Syndrome (AIDS)-dementia complex, is a 
neuroinflammatory disorder caused by the production of pro-
inflammatory cytokines and neurotoxins, including glutamate and 
reaction oxygen species (ROS), produced by HIV-infected monocytes 
and microglia (Soontornniyomkij et al., 1998).  
PD is a neurodegenerative disease characterized by the selective loss 
of dopaminergic neurons in the substantia nigra pars compacta and 
GHSRVLWLRQRIĮ-synuclein aggregates in nigral neurons (Hirsch et al., 
2012; Nakajima and Kohsaka, 2004). In the neuroinflammatory 
diseases described above, there is a failure to maintain the 
immunological and overall homeostatic balance within the brain, and 
activated microglia and astrocytes play a vital role in this imbalance 
(Nakajima and Kohsaka, 2004). 
Recent reports have found that CB1 receptor activation by HU-210 
and WIN55212-2 protects against mutant Huntingtin-induced cell 
death (Scotter et al., 2010) and Sagredo et al., (2012) suggested 
that the ability of cannabinoids to improve the symptoms of 
+XQWLQJWRQ¶V GLVHDVH LV GXH WR WKHLU DQWL-inflammatory, 
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neuroprotective and neuroregenerative properties. Treatment with 
the synthetic cannabinoid agonists WIN55,212-2 and HU-210 
LPSURYHGPRWRU IXQFWLRQ LQ 7KHLOHU¶VPXULQH HQFHSKDORP\HOLWLV YLUXV
(TMEV)-infected mice (Croxford and Miller, 2003; Arevalo-Martin et 
al., 2003), a model of chronic demyelinating disease that resembles 
MS.  These same cannabinoid agonists were shown to prevent 
microglial activation and cognitive impairment in AD based on 
examination of brain samples and primary microglial function 
(Ramirez et al., 2005).  Thus, by using cannabinoid receptors as 
molecular targets, it might be possible to improve the various 
neuropathological processes associated with chronic brain 
inflammation (Croxford and Yamamura, 2005).     
1.10 Models used in microglial function  
1.10.1 Primary microglial cells 
Perhaps the most appropriate in vitro model used for gaining insight 
into the biology of microglia is that of brain microglia in primary cell 
culture. However, it is time-consuming and technically difficult to 
prepare almost pure primary microglial cultures in sufficient 
quantities for study and the cells cannot be kept in culture for 
prolonged periods of time (Tamashiro et al., 2012). Immortalized 
microglial cell lines have been generated and characterized to avoid 
some of these challenges (Cheepsunthorn et al., 2001).   
1.10.2 BV-2 cells  
BV-2 cells (a murine microglial cell) were generated by immortalizing 
primary mouse microglia. These cells possess functional and 
phenotypic properties common to primary microglial, including 
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phagocytic ability, secretion of pro-inflammatory cytokines and 
expression of surface receptors and antigens.  These cells have been 
used extensively as in vitro models to study microglial function, 
immune responses and the role of microglia in neurodegenerative 
diseases.  BV-2 cells have been shown to become activated upon 
exposure to IFN-Ǆ+DQet al., 2002; Han et al., 2002; Hwang et al., 
2004) and LPS (Blasi et al., 1990; Kim et al., 2004) and they have 
been employed to study the effects of anti-inflammatory agents on 
pro-inflammatory cytokine and iNOS gene expression (Kim et al., 
2004; Han et al., 2002), and to study the expression profiles of 
chemokines and chemokine receptors upon microglial activation 
(Kremlev et al., 2004).     
1.10.3 HAPI cells  
Highly aggressive proliferating cell type [HAPI] cells were derived 
from primary microglia-enriched cultures. This rat cell line retains 
phenotypic and morphological characteristic of activated microglia. 
Thus, HAPI cells offer a model of activated primary microglial cells 
and are the only available model of rat-derived microglial cells 
(Cheepsunthorn et al., 2001).  
1.2 Aim and Objectives 
The main aim of this project is to determine the role of cannabinoids 
in modulation of microglial cell function using in vitro approaches, and 
to investigate the molecular mechanisms underlying such modulation.  
First, the aim of this study was to examine the potential effects and 
mechanisms of action of cannabidiol and related phytocannabinoids 
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on the function of microglial cells (nitric oxide formation as indicator 
for microglia activation) in vitro. 
Second, to evaluate the effects of phytocannabinoids on microglial 
migration and phagocytosis and to gain insight into the mechanisms 
of drug action. 
It is hoped that the findings will address the potential of cannabinoids 
to be therapeutic agents for neuroinflammatory diseases that are 
pathologically hallmarked by a chronic elevation of pro-inflammatory 
mediators and microglial activation. 
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2. 1 Introduction  
Microglia are considered to be the resident macrophages of the central 
nervous system (CNS). Chronic activation of microglia is characterized by 
proliferation, migration to the site of injury, altered morphology and cell 
surface marker changes (Kim and Joh, 2006). Microglial activation has 
protective functions in the destruction of pathogens, neoplastic cells, 
removal of debris and accelerated tissue repair, and release of neurotrophic 
factors (Hanisch and Kettenmann, 2007).  
 However, excessive activation can be damaging and can exacerbate the 
effects of inflammation leading to neurodegenerative disease e.g. as seen 
in AIDs dementia and $O]KHLPHU¶V disease (Banati et al., 1993). Activated 
microglia may act as intrinsic brain phagocytes or by secretion of 
neurotoxins such as TNF-Į %DQDWL et al., 1998), nitric oxide (NO), 
proteinases, reactive nitrogen species, plasminogen activator and 
cytokines, for instance IL-1, and other factors which could cause neuronal 
injury (Gehrmann et al., 1995; Waksman et al., 1999; Izzo et al., 2009). 
Activated microglia and astrocytes are thought to be the main sources for 
reactive oxygen and nitrogen species within the CNS (Hanisch and 
Kettenmann, 2007).   
Activated microglia synthesize, release and/or up-regulate a plethora of 
mediators including cytokines, chemokines and prostaglandin E2 (PGE2) 
(Ryu et al., 2000; Barger et al., 2007; Wang et al., 2008; Rock et al. 2004) 
while both iNOS (Ryu et al., 2000, Barger et al., 2007, Wang et al., 2008), 
and COX-2 (Akundi et al., 2005) are enzymes up-regulated by 
inflammatory stimuli. 
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Brain microglial cells release substantial amounts of the radical nitric oxide 
(NO) (Weinstein et al., 2008, Kawahara et al., 2009).  Although NO has 
protective activity in the central nervous system, excessive release has 
been found to cause brain injury and to mediate neurodegenerative 
inflammatory processes (Boje et al., 1992: Martinez-Orgado et al., 2012). 
Under normal conditions, the release of NO from microglial cells is 
insignificant, but when it is released in abundance, it can pass from the cell 
of origin into surrounding tissue to act on other cells because it is small and 
without charge (Brown, 1997).  
There are three isoforms of nitric oxide synthase (NOS) that have been 
cloned, two of which are constitutively active; endothelial NOS (eNOS) and 
neuronal NOS (nNOS). These are responsible for the production of 
transient low level bursts of NO and both are calcium/calmodulin-
dependent (Kone et al., 2003). The third type is inducible by inflammatory 
stimuli, such as endotoxin, cytokines and oxidative stress, but not calcium; 
its expression is induced in many cell types including macrophages (Brown, 
1997). An accumulation of reports have indicated that cannabinoids may 
modulate formation of inflammatory factors, such as NO, released by 
activated brain microglial cells. One of the earliest links between 
cannabinoids and NO (Stefano et al., 1996, Stefano et al., 1997) showed 
that anandamide (AEA) and the CB1/CB2 receptor agonist CP55940 initiated 
the release of NO in a concentration-dependent manner from invertebrate 
microglia. 
 Cannabinoids have been found to alter the functional activity of 
macrophages and macrophage-like cells (Makriyannis et al., 1990; 
Friedman et al., 1986) and have been suggested as potential future 
treatments for different types of neurodegenerative disease (Klein and 
Newton, 2007), especially those compounds that lack psychoactive effects, 
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such as cannabidiol (CBD). The anti-inflammatory and immunosuppressive 
properties of cannabinoids have been reported to modulate the host 
immunity response against infections (Klein et al., 1998). However, the 
mechanisms underlying these actions are not fully understood.  
CBD exerts a wide variety of anti-inflammatory properties and regulates 
cell cycle and function of various immune cells. These effects include 
inhibition of humoral responses such as release of cytokines, chemokines 
and growth factors. For example, CBD decreases the activity of the NF-ǉ%
pathway, up-regulates the activation of STAT3 and reduces the activation 
of LPS-induced STAT1 transcription factors to interfere with inflammatory 
pathways in LPS-treated BV-2 microglial cells (Kozela et al., 2010). CBD is 
reported to up-regulate the transcription of nuclear factor-erythroid 2 
(Nrf2), which is responsible for regulation of protective antioxidant and 
detoxification activities (Juknat et al., 2012).  
Cannabinoid compounds produce their biological effects by acting through 
at least three G protein-coupled cannabinoid receptors.  These include CB1 
and CB2 receptors that are reported to be expressed in activated microglial 
cells (Walter et al., 2003) and the abnormal-cannabidiol-sensitive receptors 
(abn-CBD receptors) (Ja´rai et al., 1999). Alternatively, cannabinoids 
including CBD could act through the orphan GPCR GPR55 (Staton, et al., 
2008). Pietr et al., (2009) have reported the expression of GPR55 mRNA in 
mouse primary microglial cultures and the BV-2 cell line. Following its 
identification in 1998, two patents from GlaxoSmithKline, in 2001, and 
AstraZeneca, in 2004, suggested that GPR55 represents a novel 
cannabinoid receptor in spite of having only 13.5% and 14.5% sequence 
homology to CB1 and CB2 receptors, respectively (Kreitzer and Stella, 
2009).  
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The orphan receptor GPR55 has been suggested to be an additional 
member (non-CB1/CB2 receptor) of the cannabinoid receptor family based 
largely on reports indicating that a variety of different cannabinoid ligands 
interact with it, including antagonism by CBD (Ryberg et al., 2007;  Sharir 
and  Abood, 2010). There are, however, significant doubts about its 
classification as a CB receptor with a lack of agreement between different 
authors concerning its pharmacological profile (Baker et al., 2006; 
Pertwee, 2007; Ryberg et al., 2007; Ross, 2009). Putative 
endocannabinoids such as anandamide and virodhamine are reported to 
activate GTP-Ǆ-S binding via the GPR55 receptor (Baker et al., 2006). 
The suggested physiological roles of GPR55 include pain signalling, and 
control of vascular tone. Moreover, GPR55 might play a role in lipolysis and 
immune cell migration (Pertwee, 2007). Recent studies have now 
implicated GPR55 receptors in the neuroprotective activity of cannabinoids 
through an anti-inflammatory action (Pietr et al., 2009; Staton et al., 
2008). 
Studies of mitogen-activated protein kinase (MAPK) phosphorylation in 
GPR55-expressing cells lead to it being classified as a 
lysophosphatidylinositol (LPI) receptor (Oka et al., 2007). More recently, 
LPI acting on GPR55 has been reported to couple to increasing intracellular 
calcium inducing phosphorylation of P38 MAPK and activating transcription 
factor 2 (Oka et al., 2009; Oka et al., 2010). On the other hand, various 
types of lysolipids as well as a number of cannabinoid receptor ligands did 
not induce phosphorylation of the extracellular signal-regulated kinase in 
GPR55 receptor-expressing cells (Oka et al., 2007).  
Human brain GPR55 mRNA is more predominantly expressed in the 
caudate nucleus and putamen than the hippocampus, thalamus, pons, 
47 
 
cerebellum and frontal cortex (Sawzdargo et al., 1999), whereas, in rat 
brain, GPR55 mRNA is highly expressed in hippocampus, thalamic nuclei 
and regions of the midbrain (Brown, 2007). In mice, the highest levels of 
GPR55 mRNA were found in adrenal tissue, ileum, frontal cortex and 
striatum. GPR55 mRNA is also found in spleen and gut in both humans and 
rodents (Sawzdargo et al., 1999). Furthermore, GPR55 mRNA is found in 
omental adipose tissue, testis and breast but, it was not detected in 
subcutaneous fat tissue (Brown, 2007; Sawzdargo et al., 1999).  
The GPR55 receptor is implicated in modulation of inflammation via 
alterations in microglial activity, and their pharmacological treatment might 
be worthy for delaying the development of neurodegenerative diseases and 
inflammatory pain.  Furthermore, GPR18 is involved in modulation of 
microglial, endothelial and glioma cell migration (McHugh et al., 2010). 
2.2 The aim of this study was to examine the potential effects and 
mechanisms of action of cannabidiol and related phytocannabinoids on the 
function of microglial cells (nitric oxide formation) in vitro. 
2.3 Material and Methods 
2.3.1 Reagents 
The studies performed for this project included the use of 
phytocannabinoids and synthetic exogenous cannabinoid agonists and 
antagonists. All cannabinoids were purchased from Tocris Cookson (Bristol, 
UK) unless otherwise stated. Phytocannabinoids were a gift from GW 
Pharmaceuticals, (Salisbury, UK), GSK agonist and antagonist provided by 
Andrew Brown (Investigator in GlaxoSmithKline) and VSN16R (This 
compound tested by Prof David Baker (Barts and the London School of 
Medicine and Dentistry).  
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All other chemicals used in this work were purchased from Sigma-Aldrich 
Chemical Company (Poole, UK) or Tocris Bioscience (Bristol, UK). Plant-
derived and synthetic cannabinoid ligands were dissolved in ethanol to 10 
mM stock solutions except for the GSK agonist/antagonist. Ionomycin was 
dissolved in 50% DMSO and VSN16R and SNP, in media. All drugs were 
stored in stock solutions at 10 mM from which serial dilutions were made. 
Fluo-4-AM and pluronic acid were from Invitrogen (Carlsbad, CA), XAC 
(Tocris Bioscience, Bristol, UK), 1400W (Ascent Scientific). The maximum 
ethanol concentration used in this study was 0.01%.  
For cell activation, bacterial lipopolysaccharide (LPS) from Escherichia coli 
strain 0127: B8, was purchased from Sigma Aldrich (Poole, Dorset, UK).  A 
stock solution of 1mg/ml was made in complete growth medium and stored 
at -20°C. Working solutions of 100ng/ml were made from dilution of the 
stock solution for all experiments.  
2.3.2 Cell culture conditions  
The effects of cannabinoid drugs on LPS-induced NO generation were 
determined in BV2 mouse microglial cells (which have been extensively 
used for the study of microglial activity), in HAPI cells (an aggressively 
proliferating rat microglial cell line) and primary mouse microglia.  
All cell culture was performed under sterile conditions in class II, laminar 
air flow hoods; cells were generally passaged twice a week at a split ratio 
of 1:5. Almost confluent (BV-2 75-90%, HAPI cells, 70-80%; with 
passages number 10-25) cells were seeded into a new 75 mm culture 
flask. First the medium was removed and cells were washed with 10 ml 
phosphate-buffered saline (PBS). Approximately 10 ml of a trypsin/EDTA 
solution 1x (Invitrogen) was added and the flasks was incubated at 37°C 
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for 3-5 minutes to displace the cells. Trypsinization was inhibited by the 
addition of 10 ml growth medium. Cells were mixed well by pipetting up 
and down, and then pelleted by centrifugation (1300 x g, 5 minutes), re-
suspended in growth medium and seeded at the appropriate density. 
2.3.2.1 Cell counts 
The cell number was determined using a cell chamber haemocytometer. 
2.3.2.2 BV-2 cell line 
 BV-2 cells, a mouse microglial cell line, (a gift from Prof. Nephi Stella, 
Washington University, USA) werH JURZQ LQ 'XOEHFFR¶V 0RGLILHG (DJOH
Medium (DMEM) with Ham-F12 obtained sterile from Sigma, supplemented 
with penicillin (100 U/ml) / streptomycin (100 µg/ml) solution, HEPES (15 
mM), NaHCO3 (5mM), L-glutamine (2 mM) and 10% fetal bovine serum 
(FBS) which was heat inactivated. All cell culture solutions were stored at 
4ǎC and pre-warmed to 37ǎC in a water bath prior to use. The cells were 
grown to 95% confluence in 75cm2 flasks at 37°C with 5% CO2 and 95% 
atmosphere.   
2.3.2.3 HAPI cell line 
 HAPI cells, an aggressively proliferating rat microglial cell line employed as 
a model of activated microglia, were a gift from Dr J.R. Connor, 
3HQQV\OYDQLD6WDWH8QLYHUVLW\86$&HOOVZHUHH[SDQGHG LQ'XOEHFFR¶V
Modified Eagle Medium (DMEM) with 5% heat inactivated FBS, L-glutamine 
(2 mM), penicillin (100 U/ml) / streptomycin  (100 µg/ml) solution and 
maintained in a humidified incubator with 5% CO2 at 37
ǎC. 
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2.3.2.4 Primary mouse microglial cultures 
Two male adult 8-10 week old C57bl6 mice were deeply anesthetized with 
sodium pentobarbital, transcardially perfused with heparinised 1U/ml 0.9% 
saline and decapitated according to UK Home Office guidelines and the 
whole spinal cord (C1-S1) was dissected. The brain and spinal cord were 
put in ice cold Modified Hibernate A media (MHibA) ( trademark of Life 
Technologies) [20 ml Hibernate A, 0.4 ml B27 supplement, 50 µl 200 mM 
glutamine and 174 µl 454 mM EGTA]. 
Meninges were removed and the brain and spinal cord cut into 0.5 mm 
slices using a McIlwain tissue chopper. The tissue was incubated in MHibA 
containing (20 ml Hibernate A, 0.4 ml B27 supplement, 50 µl 200 mM 
glutamine and 174 µl, 454 mM EGTA plus papain 12 mg, Worthington) at 
30ǎC for 30 minutes on shaker. The tissue is allowed to settle for 5 
minutes, the media is removed and replaced by 2mls of DFP media (DMEM, 
glutamax-1, 15% heat inactivated fetal bovine serum and 1% penicillin, 
streptomycin). The tissue is quickly triturated 3 times using a 1ml pipette, 
the tissue is allowed to settle for 2 minutes, and the supernatant layer is 
removed and kept. The trituration process is repeated twice more; this 
results a total of 6mls of supernatant containing suspended cells. The cell 
suspension was centrifuged, and the pellet re-suspended in 1 ml of 15% 
FBS of DMEM (see above for details).  
Cell density is adjusted to 80,000 cells/ml. 500µl of the cell suspension is 
added to the wells, then the cells are incubated at 37oC with 5% CO2 for 
between 2 and 24 hours media from the wells was aspirated to remove 
additional debris and non-adherent cells, and then rinsed once with 500µl 
warm 15% FBS of DMEM media before finally replaced with another 500µl 
fresh warm 15% FBS of DMEM. The cells are incubated for a further 4 
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days. A purity of 99% microglia cells with little or no neuronal or astrocytic 
contamination can be achieved by this protocol. 
Our protocol contains several steps to prevent cellular contamination, 
which is important when there is a need to study pure microglia alone. 
Other monocytic linage cells such as circulating macrophages may be one 
potential contaminant of microglia cultures (Chan et al., 2007). This 
contaminant is removed by transcardial perfusion with heparinised saline. 
Other contaminants include neurones and astrocytes present in the spinal 
cord. However, under the conditions described in this study, no neurones, 
and very few astrocytes were observed. One possibility for the high purity 
obtained may be due to the absence of any substrata, such as poly-L-lysine 
or laminin which is often used to culture neurones and astrocytes due to 
their adhesive properties (Wong et al., 2006; Imura et al., 2006). We also 
suggest the limited astrocytic presence under our conditions may be due, 
at least in part, to the short time in culture, which reduces the possibility 
for these cells to proliferate. 
2.3.3 Nitric oxide (NO) assay 
In the Griess NO assay, BV-2, HAPI and primary mouse microglia cells 
were used. BV-2 or HAPI cells were plated onto 24 well plates (Costar, UK) 
at (5 x 105 cells/well) overnight. All cell culture was performed under 
sterile conditions in a laminar airflow hood.  The cells were activated by 
incubation with bacterial LPS (1 ± 4000ng) for 24 hours to choose an 
appropriate concentration. 100ng LPS was used in most experiments 
because this concentration did not adversely affect the viability of the cells. 
Cells were co-incubated with LPS and cannabinoids (over the concentration 
range 10nM-10µM). For experiments with the intracellular Ca2+ chelator 
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BAPTA-AM (10-50µM) and the microglial inhibitor minocycline (1-20µM), 
cells were exposed to the drug for 1 hour prior to LPS and/or cannabinoids.  
NO formation was monitored by measuring nitrite accumulation following 
the method of Griess (Green et al., 1982). After 24 hours of incubation, 
100µl of the cell culture supernatant from each well was collected and an 
equal volume of Griess reagent (2% sulfanilamide and 0.1% N-
naphthylethylenediamine dihydrochloride in 1mM HCL) was added after 10 
minutes and the reaction mixture incubated at room temperature. The 
standard curve for NO formation using a serial dilution of sodium nitrite 
standard ranging from 6.25 µM to 100µM is shown in (Figure 2.1). 
The optical density of the samples was determined spectophotometrically 
at 540 nm. Results are expressed as the means of 3 separate experiments, 
each performed in duplicate.  
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Figure 2.1:  Sodium nitrite standard curve in BV-2 cell media. Standards were 
measured using the Griess reaction as described in Methods. The figure represents 
means of three determinations. 
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2.3.4 Cell viability  
The Neutral Red (NR) cytotoxicity assay procedure is a measure of the 
ability of viable cells to incorporate and bind to the supravital dye NR in 
lysosomes. The cells were grown and treated using the same protocols to 
those used for measuring LPS-induced NO release or the effects of 
cannabinoids or other drugs. The 24 well plates were incubated for 1 hour 
with serum-free medium containing NR; the cells were subsequently 
washed twice with phosphate-buffered saline (PBS), the NR dye was 
extracted into fixative solution (50% ethanol, 45% water and 5% glacial 
acetic acid) and incubated for 1 hour. 200µl aliquots of desorbed NR were 
transferred to a 96 well plate and absorption was read 
spectophotometrically at a wavelength of 540 nm. 
2.3.5 Intracellular Ca2+ ([Ca2+]i) measurement using the 
Flexstation 
BV-2 cells were seeded onto black-walled, clear-bottomed, 96-well 
microtitre plates poly-L-lysine coated at 40,000 cells per well and allowed 
to proliferate overnight at 37 °C in 5% CO2 to achieve 95% confluence. 
The cells were loaded with 100µl/well of media containing Fluo4-AM (1µM), 
10% FCS, 2.5 mM probenecid and incubated in the dark at 37°C for 
45mins. Then the cells were washed twice with HEPES buffer saline (HBSS; 
25 mM HEPES, 10 mM glucose, 146 mM NaCl, 5 mM KCl, 1 mM MgSO4, 2 
mM sodium pyruvate, and 1.3mM CaCl2) containing 2.5 mM probenecid and 
incubated for 30 minutes at 37°C in the absence and presence of 
antagonists prior to monitoring intracellular calcium responses using a 
FlexStation II plate-reader (Molecular Devices, Sunnyvale, CA). 
Fluorescence was measured (excitation, 485 nm, and emission detected at 
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525 nm with a 515 nm cut off filter) every 1.52 second intervals for up to 
200 seconds.  Analysis of the data was conducted using SOFTmax PRO® 
Software. Responses to a positive control stimulant ( ǋ0 $73) were 
used to normalize responses across the plates. 
$VXEVHWRIH[SHULPHQWVLQYROYHGH[SRVXUHRIFHOOVWRǋ0$73; in these 
experiments, cells were incubated either with LPS (ǋJ or 100 ng) in the 
absence DQG SUHVHQFH RI ǋ0 %$37A-AM. Ionomycin was used as a 
positive control. 
2.3.6 Immunoblotting  
2.3.6.1 Whole Cell Protein Extraction and protein determination 
Whole cell protein lysates of BV-2 cells were used in immunoblotting 
assays. BV-2 cells (5 x 105 cells/well) were plated onto 24-well tissue 
culture plates and allowed to attach overnight. Triplicate wells of cells were 
treated with fresh media or treatments for the times indicated; BV-2 cells 
were then washed twice in cold PBS. The cells were suspended in cold lysis 
buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl and 1% NP-40) containing 1 
tablet of protease inhibitor cocktail (4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride (AEBSF), Bestatin hydrochloride, Leupeptin, E-64, 
Aprotinin, Pepstatin A, and Phosphoramidon disodium salt; Sigma) for 15 
minutes on ice. The lysed cells were centrifuged at 13,000g for 1 minute at 
4°C, and the supernatant (protein lysate) was collected and assayed for 
total protein.  
Lysed cell pellets were assayed for total protein content using the Lowry 
method (Lowry et al., 1951). Serial dilutions of standards were prepared by 
using 1 mg/ml BSA as a stock solution. 200µl of each standard 
concentration and 200µl of diluted samples were transferred into a new 
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microfuge tube. 1 ml of Lowry reagent was added into the samples and the 
standards. After 10 minutes 100 µl of Folin phenol reagent were added into 
the samples and standards left for 45 minutes. Then 200µl of samples, 
blank and standards were loaded in 96-well plate in triplicate. The 
absorbance was measured at 750 nm using a spectrophotometric plate 
reader (Dynatech Laboratories, MRX) with Dynex Revelation software. The 
protein concentrations were expressed in mg/ml. 
The supernatant fractions were kept in solubilisation buffer (2.5 ml Tris 
buffer, 2.0 ml glycerol, 2.0 ml 10% SDS, 2.5 ml DH2O, 1.0 ml 2-
mercaptoethanol and 40 µl 2.5% Bromophenol Blue). The samples were 
used immediately or stored at -20 C until needed. 
2.3.6.2 Cytoplasmic and Nuclear Protein Extraction  
Cytoplasmic and nuclear protein fractions were prepared from BV-2 cells 
(approximately 500,000). Cell pellets were re-VXVSHQGHG LQ  ǋO RI
hypotonic lysis buffer [10 mM HEPES (pH 7.9), 10 mM KCl, 1.5 mM MgCl2, 
0.1% NP40, and 5% protease inhibitor (0.2 mM DTT, 10 mM benzamidine, 
ǋJPOOHXSHSWLQǋJPOVR\EHDQWU\SVLQLQKLELWRUǋJPODSURWLQLQ
ǋJPOantipain, 0ǋJPOSHSVWDWLQPM phenylmethylsulfonyl fluoride, 
and 0.5 mM 4-(2-aminoethyl) benzenesulfonylfluoride)] and incubated on 
ice for 15 minutes, then briefly vortexed and centrifuged (16,000g) for 5 
PLQ DW ň 7KH VXSHUQDWant containing the cytoplasmic protein fraction 
was collected and stored at -80°C until used in experiments.  
The pellet containing nuclei was washed with hypotonic buffer and 
centrifuged (16,000g) for 5 minutes DW ň (3 times) and was re-
suspended in complete lysis buffered (1 mM DTT, lysis buffer AM1, 
protease inhibitor cocktail) and incubated on ice for 30 minutes.  Re-
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suspended nuclei were vortexed briefly and centrifuged (16,000g) for 5 
minutes, and these nuclear extracts were stored at -80°C until use. 
2.3.6.3 Gel electrophoresis 
The 10% sodium dodecyl sulphate (SDS) polyacrylamide gels were 
transferred into an electrophoresis tank (Bio-Rad, USA). The combs were 
removed from the gels and 500 ml electrophoresis buffer 1x (30.3g Tris, 
144g glycine and 10 g SDS in 1L distilled water) was added into the tank. 
ǋJRIGHQDWXUHGSURWHLQVDPSles were loaded into the wells with 2 µl of 
the All Blue standard molecular weight markers (Bio-Rad laboratories Ltd, 
UK); electrophoresis was conducted at 200 V for 45 minutes.   
1 membrane and 2 filter papers were placed in sequence in transfer buffer 
(30.3g Tris, 144g glycine dissolved in 8 litres distilled water, to which 
another 2 litres of methanol was added) and then the proteins were 
transferred at 100V for 60 minutes at 4ǎC using Bio-Rad kit. The protein 
transfer was checked by using a few drops of Ponceau S solution. The 
membranes were incubated with 5% fat-free dried milk powder in TBST 
(30.3g Tris, 73.12g NaCl, in 1L distilled water adjusted to pH 7.6 and then 
diluted to 10 litres with water and the addition of Tween 20 to a final 
concentration of 0.1%) on a shaker at room temperature for 60 minutes 
and then washed with 0.1% TBS-Tween twice.  
The indicated primary antibodies were diluted in 5% milk powder in TBST 
then the membranes with diluted primary antibodies and GAPDH were 
incubated in small plastic bags on a shaker at 4°C overnight.  The 
membranes were washed with TBS-Tween on a shaker at room 
temperature for 3 times of 10 minutes each and then incubated with 5% 
milk in TBST diluted [IRDye infrared LI-COR, USA] -secondary antibodies  
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(1:2000, dilution) goat anti-Rabbit IgG or goat- anti-mouse IgG with 
shaking for 1 hour at 37ǎC.  
The membranes were washed with TBS-Tween on a shaker at room 
temperature for 3 times of 10 minutes each. Then washed once with Milli-
Q-water and the blots were scanned using the Li-COR Odyssey Infrared 
Imaging system (Li-Cor Bioscience), in the 700 and 800 nm channels, with 
a resolution of 42 µm, quality, an intensity of 5, and focal offset of 2mm. 
The data were analyzed by Odyssey application software. The membranes 
were kept at 4°C for future reference. 
2.3.6.3.1 Antibodies Used  
Anti-ERK1/2 (1:1000), NF-KB, pNF-KB (1:1000, Signaling Technology, # 
,.%Į3-,.%Į&HOO6LJQDOLQJ7HFKQRORJ\
9246), JNK, P-JNK (1: 1000, , P-JNK (1: 1000, Life Technologies, # 44-
682G), iNOS (1: 1000; Cell Signaling Technology, #2977), COX 2 (1: 
1000, Cell Signaling Technology, #4812) and anti-GAPDH (1:2000, 
Sigma).  
2.3.7 Immunocytochemistry  
BV-2 cells (5 x 105) were seeded on poly-L-lysine-coated 13 mm glass 
coverslips and allowed to attach overnight in the conditioned medium. The 
following day, cells were serum-starved for 24 hours in a medium 
containing no fetal bovine serum (FBS), when indicated 10% FBS was 
added to other cells. The cells were incubated with medium alone or with 
LPS with or without drug for indicated times. Cells were fixed with 4% 
paraformaldehyde in phosphate buffered saline (PBS) for 30 minutes at 
room temperature, washed with PBS and then permeabilized using 0.1% 
Triton-X100 for 30 minutes.  
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Blocking of non-specific binding sites was performed by incubating cells 
with PBS containing 1% bovine serum albumin (BSA) for 1 hour at room 
temperature. Cells were incubated with the indicated primary antibody 
overnight at 4 °C.  
 After 3 times washes with PBS, FIT-C-conjugated goat anti-rabbit IgG 
(1:800) or FIT-C-conjugated goat anti-mouse IgG (1:500, both IgG from 
Jackson Immuno Research) was incubated for 1 hour at 37 °C.  To 
visualize all the cells present on coverslips, the cell nuclei were stained with 
4, 6-diamidino-2-phenylindole (DAPI, Molecular Probes) dye (1:1000) for 5 
minutes at room temperature. After extensive washing, coverslips were 
mounted with mounting medium without DAPI (Vectashield) and viewed 
through a 63 x glycerine immersion lens objective or 40 magnifications oil 
immersion with a Leica DMRA2 fluorescent microscope.  
Images were cropped and brightness and contrast were adjusted equally 
using Image J Software. The intensity of immunoreactivity was defined as 
the product of relative optical density (ROD) and area of immunoreactivity 
was measured using Image J Software and velocity Demo 6 software was 
used for confirmation. Negative controls without primary antibody were 
included to identify non-specific staining. 
2.3.7.1 Antibodies used  
GPR55; 1:250, Cayman Chemical, USA # 10225, iNOS 1:250, Cell 
Signaling Technology, NF-KB; 1:500, Cell Signaling Technology and LBɲ-1; 
1:100, alpha laboratories; # 019-19741, Hampshire, UK. 
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2.3.8 Dichlorofluorescein (DCF) assay 
To measure ROS released into the medium by the cells, a DCF (2Ļ7Ļ-
dichlorodihydro-fluorescein diacetate) assay was employed.  BV-2 cells 
were seeded in 24 well plates then loaded with 10µM of DCF in PBS for 30 
minutes in the dark at 37ǎC. Cells were washed twice with PBS then 
stimulated with LPS with or without CBD at different times and 
concentrations. At the end of the time course, cells were washed with PBS. 
The fluorescence of the supernatant was determined using a 
spectrofluorometer (Synergy-2 plate reader; BioTek Instruments Inc, 
Winooski, VT) with 485 nm excitation and 520 nm emission. 
2.3.10 Antioxidant effect of CBD 
BV-2 cells were cultured in 24 well plates then treated with 10µM CBD for 
24 hours before exposure to hydrogen peroxide for 2 hours in the presence 
and absence of CBD. Cell viability was measured using the Neutral Red 
(NR) assay. Fluorescence was measured at 540 nm in a microplate reader 
and normalized to the negative control. 
2.3.11 Reverse transcription polymerase chain reaction (RT-PCR) 
2.3.11.1 RNA extraction 
Cultured BV-2 cells (5 x 105 cells/ well) were plated onto 6-well tissue 
culture plates and incubated overnight until attached. Triplicate wells were 
treated with vehicle and CBD for 24 hours, cell cultures were washed twice 
with PBS.  
The BV-2 cell pellets were homogenized in lysis reagent (Tri-reagent®, 
Ambion, UK). The homogenate was incubated for 5 minutes on ice to 
promote a complete dissociation of nucleoprotein complexes before 
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addition of 1-bromo-3-chloro-propane (BCP) and centrifugation (10,000g 
for 15 minutes at 4 °C) to separate the mixture into an aqueous, RNA 
phase and an organic, protein phase separated by thin layer of DNA. The 
upper aqueous phase was used for RNA precipitation at 20 °C for 30 
minutes with 2 M sodium acetate and isopropanol at pH 4.  
The organic phase was kept at -80oC for further protein extraction. RNA 
was collected by centrifugation (10000 g for 15 min at 4 °C) and washed 
twice with 70% ethanol. 50 µl of DEPC-treated water was added to dissolve 
pellets; the concentration of total RNA and purity were assessed using a 
NanoDrop (ND-1000 Spectrophotometer, NanoDrop Technologies, USA) at 
260 nm.  
2.3.11.2 Complementary DNA (cDNA) synthesis  
5 µl (1 µg/µl) purified RNA was used to synthesis cDNA with superscript III 
reverse transcriptase (Invitrogen, UK) and another 5 µl underwent the 
same reaction but with superscript III reverse transcriptase replaced by 
HPLC water to generate a non-reverse transcriptase control (NRTs). To 
each 5 µl of RNA, 1 µl of random primer and 1 µl of dNTP were added, 
made up to a volume of 13 µl with 6 µl of HPLC grade water; the mixture 
was incubated at 65 °C for 5 minutes and quickly chilled on ice followed by 
addition of the following to make up the final reaction volume of 20µl (4 µl 
first strand buffer X5; 1 µl 0.1 M DDT; 1 µl RNAse inhibitor and 1 µl 
superscript III for cDNA sample or 1 µl NRTs sample). Finally, the mixture 
underwent an incubation period of 20 minutes at 37 °C then 60 minutes at 
50 °C and at 70 °C for 15 minutes. cDNA and NRTs synthesized were 
stored at -20 °C for future use. 
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2.3.11.3 Designing the Primers and Probe 
Primers for the target gene were designed using Primer Express 2 (Applied 
Biosystems, UK) following the PDQXIDFWXUHU¶V LQVWUXFWLRQV DQG SXUFKDVHG
through Eurofins MGW Operon. Primer and probe were ³blasted´ using the 
National Center for Biotechnology Information (NCBI) BLAST to ensure that 
the chosen sequence was specific for the gene of interest. Primer and 
probes were constituted and diluted to 10µM prior to use. Mouse actin, 
beta (ACTB) endogenous control (FAMTM Dye/MGB probe, Non-Primer 
limited) Part Number 4352933E from Applied Biosystems (UK) was used as 
control. 
Gene Primers sequence 
Mouse 
GPR55 
Forward Primer GAGCAGATATGGACTGCAGCTGCAA 
Reverse Primer      GAGGCACGAACATGA  
 Probe CCAGAGCGTGACAACTGCTCATTCGA 
2.3.11.4 Taqman Real-Time PCR 
A mix of cDNA from different samples of positive control was used to form 
the standard curve and 2 fold dilutions (1:2, 1:4, 1:8, etc) of each cDNA 
and non-template control to quantify relative concentrations of the target 
and reference genes in the samples, cDNA samples were diluted.  
A master mix prepared for the reference and target gene were calculated 
according to desired number of wells each containing a mix of Taqman 
master mix, forward primer, and reverse primer, probe and HPLC water. 10 
µl from this mix was added to each well of a 96 well reaction plate (Applied 
Bioscience, USA) then 3 µl from each cDNA sample or standard was added 
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in triplicate. The StepOne plus real time PCR system (Applied Biosystem, 
UK) was setup. 
2.3.12 [35S]-*73Ǆ6ELQGLQJDVVD\ 
Cannabinoid receptor-effector coupling efficiency was determined using the 
[356@*73Ǆ6ELQGLQJDVVD\IROORZLQJRSWLPLVDWLRQ (Happe et al., 2001). 
2.3.12.1 Reagents  
Tris, hydrated magnesium chloride (MgCl2.6H2O), bovine serum albumin 
(BSA), guanosine diphosphate (GDP), theophyliine and gXDQRVLQH Ļ->Ǆ-
WKLR@WULSKRVSKDWH WHWUDOLWKLXP *73Ǆ VDOW ZHUH SXUFKDVHG IURP 6LJPD
Aldrich (UK), sodium chloride (NaCl) from Fisher Scientific, [35S]guanosine 
5Ļ->Ǆ-thio]triphosphate was purchased from Perkin Elmer (MA, USA) and all 
cannabinoids used in this section were purchased from Tocris Bioscience 
(Bristol, UK). 
2.3.12.2 Brain membranes 
Membrane fractions were prepared using tissue from the whole rat brain. 
Rats were sacrificed by decapitation and brain was weighed and excess 
fluid was removed and homogenised in 10 ml of ice-cold Tris-Mg2+ buffer 
(50 mM Tris-HCl/3 mM MgCl2/1 mM EGTA, pH 7.4) using 10 strokes of a 
motor-driven ground glass pestle and homogenate was diluted to 10 
volumes of brain tissue with cold Tris buffer. The homogenate was 
centrifuged at 20,000g at 4 °C for 10 minutes, and the supernatant was 
removed. Samples were re-suspended in a further 20 x volume of 50mM 
Tris and the process repeated 4 times in total.  Following the final 
centrifugation step, samples were re-suspended to final concentration of 
2mg/ml and divided into 1 ml aliquots then stored at -Û&XQWLOQHHGHG
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Protein levels were determined using the Lowry method (Lowry et al., 
1951).  
2.3.12.3 [35S]-*73Ǆ6DVVD\ 
Using whole rat brain, homogenates were re-suspended in binding buffer 
(50 mM Tris, 100 mM NaCl, 10 mM MgCl2.6H2O, 0.2 mg/ml BSA in distilled 
water).  10 µg of brain membrane was added to each tube, 2 mM 
theophylline. [35S]-*73Ǆ6ELQGLQJDORQJZLWK0*'3RSWLPL]HGYDOXH
Figure 2.56). GDP was included in the assay to promote G protein 
inactivation. Increasing GDP decreased basal binding of [356@ *73Ǆ6 DQG
allowed a higher percent stimulation of binding by agonist (Breivgel et al., 
1998).  
6DPSOHVZHUHYRUWH[HGDQGLQFXEDWHGDWÛ&IRUPLQXWHV)ROORZLQJ
incubation, samples were separated into one of three conditions: basal, 
non-specific binding and drug-stimulated.  Each assay was conducted in 
triplicate for each drug concentration.  Drug buffer was added to basal 
VDPSOHV 0 XQODEHOOHG *73Ǆ6 WR QRQ-specific binding samples and 
different concentration range samples. All samples were subsequently 
incubated with 0.02 nM [35S]-*73Ǆ6 IRU  PLQXWHV LQ D VKDNLQJ ZDWHU
EDWKDWÛ&WRDWWDLQVWHDG\VWDWH)ROORZLQJLQFXEDWLRQWKHUHDFWLRQZDV
terminated by rapid filtration of membrane samples through a Brandel 
Tissue Harvester (Gaithersburg, MD, USA) onto Whatman GF/B glass-fibre 
filters (Clifton, NJ) for 4 times washing by cold distilled water. Filter discs 
were subsequently transferred to scintillation vials and covered with Ultima 
Gold XR scintillant (Perkin Elmer, MA, USA) and the radioactivity measured 
using a Packard Tri-Carb 2100 TR scintillation counter (Isotech, 
Chesterfield, UK) with a count time of 3 minutes.  
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2.3.13 Statistical analysis 
Data were collected from three or more independent experiments (using 
different passages of cells) and are expressed as mean ± S.E.M. Statistical 
analysis was performed, where indicated, using repeated measures one 
way ANOVA, with post-hoc %RQIHURQQL¶V PXOWLSOH FRPSDULVRQ WHVW RU D
'XQQHWW¶V post hoc analysis assessed using GraphPad Prism© version 5 
software (GraphPad Software, La Jolla, CA). Differences were considered 
statistically significant at pޒ0.05.   Prism was also used to fit sigmoidal 
curves to concentration-response data. 
[35S]-*73Ǆ6 GDWD DQDO\VLV WKH PHDQ ZDV FDOFXODWHG IRU WULSOLFDWHV 7KH
non-specific binding was measured which was subtracted from the total 
binding without drugs then calculated as dpm (every concentration) ± dpm 
(basal)/ dpm (total) %. The data are the mean of three independent 
assessments each performed in triplicate. Radioligand binding data were 
analysed by non-linear regression analyses, agonist concentration±effect 
curves using the software GraphPad Prism© version 5. The agonists 
increase nucleotide binding above basal levels, and therefore display 
percentage activation above 100%. Inverse agonists decrease nucleotide 
binding below basal levels and therefore give a percentage below 100%.  
Finally, neutral antagonists, that do not affect nucleotide binding, display a 
percentage activation of 100%. EC50 values were calculated for compounds 
which displayed a half affinity. 
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2.4 Results  
2.4.1 Characterization of LPS-evoked nitric oxide production in BV2 
cells  
 
 
2.4.1.1 The influence of LPS concentration, time, serum and 
minocycline  
The BV-2 mouse microglial cell line, which has been reported to express 
cannabinoid receptors (Walter, Franklin et al. 2003), was employed to 
investigate the effects of cannabinoids on NO formation.  BV-2 cells 
showed a concentration-dependent increase in NO formation in response to 
bacterial lipopolysaccharide (LPS) application (1ng-4µg/ml), measured by 
nitrite accumulation, in a concentration-dependent manner as shown in 
Figure 2.2; A. Maximum NO formation occurred between 24 and 30 hours 
of LPS exposure (Figure 2.2; B).  
The LPS-stimulated enhancement of nitrite accumulation was abolished in 
the presence of minocycline, a microglial inhibitor, in a concentration- 
dependant manner (5-20 µM) (Figure 2.3; A). LPS-stimulated NO formation 
was inhibited by approximately 50% when incubated in 5% serum-
containing media and was completely blocked in serum-free media (Figure 
2.3; B). Ethanol (0.01%) vehicle had no effect on basal or LPS-stimulated 
NO formation. 
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Figure 2.2: (A) Histogram represent the concentration-dependence of LPS 
effects on NO production in BV-2 cells. (B) Time-dependence of LPS effects on NO 
formation in BV-2 cells (by time). BV-2 cells (5 x 105 cells/well) were pre-treated 
with LPS at the indicated concentrations for the indicated time. Control wells were 
incubated in culture medium alone. Culture supernatant was assayed for nitrite 
levels using the Griess reagent. Data are mean ± SEM of triplicates from three 
separate experiments. Data were analysed using one-way ANOVA followed by 
'XQQHWW¶VWHVW3DQHO$DQG%S.01 compared with (C) control, ***p < 0.001 
compared with (C) control. 
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Figure 2.3: (A) Histogram represent the effects of a selective microglial inhibitor, 
minocycline, on LPS-mediated NO release in the BV-2 cell line. (B) Effect of fetal 
bovine serum (FBS) and ethanol (01%) on LPS-induced NO production in BV-2 
cells. BV-2 cells (5x105 cells/well) were pre-treated with minocycline at the 
indicated concentrations for 1 hour then incubated with LPS (100ng) for 24 hours. 
Control wells in culture medium 10% FBS (C) or at the indicated concentrations of 
FBS for 24 h. Culture supernatant was assayed for nitrite levels using the Griess 
reaction as described in Methods. The figure represents means ± SEM of triplicates 
of three independent experiments. Data were analysed using one-way ANOVA 
IROORZHGE\'XQQHWW¶VWHVWcompared with LPS alone. 
2.4.1.2 The influence of calcium ions  
BV-2 cells were incubated with BAPTA-AM (a cell-permeant calcium 
chelator) 40µM for 1 hour, then in the absence or presence of LPS 
(100ng/ml) for 24 hours and NO was measured by the Griess assay. 
BAPTA-AM alone had no effect but significantly reduced LPS-stimulated NO 
in a concentration-dependent fashion (Figure 2.4). To exclude any toxic 
effect of BAPTA-AM, cell viability was assessed using the Neutral Red 
assay. Cells were 98-100% viable under all conditions (data not shown). 
BV-2 cells were treated with different concentrations of the calcium 
ionophore ionomycin in the absence of LPS (24 hours) and release of NO 
was measured by the Griess assay. Ionomycin had no effect on microglial 
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NO formation (Figure 2.5), despite its ability to increase intracellular 
calcium concentration (Figure 2.6). 
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Figure 2.4: Histogram represents the effect of BAPTA-AM on LPS-induced NO 
formation. BV-2 cells (5x105cells/well) were pre-treated with BAPTA-AM (at 
indicated concentrations) 1 hour prior to LPS (100ng) or LPS alone, and then 
incubated for 24 hours. Culture supernatant was assayed for nitrite levels using the 
Griess reaction as described in Methods. The figure represents means ± SEM of 
triplicates of three independent experiments.  Data were analysed using one-way 
$129$ IROORZHG E\ 'XQQHWW¶V WHVW *P<0.01, LPS+BAPT-AM compared with LPS 
alone.   
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Figure 2.5: Histogram represents the effect of ionomycin-induced elevation of the 
basal Ca2+ on NO formation. BV-2 (5x105 cells/well) treated with different 
concentrations of ionomycin or LPS 100ng/ml 24 hours. Culture supernatant was 
assayed for nitrite levels using the Griess reaction as described in methods. The 
figure represents means ±SEM of triplicates of three independent experiments.  
Data were analysed using one-ZD\$129$ IROORZHG E\'XQQHWW¶V WHVW **P<0.01, 
compared with control. 
2.4.1.2.1The role of intracellular Ca2+ [Ca2+]i in microglial  
activation 
Intracellular Ca2+ concentrations [Ca2+]i in BV2 cells were assessed in the 
presence of  LPS and ionomycin and in the presence of the calcium chelator 
BAPTA-AM. There was a marked concentration-dependant increase in the 
levels of [Ca2+]i in the LPS-activated cells (Figure 2.6; A). Ionomycin (40 
µM) also increased [Ca2+]i and this was partially inhabited by BAPTA-AM 
(50 µm). In addition, ATP (100 µM), another widely employed microglial 
activator, significantly increased [Ca2+]i and this was, again, partially 
reduced by BAPTA-AM (10 µM) (Figure 2.6; B).  
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Figure 2.6: (A) Histogram shows the effect of LPS on [Ca2+]i in BV-2 (1x1o6 
cells/well). Cells were treated with LPS at indicated concentrations (10ng, 100ng 
and 1µg /ml). (B) Effect of ATP (100 µM) on [Ca2+]i in the presence or absence of 
BAPTA-AM (50µM) on [Ca2+]i in BV-2 cells and control cells (basal). Using fura-4-
based imaging, [Ca2] was measured at baseline (1¶¶-14¶¶), peak (15''-60''). The data 
represent means ±SEM of three independent experiments.  Data present as % 
basal values. Data were analysed using one-way $129$IROORZHGE\'XQQHWW¶VWHVW 
Panel A; **P<0.01 and ***P< compared with the control. Panel B; test 
***P<0.001 compared with control and *P<0.05 (ATP+BAPT-AM) compared with 
ATP alone. 
 
2.4.1.2 The involvement of inducible NOS 
1400W (a selective iNOS inhibitor (Jarvinen et al., 2008); 10µM) 
significantly attenuated NO formation in BV-2 cells (Figure 2.7; A). In order 
to characterize our model further, we tested dexamethasone, a synthetic 
glucocorticoid receptor agonist, reported to inhibit iNOS and NO production 
at 1 µM (Hamalainen et al., 2008).  Dexamethasone at 1µM reversed 
significantly LPS-induced NO release (Figure 2.7; B). 
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Figure 2.7: (A) Histogram shows the effect of 1400W, an iNOS inhibitor, on LPS-
induced NO production in BV-2 cells. (B) Effect of dexamethasone (DEX) on LPS-
induced NO production in BV-2 cells. BV-2 cells (5 x 105 cells/well) were pre-treated 
with 1400W (10µM) for 1 hour with and without LPS (100 ng/ml) for 24 hour or 
DEX. Control wells were incubated in culture medium alone. Culture supernatant 
was assayed for nitrite levels using the Griess reagent. Figure represents mean ± 
SEM of triplicates from three separate experiments. Data were analysed using one-
ZD\ $129$ IROORZHG E\ 'XQQHWW¶V WHVW Panel A **p < 0.01 compared with LPS 
alone.   
 
2.4.2 The effect of cannabinoid ligands on LPS-evoked nitric oxide  
               production in BV2 cells  
2.4.2.1 Endocannabinoids and related compounds  
A number of endocannabinoids and endocannabinoid-like compounds, N-
oleoyl- (OEA),  N-palmitoyl- (PEA), N-arachidonoylethanolamine (AEA), 2-
arachidonoyl-glycerol (2-AG) and N-stearoyl-ethanolamine (SEA), all at 10 
µM concentrations failed to alter significantly basal NO or LPS (100ng)-
evoked increases in NO formation (Figure 2.8). 
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Figure 2.8: Histogram shows the effect of endocanabinoids on LPS-induced NO in 
BV-2 cells. BV-2 cells (5 x 105 cells/well) were pre-treated with endocannabinoid-
like molecules N-oleoyl- (OEA),  N-palmitoyl- (PEA), N-arachidonoylethanolamine 
(AEA), 2-arachidonoyl-glycerol (2-AG) and N-stearoyl-ethanolamine (SEA), (all at 
10µM) for 1 hour before LPS (100 ng/ml) for 24 hour. Control wells were incubated 
in culture medium alone. Culture supernatant was assayed for nitrite levels using 
the Griess reagent. Figure represents means ± SEM of triplicates from three 
separate experiments. Data were analysed using one-way ANOVA followed by 
'XQQHWW¶VWHVWSFRPSDUHGZLWK/36DORQH. 
2.4.2.2 Cannabinoid receptor ligands  
On the other hand, the synthetic cannabinoid ligand, CP-55,940, and 
AM251 (CB1 antagonist and putative GPR55 antagonist) significantly 
attenuated LPS-induced NO release only at the highest concentration (10 
ǋ0ZKHQ/36100 ng/ml) was applied to the BV-2 cells for 24 hours. At 
WKHVDPHFRQFHQWUDWLRQǋ0WKHSK\WRFDQQDELQRLG-related ligand, HU-
210 and the CB2 receptor-selective agonist, JWH015, all failed to alter 
significantly LPS-evoked increases in NO formation. The CB1 and CB2 
receptor-agonist, WIN55212-2 and AM251 inhibited LPS-induced NO 
formation at 10µM (Figure 2.9 - 2.13). 
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Figure 2.9: Histogram shows the effect of CP-55,940 on LPS-induced NO in BV-2 
cells. BV-2 cells (5 x 105cells/well) were pre-treated with CP55940 at the indicated 
concentrations for 1 hour prior to LPS (100ng/ml). Control wells were incubated in 
culture medium alone. Culture supernatant was assayed for nitrite levels using the 
Griess reagent. Figure represents mean ± SEM of triplicates from three separate 
experiments. Data were analysed using one-ZD\$129$IROORZHGE\'XQQHWW¶VWHVW
**p < 0.01 compared with LPS alone.   
 
 
 
 
 
 
74 
 
C
LP
S 1
00
ng
LP
S+
AM
25
1 (1
0n
M)
LP
S+
AM
25
1 (1
00
nM
)
LP
S+
AM
25
1 (1
µM
)
LP
S+
AM
25
1 (1
0µ
M)
AM
25
1(1
0µ
M)
0.0
0.1
0.2
0.3
0.4
**
**
O
pt
ic
al
 
de
n
si
ty
 
54
0n
m
 
Figure 2.10: Effect of AM251 on LPS-induced NO in BV-2 cells. BV-2 cells (5 x 
105 cells/well) were pre-treated with AM251 at the indicated concentrations for 1 
hour prior to LPS (100 ng/ml). Control wells were incubated in culture medium 
alone. Culture supernatant was assayed for nitrite levels using the Griess reagent. 
Figure represents mean ± SEM of triplicates from three separate experiments. Data 
were analysed using one-ZD\ $129$ IROORZHG E\ 'XQQHWW¶V WHVW S  
compared with LPS alone.  
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Figure 2.11: Effect of HU-210 on LPS-induced NO in BV-2 cells. BV-2 cells (5 x 
105 cells/well) were pre-treated with HU-210 (10 µM) for 1 hour prior to LPS (100 
ng/ml). Control wells were incubated in culture medium alone. Culture supernatant 
was assayed for nitrite levels using the Griess reagent. Figure represents mean ± 
SEM of triplicates from three separate experiments. Data were analysed using one-
ZD\$129$IROORZHGE\'XQQHWW¶VWHVW**p < 0.001 compared with LPS alone. 
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Figure 2.12: Histogram shows the effect of JWH015 on LPS-induced NO in BV-2 
cells. BV-2 cells (5 x 105cells/well) were pre-treated with JWH015 at the indicated 
concentrations for 1 hour prior to LPS (100ng/ml). Control wells were incubated in 
culture medium alone. Culture supernatant was assayed for nitrite levels using the 
Griess reagent. Figure represents mean ± SEM of triplicates from three separate 
experiments. Data were analysed using one-ZD\$129$IROORZHGE\'XQQHWW¶VWHVW
**p < 0.01 compared with LPS alone.   
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Figure 2.13: Histogram shows the effect of WIN55212-2 on LPS-induced NO in 
BV-2 cells. BV-2 cells (5 x 105 cells/well) were pre-treated with WIN55212-2 at the 
indicated concentrations for 1 hour prior to LPS (100 ng/ml). Control wells were 
incubated in culture medium alone. Culture supernatant was assayed for nitrite 
levels using the Griess reagent. Figure represents mean ± SEM of triplicates from 
three separate experiments. Data were analysed using one-way ANOVA followed by 
'XQQHWW¶VWHVWS compared with LPS alone.   
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2.4.2.3 Phytocannabinoids  
A number of phytocannabinoids and their acids including cannabigerol 
(CBG), cannabidivarine (CBDV), tetrahydrocannabivarin (THCV), 
cannabidiolic-acid (CBDA) and cannabigerol acid (CBGA)] and THC, all 
failed to alter significantly LPS-stimulated NO formation in BV-2 cells at 
concentrations  of 10 µM (Figure 2.14 and 2.15). However, cannabidiol 
(CBD) also a putative GPR55 antagonist (10 µM) significantly inhibited LPS-
stimulated NO formation (Figure 2.16). HAPI cells (highly aggressive 
proliferating rat microglia) and primary mouse microglial cells were 
employed to confirm that the effects of CBD on NO release were not cell 
line-specific. HAPI cells and primary mouse microglial cells showed a 
significant increase in LPS-stimulated NO formation and this was inhibited 
by CBD (10µM) as shown in Figure 2.17. 
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Figure 2.14: Histogram shows the effect of phytocanabinoids on LPS-induced NO 
in BV-2 cells. BV-2 cells (5 x 105 cells/well) were pre-treated with 
phytocannabinoids; CBDV, CBDA, CBDG THCV and CBGA all at 10 µM) for 1 hour 
before LPS (100ng/ml) for 24 hours. Control wells were incubated in culture 
medium alone. Culture supernatant was assayed for nitrite levels using the Griess 
reagent. Figure represents mean ± SEM of triplicates from three separate 
experiments. Data were analysed using one-ZD\$129$IROORZHGE\'XQQHWW¶VWHVW 
***p < 0.001 compared with LPS alone. 
77 
 
Co
ntr
ol 1n
g
10
ng
10
0n
g
1u
g
4u
g
0.0
0.1
0.2
0.3
0.4
0.5
LPS
THC+LPS
O
pt
ic
al
 
D
e
n
si
ty
 
(54
0n
m
)
 
Figure 2.15: Histogram shows the effect of THC on LPS-induced NO in BV-2 cells. 
BV-2 cells (5 x 105 cells/well) were pre-treated with THC 10µM for 1 hour prior to 
LPS (10-4000 ng/ml). Control wells were incubated in culture medium alone. 
Culture supernatant was assayed for nitrite levels using the Griess reagent. Figure 
represents mean ± SEM of triplicates from three separate experiments. Data were 
analysed using Two-ZD\$129$IROORZHGE\'XQQHWW¶V WHVWSFRPSDUHG
with LPS alone.   
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Figure 2.16: Histogram shows the effect of CBD on LPS-induced NO in BV-2 cells. 
BV-2 cells (5 x 105 cells/well) were pre-treated with CBD 10µM for 1 hour with or 
without LPS (100 ng/ml) for 24 h. Control wells were incubated in culture medium 
alone. Culture supernatant was assayed for nitrite levels using the Griess reagent. 
Figure represents mean ± SEM of triplicates from three separate experiments. Data 
were analysed using one-ZD\ $129$ IROORZHG E\ 'XQQHWW¶V WHVW **p < 0.001 
compared with LPS alone.   
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Figure 2.17: Histogram shows the effect of CBD on LPS-induced NO in (A) HAPI 
cells (5 x 105 cells/well) (B) primary microglial mouse cells were pre-treated with 
CBD at 10µM concentrations for 1 hour prior to LPS 100 ng/ml. Control wells were 
incubated in culture medium alone. Culture supernatant was assayed for nitrite 
levels using the Griess reagent. Figure represents mean ± SEM of triplicates from 
three separate experiments. Data were analysed using one-way ANOVA followed by 
'XQQHWW¶VWHVW$S LPS+CBD compared with LPS alone; ***P <0.001 C 
(control). (B) **p< LPS+CBD compared with LPS alone; ***P <0.001 C (control). 
2.4.2.4 GPR55  
The actions of different putative GPR55 receptor ligands on LPS 
(100ng/ml)-stimulated NO formation were investigated. The putative 
GPR55 ligand VSN16R and O-1602 (both 10µM) were without effect (Figure 
2.18 and 2.19) as was the endogenous GPR55 activator 
lysophosphatidylinositol (LPI) and a novel GPR55 receptor agonist from 
GSK Pharmaceuticals also failed to significantly affect NO formation (Figure 
2.20 and 2.21), whereas a GSK-supplied selective GPR55 receptor 
antagonist, produced significant inhibitions of LPS-stimulated NO formation 
(Figure 2.22). 
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Figure 2.18: Effect of VSN16R on LPS-induced NO production in BV-2 cells. BV-2 
cells (5 x 105 cells/well) were pre-treated with VSN16R at 10µM for 1 hour prior to 
LPS (100 ng/ml) for 24 hours. Control wells were incubated in culture medium 
alone. Culture supernatant was assayed for nitrite levels using the Griess reagent. 
Figure represents mean ± SEM of triplicates from three separate experiments. Data 
were analysed using one-ZD\ $129$ IROORZHG E\ 'XQQHWW¶V WHVW S  
compared with LPS alone.   
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Figure 2.19: Histogram shows the effect of O1602 on LPS-induced NO release. 
BV-2 cells (5x105cells/well) were pre-treated with O1602 (10µM) for 1 hour with or 
without LPS (100 ng/ml) for 24 hours. Control wells were incubated in culture 
medium alone. Culture supernatant was assayed for nitrite levels using the Griess 
reaction as described in Methods. The figure represents means ±SEM of triplicates 
of three independent experiments. Data were analysed using one-way ANOVA 
IROORZHGE\'XQQHWW¶VWHVW ***P<0.001 compared with LPS alone.  
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Figure 2.20: Histogram shows the effect of LPI on LPS-induced NO release. BV-2 
cells (5x105cells/well) were pre-treated with LPI (10µM) for 1 hour with or without 
LPS (100 ng/ml) for 24 hours. Control wells were incubated in culture medium 
alone. Culture supernatant was assayed for nitrite levels using the Griess reaction 
as described in Methods. The figure represents means ±SEM of triplicates of three 
independent experiments. Data were analysed using one-way ANOVA followed by 
'XQQHWW¶VWHVW ***P<0.001 compared with LPS alone.  
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Figure 2.21: Histogram shows the effect of GSK agonist on LPS-induced NO 
production in BV-2 cells. BV-2 cells (5x 105 cells/well) were pre-treated with GSK 
agonist at the 10µm concentrations for 1 hour with or without LPS (100 ng/ml). 
Control wells were incubated in culture medium alone. Culture supernatant was 
assayed for nitrite levels using the Griess reagent. Data are mean ± SEM of 
triplicates from three separate experiments. Data were analysed using one-way 
$129$IROORZHGE\'XQQHWW¶VWHVWSFRPSDUHGZLWK/36DORQH 
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Figure 2.22: Histogram shows the effect of GSK antagonist on LPS-induced NO 
production in BV-2 cells. BV-2 cells (5 x 105 cells/well) were pre-treated with GSK 
antagonist 10µM for 1 hour with or without LPS (100 ng/ml). Control wells were 
incubated in culture medium alone. Culture supernatant was assayed for nitrite 
levels using the Griess reagent. Data are mean ± SEM of triplicates from three 
separate experiments. Data were analysed using one-way ANOVA followed by 
'XQQHWW¶VWHVWSFRPSDUHGZLWK/36DORQH; *p <0.05 LPS+GSK antagonist 
compared with LPS alone.   
2.4.2.5 GPR18 /abn-CBD  
The role of the GPR18 receptor on NO formation was examined using N-
arachidonoyl glycine (NAGLY), an endogenous metabolite of the 
endocannabinoid anandamide which acts as an agonist at GPR18 (McHugh 
et al, 2010), and 0-1918 which is an abn-CBD antagonist. NAGLY had no 
effect on LPS-stimulated NO release and O-1918 did not reverse the 
inhibition due to CBD (Figure 2.23; 2.24) suggesting that GPR18 and abn-
CBD have no role to play in the effects of the phytocannabinoid.  
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Figure 2.23: Histogram shows the effect of NAGLY, a GPR18 agonist. BV-2 cells 
(5x105 cells/well) were treated with NAGLY (10µM) 1 hour prior to LPS 100ng/ml 
for 24 hours. NO levels in supernatant were measured using the Griess reaction as 
described in Methods. The figure represents means ±SEM of triplicates of three 
independent experiments.  Data were analysed XVLQJ$129$IROORZHGE\'XQQHWW¶V
test. *** P<0.001 compared with LPS alone. 
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Figure 2.24: Histogram shows the effect of O-1918, a GPR18 antagonist, on CBD 
inhibition of NO induced by LPS. BV-2 cells (5x105 cells/well) were treated with 
O1918 1hour (10µM) then with CBD prior to LPS (100ng/ml) for 24 hours. NO 
levels in supernatant were measured using the Griess reaction as described in 
Methods. The figure represents means ±SEM of triplicates of three independent 
experiments. Data were analysed using one-way ANOVA followed by post-hoc 
BonferonQL¶VPXOWLSOHFRPSDULVRQWHVW301 LPS+CBD vs. LPS; not significant 
LPS+O-1918+CBD vs. LPS+CBD; ***p< 0.001 compared with LPS alone. 
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2.4.2.6 TRPV channels  
In order to test the possibility that CBD might exert its effect via TRP 
channels, the TRPV1 antagonist capsazepine (CPZ) and the non-selective 
TRP channel blocker ruthenium red (RR) were administered, at the 
indicated concentrations, prior to CBD and LPS.  Neither antagonist 
reversed the CBD inhibition of LPS-stimulated NO release (Figure 2.25).   
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Figure 2.25: Histogram shows the effect of TRPV channel blockade on CBD 
inhibition of NO in BV-2 cells. BV-2 (5x105 cells/well) were treated with RR a non-
selective TRP inhibitor (10µM) or with capsazepine (10µM) (TRPV1 antagonist) for 1 
hour then with CBD prior to LPS (100ng/ml) for 24 hours. NO levels in supernatant 
were measured using the Griess reaction as described in Methods. The figure 
represents means ±SEM of triplicates of three independent experiments.  Data 
were analysed using ANOVA followed by post-hoc BonferonQL¶VPXOWLSOHFRPSDULVRQ
test ***P<0.001 LPS+CBD vs. LPS alone; not significant LPS+CBD+RR vs. 
LPS+CBD; not significant LPS+CBD+Capz. vs. LPS+CBD. 
2.4.2.7 PPARs receptors  
The peroxisome proliferator-activated receptors (PPAR ɲ and Ȗ) play an 
important role in lipid metabolism and inflammation (Storer et al, 2005). 
Potential PPAR involvement in the effects of CBD was tested using 
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GW6471, a PPAR Į antagonist, and GW9662, an antagonist of PPAR-Ȗ. 
Neither antagonist reversed CBD-induced inhibition of LPS-stimulated NO 
release or altered basal NO levels in cells (Figure 2.26; A-B). 
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Figure 2.26: Histogram shows the effect of PPAR antagonists on NO release in 
BV-2 cells.  BV-2 cells (5x105 cells/well) were WUHDWHG ZLWK *: D 33$5Į
DQWDJRQLVWRUZLWK*:D33$5ǄDQWDJRQLVW µM), for 1 hour then treated 
with CBD prior to LPS (100ng/ml) for 24 hours. NO levels in supernatant were 
measured using the Griess reaction as described in Methods. The figure represents 
means ±SEM of triplicates of three independent experiments.  Data were analysed 
using one-way ANOVA followed by post-hoc %RQIHURQQL¶VPXOWLSOHFRPSDULVRQWHVW
(A) *P<0.05 LPS+CBD vs. LPS; ***P< 0.001 compared with LPS alone; (B) **p< 
0.01 compared with LPS alone; not significant compared with LPS+CBD. 
 
2.4.3 Characterization of CBD effects on LPS-evoked nitric oxide  
             production in BV2 cells  
2.4.3.1 Effect on Cell viability  
To investigate the potential non-specific toxicity of CBD on the viability of 
BV-2 microglial cells, 5x105 cells/well were incubated with LPS alone or 
with CBD in combination in the Neutral Red (NR) cell viability assay. LPS 
slightly reduced viability of BV-2 cells in a concentration-dependent manner 
and this was totally reversed by 10 µM CBD (Figure 2.27). To confirm this 
CBD-mediated protection against cell toxicity, we used H2O2 as a well-
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known cellular toxin. Remarkably, CBD again completely reversed the 
reduced cell viability due to H2O2 (Figure 2.28). 
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Figure 2.27:  Histogram shows the effect of LPS on BV-2 cell viability by NR 
assay. Cells were treated with LPS (100 ng) prior to CBD (10µM) for 1 hour. Control 
wells were incubated in culture medium alone after that media was removed and 
fresh media with NR was added for 1 hour then optical density at 540 nm. The 
figure represents means ±SEM of triplicates of three independent experiments.  
Data were analysed using two-way ANOVA post-hoc test ***P<0.001 CBD+LPS 
compared with LPS (4000ng/ml); *P< 0.05 CBD+LPS compared with LPS 1000 
ng/ml.  
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Figure 2.28: Histogram shows the effect of CBD on H2O2 toxicity in BV-2 cell 
viability by NR assay. Cells were pre-treated with CBD for 1 hour prior to H2O2 (100 
µM). Control wells were incubated in culture medium alone after that media was 
removed and fresh media with NR was added for 1 hour then optical density at 540 
nm. The figure represents means ±SEM of triplicates of three independent 
experiments.  Data were analysed using one-way ANOVA post hoc %RQIHURQQL¶V
multiple comparison test. *** P<0.01 compared with H2O2 alone. 
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2.4.3.2 Reactive oxygen species  
ROS generated from nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase (an enzyme that reduces O2 to superoxide (O2
±)). Activation of 
microglia leads to produce ROS (Mao et al, 2007). LPS-induced 
neurotoxicity was shown to be mediated through ROS-mediated microglial 
activation, the generation of microglial-derived extracellular neurotoxic 
ROS, and the amplification of microglial proinflammatory gene expression. 
Therefore, we investigated whether apocynin, a NADPH oxidase inhibitor, 
was able to reduce LPS-induced NO release in microglia. BV-2 cells were 
treated with apocynin in different concentrations 1 hour prior to LPS alone 
or together with CBD for 24 hours. Although apocynin did not alter the 
basal level of NO, it was able significantly to reduce the LPS response in a 
concentration-dependant manner (Figure 2.29). 
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Figure 2.29: Histogram shows the effect of apocynin, a NADPH oxidase inhibitor 
(10-20µM) treatment on CBD-mediated NO inhibition LPS-induced in BV-2. BV-2 
cells (5 x 105 cells/well) were pre-treated with apocynin (10-20µM) for 1 hour in 
presence or absent of LPS (100 ng/ml) and CBD (10 µM) for 24 hours. Control wells 
were incubated in culture medium alone. Culture supernatant was assayed for 
nitrite levels using the Griess reagent. Data were analysed using one-way ANOVA 
followed by post-hoc %RQIHURQQL¶V PXOWLSOH FRPSDULVRQ WHVW **P<0.01 compared 
with LPS alone; ***P<CBD+LPS+ apocynin compared with LPS+CBD. 
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2.4.3.3 cannabinoid receptor antagonists  
In this series of experiments, the cells were pre-incubated with either 
cannabinoid receptor antagonist or vehicle for 60 minutes followed by CBD 
for 30 minutes before exposure to 100 ng/ml LPS for 24 hours. Under 
these conditions, inhibition of nitric oxide release by LPS was not 
significantly attenuated by pre-incubation ZLWK  ǋ0 RI WKH &%1-selective 
receptor antagonist, SR141716A. The same concentration of the CB2-
selective receptor antagonist, SR144528, had no significant effect on the 
inhibition of nitric oxide release by LPS (data not shown). Neither 
antagonist had a significant effect on the inhibition of nitric oxide release 
E\/36QJPOZKHQDGPLQLVWHUHGDORQHQHLWKHUGLGǋ065$
(SR1) or SR144528 (SR2) have any significant effect on LPS-induced nitric 
oxide production (Figure 2.30).  
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Figure 2.30: Histogram shows the effect of CB1/CB2 antagonist treatment on 
CBD-mediated NO inhibition LPS-induced in BV-2. BV-2 cells (5 x 105 cells/well) 
were treated with  LPS (100 ng/ml) in presence or absence of CBD (A) CB1-
selective receptor antagonist, SR141716A (SR1) (B) CB2-selective receptor 
antagonist, SR144528 (SR2) at 1 µM concentrations for 24 hours. Control wells 
were incubated in culture medium alone. Culture supernatant was assayed for 
nitrite levels using the Griess reagent. Data were analysed using one-way ANOVA 
followed by post-hoc %RQIHURQQL¶V PXOWLSOH FRPSDULVRQ WHVW 3, 
**P<0.01compared with LPS alone; not significant compared with LPS+CBD. 
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2.4.3.4 Other receptors  
2.4.3.4.1 (5-HT) receptors  
CBD acts as an agonist at the human 5-HT1A receptor and this action could 
possibly be involved in the protective effect of CBD in ischemia (Russo et 
al., 2005; Mishima et al., 2005). We, therefore, tested the effects of the 
5-HT1A receptor antagonist (WAY 100635) on the CBD inhibition of LPS-
mediated nitric oxide release from BV-2 cells (Figure 2.31). The cells were 
incubated at 37°C for 1 hour with 10 µM WAY 100635, then for 30 
minutes ZLWK  ǋ0 &%' SULRU WR WKH DGGLWLRQ RI  ng/ml LPS for 24 
hours. WAY 100635 had no effect on basal levels, neither did it affect the 
inhibition of LPS-mediated NO formation by CBD. 
C
LP
S 1
00
ng
LP
S+
CB
D 1
0µ
M
LP
S+
CB
D+
WA
Y1
00
WA
Y1
00
 (10
µM
)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
*** **
ns
O
pt
ic
al
 
de
n
si
ty
 
54
0n
m
 
 
Figure 2.31: Histogram shows the effect of WAY100635 (a 5-HT antagonist) on 
CBD-inhibited NO formation induced by LPS. BV-2 cells (5x105cells/well) were per-
treated WAY100635 (10µM) for 1 hour with CBD (10µM) and with LPS (100ng) for 
24 hours. Control wells were incubated in culture medium alone.  Culture 
supernatant was assayed for nitrite levels using the Griess reaction as described in 
Methods. The figure represents means ±SEM of triplicates of three independent 
experiments. Data were analysed using one-way ANOVA followed by post-hoc 
%RQIHURQQL¶VPXOWLSOH FRPSDULVRQ WHVW. P***<0.001 and **P<0.01 compared with 
LPS alone; not significant compared with LPS+CBD. 
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2.4.3.4.2 Adenosine receptors  
We investigated the role of adenosine receptors on CBD inhibition of NO 
induced by LPS. Adenosine receptors have been shown to have both pro-
inflammatory and anti-inflammatory effects and to regulate the 
inflammatory process in the brain; moreover, CBD exerts anti-
inflammatory effects via blockade of adenosine uptake (Liou et al., 2008). 
We used the non-selective adenosine receptor antagonist xanthine amine 
congener (XAC) at 10 µM for 1 hour before CBD, followed by LPS 
(100ng/ml) for 24 hours. XAC failed to reverse the CBD inhibition of NO 
induced by LPS and did not affect the basal NO release (Figure 2.32). 
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Figure 2.32: Histogram shows the effect of xanthine amine congener (XAC), an 
adenosine receptor antagonist, on CBD-inhibited NO formation induced by LPS.  BV-
2 cells (5x105cells/well) were pre-treated XAC (10µM) for 1 hour with CBD (10µM) 
and with LPS (100ng) for 24 hours. Control wells were incubated in culture medium 
alone.  Culture supernatant was assayed for nitrite levels using the Griess reaction 
as described in Methods. The figure represents means ±SEM of triplicates of three 
independent experiments. Data were analysed using one-way ANOVA followed by 
post-hoc BonfHURQQL¶VPXOWLSOHFRPSDULVRQWHVW3FRPSDUHGZLWK/36QRW
significant compared with LPS+CBD. 
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2.4.3.4.3 Purinergic receptors  
We tested the potential involvement of P2X and P2Y receptors on microglial 
activation (NO formation) using ATP and UDP-glucose as stimuli. ATP (100 
nM to 400 µM) failed to induce nitric oxide release from BV-2 cells in 
comparison to LPS (100 ng/ml). It also failed to alter LPS-induced NO 
release Figures (2.33-A and B). Moreover, UDP-glucose did not attenuate 
the NO release from BV-2 cells (Figure 2.34). 
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Figure 2.33: Histogram shows the effect of different concentrations of ATP on NO 
production in BV-2 cells. BV-2 cells (5 x 105 cells/well) were pre-treated with LPS 
(100 ng/ml) and ATP at the indicated concentrations for 24 hours. Control wells 
were incubated in culture medium alone. Culture supernatant was assayed for 
nitrite levels using the Griess reagent. Figure represents mean ± SEM of triplicates 
from three separate experiments. Data were analysed using one-way ANOVA 
IROORZHGE\'XQQHWW¶VWHVW**p < 0.001 compared with (C) control.   
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Figure 2.34: Histogram shows the effect of UDP-glucose on NO production in BV-
2 cells. BV-2 cells (5 x 105 cells/well) were pre-treated with LPS (100ng/ml) and 
UDP-glucose at the indicated concentrations for 24 hour. Control wells were 
incubated in culture medium alone. Culture supernatant was assayed for nitrite 
levels using the Griess reagent. Figure represents mean ± SEM of triplicates from 
three separate experiments. Data were analysed using one-way ANOVA followed by 
'XQQHWW¶VWHVWSFRPSDUHGZLWK(C) control.   
 
2.4.3.5 The effect of pertussis toxin on CBD mechanism of action 
To further exclude any interaction with classical cannabinoid receptors and 
/or Gi/o protein-coupled receptors, in subsequent experiments, we pre-
treated cells with 50 ng /ml of PTX for 18 hours to inactivate susceptible G 
proteins. This did not impair CBD inhibition of NO formation induced by LPS 
(Figure 2.35). 
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Figure 2.35: Histogram shows the effect of PTX treatment on CBD-mediated NO 
inhibition LPS-induced NO in BV-2. BV-2 cells (5 x 105 cells/well) were pre-treated 
with 50 ng/ml PTX for 18 hours at 37°C then followed  with  LPS (100 ng/ml) in 
presence or absence of CBD 10  µM for 24 hours. Control wells were incubated in 
culture medium alone. Culture supernatant was assayed for nitrite levels using the 
Griess reagent. Figure represents means ± SEM of triplicates from three separate 
experiments. Data were analysed using one way ANOVA followed by post-hoc 
%RQIHURQQL¶VPXOWLSOHFRPSDULVRQ test. P***<0.001 compared with LPS alone; not 
significant compared with LPS+CBD. 
2.4.3.6 Kinases 
Previous evidence has shown that inhibition of different MAPK pathways is 
associated with decreases in LPS-induced NO production (Kaminska et al., 
2009). To further clarify which pro-inflammatory pathways might be 
involved in mediating the inhibition of LPS-induced NO by CBD, selective 
inhibitors for p38 MAPK (SB203580 10ǋM), a selective inhibitor of MEK-1/2 
(U0126 10 ǋM), PI3K inhibitor (wortmannin 10ǋM) and the Rho/Rock 
inhibitor (Y27632 10ǋM) were administered 1 hour before CBD with or 
without LPS stimulation for 24 hours (Figures 2.36 A- B -2.38). The results 
show that although SB203580 inhibited LPS-induced NO production, the 
p38 inhibitor was unable to block the inhibitory effects of CBD. These 
results suggest that p38 MAPK is associated with LPS-mediated NO 
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regulation. However, wortmannin, Y27632 and U0126 did not affect NO 
formation.  
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Figure 2.36: (A) Histogram shows the effect of P38 inhibitor (SB203580) 
treatment and (B) MEK1 (ERK 1/2) inhibitor (U0126) on CBD-mediated NO 
inhibition LPS-induced in BV-2. BV-2 cells (5 x 105 cells/well) were pre-treated with 
SB203580 or U0126 (10 µM) for 1 hour in presence or absence of LPS (100 ng/ml) 
and CBD (10 µM) for 24 hours. Control wells were incubated in culture medium 
alone. Culture supernatant was assayed for nitrite levels using the Griess reagent. 
Figure represents means ± SEM of triplicates from three separate experiments. 
Data were analysed using ANOVA followed by post-hoc %RQIHURQQL¶V PXOWLSOH
comparison test (A) *P<0.05 compared with LPS alone ***P< 0.001 (C) control vs. 
LPS alone and **P<0.01 vs. LPS+ CBD. (B) **p<0.01 LPS alone vs. (C) control, 
LPS+CBD. 
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Figure 2.37: Histogram shows the effect of PI3K inhibitor (wortmannin) 
treatment on CBD-mediated NO inhibition LPS-induced in BV-2. BV-2 cells (5 x 105 
cells/well) were pre-treated with wortmannin (10 µM) for 1 hour in presence or 
absence of LPS (100 ng/ml) and CBD (10 µM) for 24 h. Control wells were 
incubated in culture medium alone. Culture supernatant was assayed for nitrite 
levels using the Griess reagent. Figure represents means ± SEM of triplicates from 
three separate experiments. Data were analysed using one-way ANOVA followed by 
post-hoc %RQIHURQQL¶V PXOWLSOH FRPSDULVRQ WHVW 3 FRPSDUHG ZLWK /36
alone; not significant compared with LPS+CBD. 
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Figure 2.38: Histogram shows the effect of Rho/ROCK inhibitor (Y27632, 10 µM) 
treatment on CBD-mediated NO inhibition LPS-induced in BV-2. BV-2 cells (5 x 105 
cells/well) were pre-treated with Y27632 (10 µM) for 1 hour in presence or absent 
of LPS (100 ng/ml) and CBD (10 µM) for 24 hours. Control wells were incubated in 
culture medium alone. Culture supernatant was assayed for nitrite levels using the 
Griess reagent. Data were analysed using ANOVA followed by post-hoc %RQIHURQQL¶V
multiple comparison test **P<0.01 and **P<0.01 compared with LPS alone. 
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2.4.4 Characterization of CBD effects on LPS-evoked changes in  
 
           inflammatory markers 
 
2.4.4.1 iNOS expression  
Cannabidiol (CBD) at 10 µM significantly inhibited LPS-stimulated NO 
formation (see Figure 2.16). Using Western blotting, we found that LPS 
application (100ng/ml for 24h) significantly stimulated iNOS protein 
expression in BV-2 cells. CBD was able to significantly inhibit LPS-induced 
increases in expression at 1µM and completely blocked it at 10µM. In the 
presence of 1400W, a selective inhibitor of iNOS activity, (Saura, 2007) 
CBD significantly affected LPS-induced iNOS stimulation only at 10µM. 
there was a strong trend towards a reduction in the presence of 1 µM CBD. 
This was not apparently secondary to a reduction in iNOS activity since the 
iNOS inhibitor 1400W was without effect (Figure 2.39 A-B).  
In order to determine whether the increase in NO by LPS was due to 
enhanced iNOS expression; we tested the effect of various MAPK and 
NADPH oxidase inhibitors on BV2 iNOS expression. We examined the effect 
of the NADPH oxidase inhibitor (apocynin 15µM) on LPS-induced iNOS 
expression in BV-2 cells. LPS significantly stimulated iNOS protein 
expression at 5, 24 and 30 hours (Figure 2.40 A-B) and this was 
completely blocked by apocynin at 24 hours.  Also, to examine the role of 
MAPKs in /36¶V enhancement of iNOS expression, a variety of inhibitors 
(used in NO release experiments described earlier in this chapter) were 
employed. We found that SB203580, a P38 inhibitor, and wortmannin, a 
PI3K inhibitor, significantly reduced iNOS induced by LPS, whereas Y27632, 
a ROCK inhibitor, and U0126, a MEK 1/2 inhibitor, were not able to 
attenuate the LPS-mediated induction of iNOS protein (Figure 2.41 A-B). 
To confirm that the microglial cells had actually been activated to increase 
expression of iNOS, we used an immunohistochemical approach to visualize 
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iNOS expression in primary microglial and BV-2 cells. LPS enhanced iNOS 
expression in both cell types and this was completely reversed by CBD 
(Figure 2.42; A-C). To distinguish between microglia and other glial cells, 
LBɲ-1 a microglia marker was employed (Figure 2.42; D-F).  
 
 
Figure 2.39: Western blot and histogram show increase in the expression of the 
ratio of iNOS expression and GAPDH in whole cell lysates of BV-2 (20µg protein) at 
24 hours. BV-2 cells (5x105) treated with 1400W (10 µM) for 1 hour prior to CBD 
then stimulated LPS 100 ng/ml and control cell (basal) blots were incubated with 
Rabbit antibody to iNOS followed by IRDY®  conjugatesgoat anti-Rabbit IgG. (A) 
Histogram; Data shown are the mean of 3 experiments± SEM. (B) green presented 
of the iNOS at 130KDa, red is GAPDH. Data were analysed using one-way ANOVA 
followed by post-hoc %RQIHURQQL¶VPXOWLSOHFRPSDULVRQWHVW3 
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Figure 2.40: Western and histogram show the effect of apocynin on the ratio of 
iNOS expression and GAPDH levels in whole cell lysates of BV-2 cells (20µg 
protein). BV-2 cells (5x105) were treated with LPS 100 ng/ml at indicated times 
alone or with apocynin 15µM and control cell (C) blots were incubated with a rabbit 
antibody to iNOS followed by IRDY®  conjugatesgoat goat anti-Rabbit IgG. (A) 
Histogram; Data shown are the mean of 3 experiments± SEM. (B) Red bands 
represents iNOS 130 KDa, green is GAPDH. Data were analysed using one-way 
A129$ IROORZHGE\'XQQHWW¶V WHVW33FRPSDUHGZLWKFRQWURO3
LPA+apocynin compared with LPS alone. 
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Figure 2.41: Western and histogram show the effect of MAPKs on the ratio of 
iNOS expression and GAPDH levels in whole cell lysates of BV-2 cells (20µg 
protein). BV-2 cells (5x105) were treated with LPS 100 ng/ml or 10 ng/ml incubated 
at indicated times alone or with CBD (10 µM), p38 inhibitor SB203580 (10 µM),  
PI3K inhibitor wortmannin,  Y27632 and U0126 (all 10 µM)  for 24 hours and basal 
(vehicle) blots were incubated with rabbit antibody to iNOS  followed by IRDY®  
conjugatesgoat anti-Rabbit IgG anti-rabbit IgG. (A) Histogram; Data shown are the 
mean of 3 experiments± SEM. (B) Red represents GAPDH, green is iNOS. Data 
were analysed using one-ZD\$129$IROORZHGE\'XQQHWW¶VWHVW3DQG
*P<0.05 compared with control (C) or with LPS alone.  
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Figure 2.42: Immunocytochemstry shows the effect of CBD on iNOS expression 
induced by LPS in BV-2 and mouse primary microglial cells. (A) control  (B) LPS 
stimulated cells for 24 hours (C) Cells were pretreated with CBD for 1 hour before 
stimulation by LPS (100 ng/ml) for 24 hours (D) primary microglia control (E) LPS 
stimulated cells for 24 hours (F) Cells were pretreated with CBD for 1 hr before 
stimulation by LPS (100 ng/ml) for 24 hrs. (A-B) Green; iNOS and Blue; DAPI (40 
x), (D-)*UHHQL1265HG/%Į-1 microglia marker and Blue DAPI nucleus (40 X 
magafication). 
2.4.4.2 Reactive Oxygen Species (ROS) 
It is reported that many stress factors, including oxidative stress, lead to 
inflammation. Therefore, to test whether both apocynin and CBD were 
capable of reducing ROS production in BV-2 after stimulation with LPS, we 
determined ROS formation after 100 ng/ml LPS treatment in the presence 
and absence of CBD. The DCF assay (Keston and Brandt, 1965) showed 
that stimulation of the cells with LPS resulted in time- and concentration-
dependent increases in ROS (30 minutes); gradually increasing at 60 
minutes (Figure 2.43; A-B). Pretreatment of BV-2 cells with either 10 µM 
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CBD or apocynin (15 µM; a selective NADPH oxidase assembly inhibitor) for 
1 hour prior to LPS (100 ng/ml) for 24 hours, significantly reduced ROS 
formation (Figure 2.44; A). To investigate the effect of CBD on ROS 
formation at different times, we also treated BV2 cells with CBD for 1 hour 
prior to LPS and LPS alone (Figure 2.44; B). DCF assay showed that 
stimulation of the cells with LPS caused increases in ROS formation 
whereas CBD  ǋ0 VLJQLILFDQWO\ UHGXFHG /36-induced superoxide 
formation at 30 minutes. In contrast, CBD alone stimulated basal ROS 
formation, (Figure 2.44; 
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Figure 2.43: Histograms show the effect of LPS on ROS formation in BV-2 by DCF 
assay. BV-2 (5x105 cells/well) treated with LPS 100ng/ml or vehicle for indicated 
time.  Maximal ROS formation and then intracellular ROS level was quantified using 
DCF assay (A):  LPS concentration response data. (B) LPS time dependence. Data 
shown are the mean ±SEM of 3 samples. Data were analysed using ANOVA 
followed by post-hoc %RQIHURQQL¶V PXOWLSOH FRPSDULVRQ WHVW 3 FRPSDUHG
with control (A and B). 
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Figure 2.44: Histograms show the effect of CBD on LPS-induced ROS in BV-2 by 
DCF assay. BV-2 (5x105 cells/well) treated with CBD (10 µM) for 1 hour, followed 
by vehicle or LPS 100ng/ml for indicated time.  Maximal ROS formation and then 
intracellular ROS level was quantified using DCF assay (A) Comparison of ROS 
formation measured by DCF assay on BV-2 cells pretreated with CBD at 1 hour, 
apocynin, and treated with vehicle (control) or LPS 100ng/ml.  (B) Effect of CBD on 
LPS-induced ROS at indicated time. Data shown are the mean ±SEM of 3 samples. 
Data were analysed using one-way ANOVA or Two-way ANOVA followed by post-
hoc BonferoQQL¶VPXOWLSOHFRPSDULVRQ WHVW $3 LPS+CBD compared with 
LPS alone; **P< 0.01 LPS+Apocynin vs. LPS alone; *P< CBD vs. control. (B)***P< 
CBD+LPS compared with LPS alone; *p< 0.05 LPS+CBD vs. LPS alone. 
2.4.4.3 COX-2 expression  
The effects of LPS on cyclooxygenase 2 (COX-2) activity were investigated 
by Western blot analysis. Under basal conditions, microglial cells did not 
appear to express COX-2, but protein levels were significantly increased by 
24 hours stimulation in the presence of LPS. CBD completely reversed the 
LPS-mediated COX-2 induction (Figure 2.45; A, B). 
102 
 
 
Figure 2.45: Western blot and histogram show increase the expression of ratio of 
COX-2 expression to GAPDH levels in whole cell lysates of BV-2 (20µg protein) at 
24 hours. BV-2 cells (5x105 cells/ell) treated with LPS 100 ng/ml incubated at times 
alone or with CBD 10 µM or vehicle. Blots were incubated with rabbit antibody to 
COX-2 followed by IRDY® conjugates goat anti-Rabbit IgG. (A) Histogram; Data 
shown are the mean of 3 experiments± SEM. (B) Red represents GAPDH; green is 
COX-2 at 74KDa. Data were analysed using one-way ANOVA followed by 
%RQIHURQQL¶VPXOWLSOH FRPSDULVRQ WHVW3/36DORQH FRPSDUHGZLWK FRQWURO
(C); *P<0.05 LPS+CBD compared with LPS alone.  
2.4.4.4 MAPK activation  
MAPKs are thought to be important in the signaling pathways that control 
the production of pro-inflammatory mediators by activated microglia and 
LPS activates MAPK signal-transduction pathways (Hill and Treisman, 
1995). Therefore, we investigated the potential effects of CBD on 
phosphorylation/activation of the MAP kinases P38, JNK, and ERK in 
response to LPS in BV-2 cells by Western blot analysis. 
103 
 
Stimulation of cells with LPS resulted in increased phosphorylation of all 
three MAPKs, and this peaked at 30-60 minutes. We investigated also the 
effect of LPS on P38 activation (phosphorylation) at early times (15, 30 and 
1 hour and at 24 hours. LPS stimulated P38 activation at 30 minutes until 
24 hours and, CBD 10 µM significantly inhibited P38 activation induced by 
LPS at 30 minutes and at 24 hours (Figure 2.46-2.47; A-B).  
Moreover, we investigated if reactive oxygen species (ROS) and SB203580 
had any effect on activation of the P38 MAPK pathway induced by LPS in 
BV-2 cells. The NADPH oxidase inhibitor (15 µM), added 60 minutes before 
stimulation with LPS for 24 hours, significantly inhibited LPS-induced P38 
activation (Figure 2.47; A-B). 
Using Western blotting, protein bands representing ERK1/2 and 
phosphorylated ERK were detected at 44/42 KDa, Figure 2.48 showed that 
LPS activated ERK1/2 significantly at 15 and 30 minutes. But CBD failed to 
activate phospho-ERK or total ERK and the phospho-ERK/ERK ratio (Figure 
2.49). To verify the role of the endogenous GPR55 ligand LPI on ERK 
phosphorylation as positive control for ERK 1/2 activation in BV-2, Figure 
2.49 shows that p-ERK/ERK ratio following treatment with LPI was 
activated. We examine the role of CBD and LPS on c-Jun N-terminal 
kinases (JNKs/SAPKs). We collected samples at different time points 
ranging from 15 minutes-24 hours. Western blot analysis showed that LPS 
triggered an early (30 minutes) increase in the activation of stress-
activated JNKs/SAPKs. CBD (10µM) inhibited LPS-induced JNK 1/2 
phosphorylation in BV-2 cells (Figure 2.50). 
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Figure 2.46: Western blot and histogram show increase the ratio of phospho-P38 
to total P38 expression in whole cells lysates (20µg protein) of BV-2 cells by LPS 
and inhabited by CBD. BV-2 cells (5x105) were treated with LPS 100 ng/ml alone 
and CBD at indicated concentrations alone or with LPS or basal (control) for 24 
hours. Blots were incubated with P38 antibody followed by IRDY® conjugates goat 
anti-mouse and anti-rabbit IgG. (A) Histogram; Data shown are the mean of 3 
experiments± SEM (B) Red represents total P38, green is phospho-P38. Data were 
analysed XVLQJ $129$ IROORZHG E\ 'XQQHWW¶V WHVW  3 DQG 3
compared with basal; ***p<0.001 LPS+CBD compared with LPS alone.  
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Figure 2.47: Western blot and histogram show increase the ratio of phospho-
P38 to total P38 expression in whole cells lysates at 30 and 60 minutes (20µg 
protein) E\/36DW´DQG´DQG LQKDELWHGE\ SB203580 and apocyanin. BV-2 
cells (5x105) treated with LPS 100 ng/ml incubated at indicated times alone or with 
P38 inhibitor SB203580 10µM or with apocyanin 10µM or control (C) and blots were 
incubated with P38 antibody followed by IRDY® conjugates goat anti-mouse and 
anti-rabbit IgG. (A) Histogram; Data shown are the means of 3 experiments± SEM. 
(B) Red represents total P38, green is phospho-P38 at 38KDa. Data were analysed 
XVLQJ$129$ IROORZHGE\'XQQHWW¶V WHVW3DQG3 FRPSDUHGZLWK
(C) control or **p<0.01 with LPS alone.  
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Figure 2.48: Western blot and histogram show the increase the ratio of phospho 
ERK 1/2 to total ERK 1/2 expression in whole cell lysates by LPS (20µg protein) of 
BV-2 E\ /36 DW ´ DQG  KUV. BV-2 cells (5x105) were treated with LPS 
(100ng/ml) or basal for indicated times. Blots were incubated with mouse antibody 
to ERK 1/2 followed by IRDY® conjugates goat anti-mouse and anti-rabbit IgG. (A) 
Histogram Data shown are the mean of 3 experiments± SEM. Two way ANOVA 
post-hoc Test; **p < 0.01 LPS vs.  basal (control) ; (B) ERK1/2, at 44 KDa and 
42KDa.  
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Figure 2.49 Western blot and histogram show the increase of phasoho-ERK 1/2 
and the ratio phospho ERK 1/2 to total ERK 1/2 expression in whole cell lysates BV-
2 E\ /3, DW ´ %9-2 cells (5x105) were treated with CBD (10µM) for indicated 
times and LPI (10 µM). Blots were incubated with mouse antibody to ERK1/2 
followed by IRDY®  conjugates goat anti-mouse and anti-rabbit IgG. (A) Histogram 
data shown are the mean of 3 experiments± SEM. Two way ANOVA post-hoc 
Test**p< 0.01 LPI vs. Basal (B) ERK 1/2 at 44 KDa and 42K Da. 
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Figure 2.50: Westren blot and histogram show increase of the ratio of phaspho 
JNK 1/2 to total JNK 1/2 expression in whole cell extracts of BV-2 cells by LPS at 
´ DQG ´ DQG LQKDELWHG E\ &%' DW WKH VDPH WLPHV (5x105) treated with LPS 
(100 ng/ml) alone or with CBD 10 µM for indicated times or control (C). Blots were 
incubated with mouse antibody to JNK1/2 followed by IRDY® conjugates goat anti-
mouse and anti-rabbit IgG.  (A) Data is the mean of 3 experiments± SEM, Two way 
ANOVA post-hoc Test***p < 0.001 LPS alone vs. control; **p < 0.01 LPS+CBD at 
(30 and 60 mins) vs. LPS alone.  (B) Red presented of the total JNK1/2, green is 
phospho JNK1/2. 
2.4.4.5 NFkB/IkB alpha expression  
NF-ǉ% LV DQ LPSRUWDQW WUDQVFULSWLRQ IDFWRU LQ WKH UHJXODWLRQ RI SUR-
inflammatory mediators and enzymes; including iNOS (Xie et al., 1994). It 
can be activated by LPS or inflammatory cytokines. We analyzed NF-ǉ%
activation by measuring (using immunocytochemistry) the levels of the p65 
subunit upon cell stimulation by LPS.  Induction of the p65 subunit was 
investigated because p65 plays a major role in NF-ǉ% activation and 
function, and it contains the transactivation domain responsible for the 
transcriptional activity of NF-ǉ% LPS treatment induced the nuclear 
translocation of p65 NF-ǉ%within 1 hour of incubation.  
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Exposure of BV2 cells to LPS resulted in intensified nuclear staining, 
compared with the diffuse cytosolic staining in untreated cells. In the un-
stimulated condition, NF-kB p65 protein was mainly located in the 
cytoplasm and there was little staining for p65 in the nuclei (Figure 2.51; 
A). In microglial cells that were activated by LPS increased NF-kB nuclear 
translocation was observed (there are more yellowish areas visible in the 
nucleus than in the cytoplasm (Figure 2.51; B). Pretreatment with CBD 
inhibited this LPS-induced nuclear translocation of p65 NF-Ʈ%)LJXUH
C). 
To confirm the inhibitory effect of CBD on the LPS-induced nuclear 
translocation of NF-ǉ% LPPXQREORWWLQJ ZDV FRQGXFWHG ZLWK ZKROH FHOO
lysates and nuclear fractions (Figure 2.52-2.53). NF-kB is a heterodimeric 
cytosolic protein which, in resting cells, is kept inactive by binding with a 
PHPEHU RI WKH ,N%Į LQKLELWRU SURWHLQ IDPLO\ (O'Neill and Kaltschmidt., 
1997)$IWHUSKRVSKRU\ODWLRQ,N%ĮLVXELTXLWLQ\ODWHGDQGGHJUDGHGE\WKH
proteasome system and NF-KB can translocate to the nucleus promoting 
transcription of a number of pro-inflammatory proteins including iNOS. We 
first determined the time course RI ,.%Į SKRVSKRU\ODWLRQ in whole cell 
lysates. For these experiments BV-2 cells were treated with LPS 100 ng/ml 
for 5, 15, 30 and 60 minutes. We found that LPS significantly activated 
,.%ĮZLWKLQPLQXWHV(Figure 2.54).  
Results from these cytosolic analyses demonstrated that phosphorylation of 
,.%ĮDWKRXUVZDVQRWGHWHFWDEOHLQXQVWLPXODWHGFHOOVRUDIWHUH[SRVXUH
to CBD alone (Figure 2.55 3KRVSKRU\ODWLRQ RI ,.%Į RFFXUUHG XSRQ /36
stimulation and the level of phosphorylation was inhibited in cells pre-
treated with CBD. These results suggest that the inhibitory effects of CBD 
on NF-ǉ%IXQFWLRQDUHGHSHQGHQWRQ,.%Į 
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Figure 2.51: Immunocytochemistry; Inhibition of LPS-induced NF-KB by CBD in 
BV-2 cells (A) control (B) LPS 100ng/ml stimulated cells for 1 hour (C) Cells were 
pretreated with CBD for 1 hour before stimulation by LPS (100 ng/ml) for 1 hr. 
Untreated cells displayed diffuse cytoplasmic staining, whereas intensified staining 
in the nucleus was observed in LPS-treated cells is indicative of NF-ǉ% QXFOHDU
WUDQVORFDWLRQ3UHWUHDWPHQWRIFHOOVZLWK&%'ǋ0DWWHQXDWHGWKH/36-induced 
translocation of NF-ǉ%  Three independent experiments were analysed by Velocity 
Demo 6 software. Green p-NF-Ʈ%5HGWRWDO1)-ǉ%DQGEOXH'$3, 
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Figure 2.52: Western blot and histogram show increase of phaspho-NF-KB and 
the ratio of phosphor-NF-KB to total NF-KB expression of nuclear lysates of BV-2 
cells (protein 5µg) at 1hour by LPS and inhabited by CBD. BV-2 cells (5x105  
cells/well) were treated with LPS 100 ng/ml alone or with CBD (10 µM) or basal 
(control) for 1 hour prior stimulated with LPS) for 1 hour. Blots were incubated with 
mouse antibody to NF-KB followed by IRDY® conjugates goat anti-rabbit and anti-
mouse IgG.  Red represents the total NF-KB, green is phospho-NF-KB. Data shown 
are the mean of 3 experiments ±SEM, Data were analysed using one-way ANOVA 
IROORZHGE\'XQQHWW¶V test * *P<0.01 compared with basal and *P<0.05 with LPS 
alone.  
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Figure 2.53: Western blot shows both total NF-KB and phospho-NF-KB 
expression in whole lysis of BV-2 (protein 20µg) at 24 hours. BV-2 cells (5x105) 
treated with LPS 100 ng/ml alone or with CBD (10 µM for 1 hour prior stimulated 
with LPS (100ng/ml) for 24 hours or basal cell blots were incubated with mouse 
antibody to NF-KB followed by IRDY®  conjugates goat anti-rabbit and anti-mouse 
IgG. LPS activated NF-KB, CBD treatment prior to LPS inhibits NF-KB. Red 
represents the total NF-KB, green is phospho NF-KB. 
 
Figure 2.54: Western blot and histogram show the increase the phospho-,.%Į
and the ratio of phospho-,.%Į WR total ,.%Į expression in cytoplasmic lysates of 
BV-2 (protein 20µg) by LPS. BV-2 cells (5x105 cells/well) treated with LPS (100 
ng/ml) or vehicle at indicated times. Blots were incubated with mouse antibody to 
,.%Į followed by IRDY® conjugates goat anti-rabbit and anti-mouse IgG.  Red 
UHSUHVHQWVWKHWRWDO,.%ĮJUHHQLVSKRVSKR ,.%ĮDQG\HOORZERWK'DWDVKRZQDUH
the mean of 3 experiments± SEM. Data were analysed using one-way ANOVA 
IROORZHGE\'XQQHWW¶VWHVW33/36FRPSDUHGZLWK&FRQWURO 
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Figure 2.55: Western blot shows the total of ,.%Į and phospho-IKBĮ expression 
of cytoplasmic lysates (protein 20µg) of BV-2 at 24 hours. BV-2 cells (5x105 
cells/well) treated with LPS 100 ng/ml alone or with CBD (10 µM) or control for 1 
hour prior stimulated with LPS (100ng/ml) for 24 hours. Blots were incubated with 
mouse antibody to ,.%Į followed by IRDY® conjugates goat anti-rabbit and anti-
mouse IgG. LPS activated IKBܤ &%' WUHDWPHQW SULRU WR /36 LQKLELWV ,.%Į 5HG
presented of the total IKBܤ, green is phospho IKBܤ and yellow both. 
 
2.4.5 Molecular investigation of BV2 cells  
2.4.5.1 GTP gamma S binding  
In order to further confirm the activity of cannabinoids in rat whole brain 
membranes, experiments of [356@*73Ǆ6ELQGLQJDVVD\ LQ WKLV WLVVXHZHUH
carried out.  
2.4.5.1.1 Optimization of assay method 
First, we tested the requirement of GDP to find the proper amount required 
for activation of [35S]-*73Ǆ6 ELQGLQJ DVVD\ LQ WKH ZKROH UDW EUDLQ
membrane using different concentrations of GDP (0-40µM) in the presence 
and absence of an effective concentration of the cannabinoid receptor 
agonist HU-210 (Figure 2.56).   The percentage stimulation of [35S]-*73Ǆ6
binding by HU-210 was increased by increasing concentration of GDP, up to 
a maximum of 215% at 46 µM GDP.  
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Figure 2.56: Histogram shows HU210 (10 µM)-induced [356@*73Ǆ6ELQGLQJZLWK
increasing GDP concentration (mean ± SEM). Percentage binding above basal 
elicited by the cannabinoid receptor agonist HU210 to cannabinoid receptors in the 
brain membrane higher concentrations of GDP produce greater binding. 
2.4.5.1.2 7KHHIIHFWRIVDSRQLQLQ*73Ǆ6ELQGLQJDVVD\V 
We investigated the role of saponin in the activation of the [35S]-*73Ǆ6
binding assay in whole rat brain membranes using different concentrations 
of saponin (3-1000nM) in the presence and absence of an effective 
concentration of HU210 (10µM) (Figure 2.57) the stimulation of [35S]-
*73Ǆ6ELQGLQJZDVLQFUHDVHGDIWHUWUHDWPHQWZLWKVDSRQLQ 
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Figure 2.57; HU-210 (10 µM)-induced [35S]-*73Ǆ6 ELQGLQJ to rat brain 
membranes with increasing saponin concentrations (mean ± SEM 3 indepandent 
expriments). Percentage binding above basal elicited by the cannabinoid receptor 
agonist HU-210 was enhanced with higher concentrations of saponin. 
2.4.5.1.3 Effects of cannabinods ligands on [356@*73Ǆ6 
The actions of different putative GPR55 receptor ligands on [35S]-*73Ǆ6
binding were investigated), As shown in Figure (2.58; A), CP-55,940 
(cannabinoid CB1/CB2 receptor agonist and putative GPR55 antagonist), as 
expected, was able to stimulate [356@*73Ǆ6ELQGLQJWRWKHZKROHUDWEUDLQ
membranes, with an EC50 value of -8; %127.7, which was not different to 
the previous reported in [35S]-*73Ǆ6ELQGLQJ 
HU-210 increased the binding of [35S]-GTPǄS in the rat whole brain 
membrane the percentage of basal binding the agonists (CB1/CB2) HU-210 
(EC50; -8.6; %133.5) (Figure 2.58; B). Conversely, cannabidiol (CBD) (EC50 
-7.6; % 89.55), in the same experimental conditions, was unable to 
stimulate or inhibit [356@*73Ǆ6ELQGLQJDWDQ\RIWKHFRQFHQWUDWLRQVWHVted 
(Figure 2.58; C). These results rule out the ability of CBD, in this range of 
concentrations, to directly bind to and activate CB1 or CB2 receptors. 
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The activation of cannabinoid receptors with Win55-212, a CB1/CB2 agonist 
with uncertain GPR55 activity also stimulated [356@ *73Ǆ6 ELQGLQJ LQ UDW
brain membranes (EC50; -8; %151.9) (Figure 2.58; D). 
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Figure 2.58; Histograms show the effects of cannabinoids on [35S]-*73Ǆ6
binding in rat brain membranes. Membranes were incubated with 0.05nM [35S]-
GTPǄS and 20 µM GDP as described in Methods, with various concentration of (A) 
CP-55,940, (B) HU210, (C) CBD, (D) WIN55212-2. Data are expressed as 
percentage basal [35S]-*73Ǆ6 ELQGLQJ DQG UHSUHVHQW PHDQ YDOXHV  6(0 IURP
three separate experiments. 
2.4.5.2 GPR55 and cannabinoids receptors expression  
2.4.5.2.1 Cannabinoid receptors expression in BV-2 cells  
The expression of CB1 and CB2 receptor mRNA in BV-2 cells was measured 
by RT-PCR. Mouse brain and CHO cells transfected with CB2 receptors were 
employed as positive controls for CB1 and CB2 in BV-2 cells. The RT-PCR 
results showed no measurable expression of CB1 or CB2 mRNA in BV-2 cells 
(Edeeb, 2009). 
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2.4.5.2.2 Expression of GPR55 receptors in BV-2 
Using RT-PCR, we found that GPR55 mRNA was present in BV-2. 
Interestingly, CBD inhibited GPR55 mRNA expression after 24 hours 
exposure; mouse brain was used as a positive control in this experiment 
(Figure 2.59). 
In order to validate this finding, BV-2 cells were stained with a GPR55 
antibody using an immunocytochemistry approach. GPR55 receptor-like 
immunoreactivity was observed in unstimulated BV2 cells (Figure 2.60; A); 
furthermore, immunoreactivity  was increased in cells stimulated with 
100ng LPS for 24 hours (Figure 2.60; B) and this was  partially reversed by 
pre-treatment with CBD (Figure 2.60; C).  
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Figure 2.59: mRNA expression levels of GPR55 receptor by RT-PCR in mouse and 
BV-2 cells. RNA was extracted using Trizole reagent and RNA samples were reverse 
transcribed using the superscript reverse transcription. Data are mean ±SEM of 
triplicate determinations of GPR55/mouse actin ratio. Data were analysed using 2-
tailed t -test *P<0.05 compared with the basal. 
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Figure 2.60: Images show the effect of CBD on GPR55 expression in BV2 cells 
shown by immunofluorescent staining (A) control (B) LPS stimulated cells for 24 
hours (C) Cells were pretreated with CBD for 1 hr before stimulation by LPS (100 
ng/ml) for 24 hrs (D) mean of fluorescent GPR55 intensity of three independent 
experiments were analysed by Volocity Demo 6 software. Untreated cells showed 
small amounts of cytoplasmic staining, whereas intensified staining in the 
cytoplasm was observed in LPS-treated cells indicative of GPR55 receptor 
activation. 3UHWUHDWPHQW RI FHOOV ZLWK &%'  ǋ0 DWWHQXDWHG WKH /36-induced 
activation of GPR55 (40 X). 
2.5. Discussion  
The anti-inflammatory and immunosuppressive properties of cannabinoids 
have been reported to modulate the immune function of macrophages and 
macrophage-like cells such as microglia (Cabral and Griffin-Thomas, 2008). 
However, the mechanisms of these actions are not fully known. Microglia 
become fully activated upon infection or injury and are able to elicit a 
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whole host of immune responses, including releasing pro-and anti-
inflammatory chemokines, cytokines, reactive nitrogen species and other 
factors may be beneficial or damaging (Waksman et al., 1999). Microglia 
DUH DOVR DFWLYDWHG DIWHU H[SRVXUH WR /36 LQWHUIHURQ RU ǃ-amyloid protein 
(Zielasek and Hartung, 1996).  
Nitric oxide (NO) plays a role in host defense against intracellular 
pathogens but, at the same time, may also contribute to 
neurodegeneration and neuronal damage (Molina-Holgado et al., 2002). 
We used lipopolysaccharide (LPS) as a microglial activator and release of 
pro-inflammatory NO as an end-point of activation.  
The BV-2 cell line used in the study possesses functional and phenotypic 
properties common to primary microglia including phagocytic ability, 
secretion of pro-inflammatory cytokines and expression of surface 
receptors and antigens (Blasi et al., 1990) and, as such, is a suitable in 
vitro model for investigation of microglial function. Upon LPS stimulation, 
NO release from BV-2 cells was observed at 6 hours post-stimulation and 
more robustly at 24 and 30 hours, after which, 24 hours was the time point 
used in all subsequent LPS-stimulation studies. The results of the NO assay 
showed that basal NO formation was more pronounced with adult mouse 
microglial cells when compared with BV-2 cells and HAPI cells.  
In order to validate our BV-2 model, the effects of ethanol and serum-free 
medium were examined; ethanol failed to significantly affect LPS-induced 
NO in BV-2. When BV-2 cells were cultured in serum free medium, they 
showed retracted processes and nitric oxide release by LPS was not 
apparent in contrast to cells cultured in 5-10% serum-containing medium. 
It, therefore, appears that the LPS-induced NO release requires a serum 
protein in the medium. LPS binds to the serum protein LPS-binding protein 
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(LBP), which facilitates binding to CD14; LPS/LBP complexes bind to CD14, 
which interacts with Toll-like receptor 4 (TLR4) to activate the cells and 
stimulate NF-KB (Haziot et al., 1996; Wright et al., 1990; Schumann et al., 
1990). 
As a control we investigated the effect of minocycline on microglial 
activation; minocycline is a second generation tetracycline which inhibits 
NO formation by blocking iNOS or P38 and it has been reported as an anti-
inflammatory agent (Tikka and  Koistinaho, 2001). Minocycline reversed 
the NO release in LPS-stimulated BV-2 in a concentration-dependent 
manner. The effects of minocycline as a microglial inhibitor have been 
documented previously (Wu et al., 2002). 
In this work, we have focused on the effects of LPS as a representative 
inflammatory stimuli. Treatment of microglial cells with LPS alone induced 
NO production. Sodium nitroprusside, (SNP) a NO donor was used to 
investigate the effects of NO on activation of microglia. Our data indicate 
that exogenous NO did not modulate the microglia, at least in the BV-2 cell 
line. Therefore, this is not likely to be the main mechanism to activate 
microglia in NO production. Since, in several cell types, iNOS is responsible 
for the high-output production of NO after exposure to LPS (Bogdan, 
2001). 
In order to confirm our model, dexamethasone (DEX) and 1400W were 
also examined. Dexamethasone is able to prevent LPS-induced NO 
formation in microglial BV-2 cells (Hinkerohe et al., 2010). DEX may 
decrease iNOS mRNA/protein expression by inhibition of NF-KB (Golde et 
al., 2003; Bauer et al., 1997). Moreover, 1400W attenuated NO formation 
in BV-2 cells. These results indicate that iNOS was the likely enzyme 
responsible for LPS-induced NO production. 
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To test the mechanism of LPS-activated NO release; the role of calcium 
was examined. Using BAPTA-AM (a cell-permeable Ca2+ chelator) a 
concentration-dependent attenuation in NO production was seen consistent 
with previously reported calcium-dependency (Hoffmann et al., 2003; 
Toescu et al, 1998). However, despite this apparent calcium dependency of 
the LPS activation of NO release, direct elevation of intracellular Ca2+ using 
ionomycin failed to increase NO release from BV-2 cells, indicating that LPS 
signaling requires other elements in addition to elevation of intracellular 
Ca2+ as suggested previously (Hoffmann et al., 2003).  
The aim of this chapter was to investigate the effects of cannabinoids on 
NO release (as a measure of microglial activation). In order to examine the 
role of cannabinoid (CB1, CB2) receptors in inhibition of lipopolysaccharide 
stimulated nitric oxide release in BV-2 microglia. Various cannabinoid 
receptor ligands were examined. Waksman et al (1999) reported an 
inhibitory effect of the CB1/2 agonist CP55,940 on endotoxin/cytokine-
activated NO formation in rat cortical microglial cells mediated by CB1 
receptors, but in the present study, CP55,940 was only effective at 10µM, 
well above the concentration range selective for CB1 activation (Ross et al., 
2000; Pertwee, 1997) and its effect was not inhibited by a CB1 antagonist. 
However, CP55,940 is also reported to be an agonist of the GPR55 receptor 
(Ryberg et al., 2007).  
Also AM251 (CB1 antagonist and putative GPR55 agonist) inhibited NO 
induced by LPS in BV-2 at micromolar concentrations, which indicated that 
it acts via GPR55 (Kapur et al., 2009; Pertwee, 2007). It was somewhat 
unexpected that none of the cannabinoid receptor agonists in 
concentrations expected to activate CB receptors affected LPS-stimulated 
NO formation, but it is clear that, under the culture conditions employed, 
the BV-2 cells failed to express either CB1 or CB2 receptors significantly. It 
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does seem that BV-2 cell expression of CB receptors is not well maintained 
with increasing passage number (Stella, personal communication) which 
might explain this deficit. Facchinetti et al., (2003) have reported that only 
micromolar concentrations of CP55, 940, WIN55, 212-1 regulate cytokine 
release from cultured microglia which is consistent with our data.  
In the present study, the phytocannabinoids CBG, CBDV, THCV, CBDA, 
CBGA and THC (is the main psychoactive component of marijuana) were all 
without effect. However, CBD attenuated LPS-induced NO formation. The 
phytocannabinoid cannabidiol (CBD) is widely reported to have anti-
inflammatory properties (Tubaro et al., 2010) although its mechanism of 
action is unclear; it has also been reported to be a GPR55 antagonist 
(Ryberg et al., 2007).  
The pharmacology of the GPR55 receptor is controversial with no well 
characterized selective ligands; nevertheless, we sought to investigate the 
role of GPR55 receptors in inhibition of LPS-stimulated nitric oxide 
formation in BV-2 microglia using various cannabinoids and other putative 
GPR55 receptor ligands.  A novel selective GPR55 agonist (a gift from GSK) 
failed to produce significant inhibition consistent with the similar lack of 
effect of the synthetic agonists VSN16R and putative GPR55 agonist O-
1602 and the endogenous GPR55 activator lysophosphatidylinositol (LPI). 
Interestingly, given that CBD is reported to be an antagonist of GPR55 
(Ryberg et al., 2007), a novel GPR55 antagonist (also from GSK) also 
inhibited LPS-induced NO release. Whether this indicates that LPS releases 
an endogenous GPR55 agonist that mediates its effects seems unlikely 
since other agonists did not increase NO formation and an off-target effect 
of the GSK antagonist is possible. 
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Neither LPI nor O1602, another GPR55 agonist (Johns et al., 2007), 
affected LPS-stimulated NO formation lending little support to the 
possibility that the effect of CBD is GPR55-mediated. Nevertheless, it is 
conceivable that the GPR55 receptors in the BV-2 are constitutively 
activated and that CBD acts as a GPR55 antagonist/inverse agonist under 
the prevailing culture conditions. In support of this model, Oka et al., 
(2010) reported that LPI enhances activity of P38 MAP kinase (Obata et al., 
2000).  We found by immunobloting, that LPI activated ERK 1/2 in BV-2 
cell line this finding to support that GPR55 is target receptor (Kapur et al., 
2009). 
To evaluate the effects of cannabinoids on NO production and hence 
microiglial activation, a number of endocannabinoids, 
arachidonoylethanolamide (AEA), and endocannabinoid-like compounds 
(palmitoylethanolamide (PEA), oleoylethanolamide (OEA) were studied. All 
failed, however, to inhibit LPS-induced NO formation. PEA is a potent anti-
inflammatory and GPR55 ligand (Mackie and Stella, 2006). This result 
argues the involvement of GPR55 receptor. 
CB receSWRU DJRQLVWV GLG QRWKLQJ DQG DQWDJRQLVWV GLG QRW UHYHUVH &%'¶V
effects and crucially, despite previous reports of CB receptors in BV 2 cells, 
there was no CBR expression by RT-PCR. Furthermore, CBD in the present 
study was found not to be a CB1 agonist because it failed to enhance brain 
*73Ǆ6ELQGLQJDOWKRXJKRWKHU&%DJRQLVWVGLG 
When CBD was given alone without LPS it did not alter the basal level of 
NO formation. The GPR55 receptors in the BV-2 cells appeared to be 
functional since the putative endogenous agonist LPI (Oka et al., 2007) 
produced a concentration-dependent elevation of intracellular Ca2+ which 
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was attenuated by CBD (Eldeeb et al., 2009), in agreement with its 
designation as a GPR55 antagonist.  
It is possible that the inhibition of NO production in LPS stimulated cells 
could be ascribed to cytotoxic effects of CBD; however, there were only 
very minor reductions in cell viability at high CBD concentration and in fact, 
CBD provided remarkable protection against toxic challenge by hydrogen 
peroxide. 
CBD has been frequently described as a potent neuroprotective and anti-
oxidant agent, which reduces glutamate excitotoxicity and peroxide-
induced oxidative neuronal damage (Hampson et al., 1998). Lastres-
Becker et al., (2005) have reported that, in animal models of Parkinson's 
disease, there is an improvement of toxic effects of 6-hydroxydopamine by 
administration of CBD as a result of anti-oxidative effects.  
The neuroprotective effects of a non-psychoactive cannabinoid, cannabidiol 
(CBD), are reported to be largely mediated by its ability to scavenge 
reactive oxygen species (ROS) (Mechoulam et al., 2007). ROS can also 
function as second messengers to regulate several downstream signaling 
molecules, including mitogen-activated protein kinase, and PI3K/Akt 
pathways (Kwon et al., 2004). 
We examined the effect of NADPH oxidase enzyme activity of LPS±treated 
microglial cells. LPS appears to stimulate NO formation via ROS as its 
effects are blocked by apocynin. Previous studies have reported that 
microglial NADPH oxidase can regulate the bioavailability of NO and the 
production of peroxynitrite (Bal-Price et al., 2001).  
CBD also blocked LPS stimulated ROS formation despite having a positive 
effect alone (the mechanism is unclear but it is partially consistent with an 
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anti-oxidant effect of CBD). CBD has been shown to be effective in 
attenuating oxidative and nitrosative stress in a number of disease models 
(Booz, 2011). Both apocynin and CBD blocked LPS-mediated enhancement 
of iNOS expression showing that the effects of CBD appear to be at the 
level of iNOS expression and not via regulation of NO availability. Although 
its mechanism of action is uncertain, it is possible that CBD may act 
directly at the level of the mitochondrion or nucleus to oppose or promote 
oxidative/nitrosative stress in a cell type-selective manner. There is 
evidence that, in some systems, ROS at lower, non-toxic levels can actually 
enhance cell proliferation and survival (Blanchetot and Boonstra, 2008). 
Therefore, the inhibitory effect CBD on LPS stimulated NO was was not due 
to any cytotoxic action on BV-2 microglia. Although neither cannabinoids 
nor cannabinoids-related receptors were implicated in the effect. In this 
study, neither CB1 nor CB2 receptors were seen to be expressed in the BV-
2 cells. Furthermore, there was no evidence for the involvement of 5-HT, 
adenosine, PPARs and TRPVs receptors. Furthermore, the PTX data argue 
against the involvement of any Gi/o linked GPCR. 
There is evidence to show the involvement in microglia activation of purine 
receptors such as P2X7 receptors, whose activation is considered a strong 
inflammatory stimulus (Skaper et al., 2006; Inoue, 2008). Our data show 
that ATP failed to induce nitric oxide release in BV-2 cells, consistent with 
previous studies showing that ATP alone did not alter iNOS activation, but 
enhanced IFN-Ǆ induced iNOS in BV-2 cells (Ohtani et al., 2000). It is likely 
that ATP itself does not have a direct effect on microglial processes, and 
that other signaling is required (Inoue et al., 1998). However, high 
concentrations of ATP have been shown to stimulate inducible nitric 
synthase mRNA leading to NO release from rat microglia through P2X7 
receptors (Ohtani et al., 2000; Honda and Kohsaka, 2001).  
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Another purine receptor P2Y14 has recently been found to be expressed by 
BV-2 cells (unpublished data, Eldeeb and Hassan) so its potential role in 
activation of microglia and LPS-induced release of NO was examined. UDP 
glucose, a selective agonist for P2Y14 (Malin and Molliver, 2010) failed, 
however, to alter NO production.  
Cannabidiol is remarkable in the diversity of its actions on receptor and 
non-receptor targets when employed in the micromolar concentration 
range (Pertwee, 2004; 2008). Whilst BV-2 cells are widely used as a 
surrogate model for studying microglial function it is worth remembering 
that the microglial phenotype is very plastic and that differences do exist 
compared with microglia in primary culture and adult brain. Thus, it could 
be argued that the effects of CBD described here are relevant only to BV-2 
cells and not to microglia in general. However, it is notable that in a very 
different cell line, HAPI (highly aggressively proliferating immortalized rat 
brain microglia) (Cheepsunthorn et al., 2001), CBD also inhibited LPS-
activated NO formation and, indeed its potency, seemed to be somewhat 
greater in the primary microglial cells. 
Consistent with the report from Pietr et al., (2009) describing GPR55 
expression in both primary microglial and BV-2 cells we were also able, 
using RT-PCR to show that GPR55 mRNA was expressed with reasonable 
quantity in BV-2 when compared with rat brain . Although no evidence was 
found implicating GPR55 in the effect of CBD on NO formation, it is 
interesting that LPS increased GPR55 expression in BV-2 cells and CBD was 
able to reduce it. What the functional significance of this might be requires 
further investigation.  
The radiobinding assay demonstrate a wide range of activities, ranged from 
the highly potent and efficacious through to compounds displaying little or 
127 
 
weak- dependent stimulation of [356@*73ʖ6 ELQGLQJ 2I WKH UDQJH RI
compounds tested; WIN 55212±2, CP55, 940, HU210, and CBD. WIN 
55212±2 was selected as a standard cannabinoid receptor agonist, acting 
as a potent full agonist, in many different assays (Howlett, 1995; Martin et 
al., 1995). It also displays a high affinity for both subtypes of cannabinoids 
receptor CB1/CB2 (Pertwee, 2006). The results obtained confirmed 
previous finding that WIN55212-2 stimulated [356@*73ʖ6ELQGLQJ%XUNH\
et al., 1997). 
Similar experiments were performed using CP55,940, an identical result 
was observed a full agonist at potency lower than previous reports at 
CB1/CB2. It has not been shown to have any significant effect on CB1 and 
CB2 receptor signaling (Ryberg et al., 2007).  
Evidence has shown that inhibition of different MAPK pathways is 
associated with decreases in LPS-induced NO production (Kaminska et al., 
2009). Therefore, we investigated MAPKs involvement in NO formation in 
BV-2 cells. In the present study, the effect of CBD was independent of 
particular kinase signaling pathways including MEK 1/2, PI3K, Rho/ROCK 
pathways suggesting that these may not be important downstream TLR4 
targets in NO release by LPS. These results are supported by recent studies 
using Rho/ROCK pathway inhibitors showing that the Rho-dependent 
activation of ROCK kinase has structural effects but is not involved in 
functional signaling including attenuation of NO or cytokine release 
(Hoffman et al., 2008).  However, some evidence was gathered showing 
involvement of p38 MAPK (which can be activated by microenviromental 
stress and regulates inflammatory cytokines release (Rajesh et al., 2008)) 
in the LPS-dependent release of NO. LPS enhanced p38 activation and this 
was reduced by CBD. However with regard to NO formation both CBD and 
128 
 
the p38 inhibitor SB203580 reduced the effects of LPS and their effects 
were additive, possibly suggesting independent actions. 
We evaluated the effect of LPS and CBD on ERK1/2 and JNK/SAPK 
signaling, in this study, LPS activated ERK1/2, JNK/SAPK and p38 MAPK in 
a time dependent manner. CBD failed to inhibit ERK1/2, whereas it did 
inhibit JNK/SAPK and p38 MAPK. It has been documented that JNK is an 
essential mediator of relevant pro-inflammatory function in microglia 
(Waetzig et al., 2005) and inhibition of this pathway may be a therapeutic 
approach for treating inflammatory neurological disease (Borsello and 
Forloni, 2007). Immunoblotting analysis showed that LPS treatment 
induced a time-dependent enhancement of P38 protein phosphorylation at 
30 minutes with a further increase at 60 minutes and this was attenuated 
by 10 µM SB03580 and 15 µM apocynin, a NADPH oxidase inhibitor. 
Oxidative stress and pro-inflammatory cytokines have been previously 
reported to activate the MAP kinases including P38 (Obata et al., 2000). 
Indeed, in this study, 10µM CBD inhibited LPS-induced P38 phosphorylation 
as suggested by Esposito et al., (2006). P38 MAPK has been implicated in 
the regulation of pro-inflammatory cytokines and apoptosis in vitro (Walton 
et al., 1998).  
The NF-ǉ% SDWKZD\ LV D SULPDU\ LQWUDFHOOXODU SDWKZD\ FRQWUROOLQJ WKH
transcription of many inflammatory genes (Rothwarf and Karin, 1999). The 
NF-ǉ% S-p50 protein complex is present in the cytoplasm through 
DVVRFLDWLRQ ZLWK WKH LQKLELWRU SURWHLQ ,ǉ% ZKLFK PDVNV WKH QXFOHDU
localization signal present within the NF-ǉ%SVXEXQLW7KHDFWLYDWLRQRI
NF-ǉ%E\H[WUDFHOOXODUVWLPXODWLRQGHSHQGVRQWKHUDSLGSKRsphorylation of 
,ǉ% E\ XSVWUHDP ,5$.-1 followed by ubiquitination and targeting for 
proteosome degradation of both proteins. The NF-ǉ% S VXEXQLW WKHQ
undergoes phosphorylation, followed by translocation to the nucleus where 
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it regulates the expression of various inflammatory genes, including IL-ǃ
and IL-6 (Covert et al., 2005). 
Our results showed that CBD reduced the activation of NF-kB which could 
result in the attenuation of downstream cytokine production (Wang et al., 
2002). The inhibition of NF-ǉB transcriptional activity exerted by CBD 
appears to be a consequence of inhibiting IǉBĮwhich would result in the 
retention of the IǉBĮ/NF-ǉB complex in the cytoplasm, and reduced NF-ǉB 
translocation to the nucleus. Several previous reports have suggested the 
involvement of the NF-ǉ% SDWKZD\ LQ FDQQDELQRLG-induced 
immunosuppression in macrophages (Jeon et al., 1996) including inhibition 
of iNOS gene expression (Burstein and Zurier, 2008). 
Microglial cells in the healthy brain do not express iNOS, but they become 
activated to produce iNOS and to release a large amount of NO following 
ischemic, traumatic, neurotoxic or inflammatory damage (Hanisch, 2002). 
In order to investigate whether the inhibition of CBD on NO and PGE2 
production was related to a modulation of iNOS and COX-2 induction, we 
evaluated iNOS and cyclooxygenase-2 (COX-2) expression in BV-2 cells. 
COX-2 expression has been associated with inflammatory and 
neurodegenerative processes of several human neurological diseases 
(Minghetti and  Pocchiari, 2007). In this study, we found that LPS activated 
expression of both iNOS and COX-2 in BV-2 cells. On the other hand, the 
effects of LPS were completely blocked by CBD (10 µM) but not by 1400W, 
an iNOS inhibitor, indicating that the effects of CBD are not secondary to 
inhibition of iNOS activity.  
MAPKs have been shown to play important roles in LPS-induced iNOS, 
COX-2, and proinflammatory cytokine expression in many types of cells 
(Gorina et al., 2011). It also has been reported that LPS-induced pro-
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inflammatory cytokines expression is mediated by MAPKs signalling in BV-2 
cells (Kim et al., 2004). We found that iNOS protein expression was 
blocked by selective inhibitors of p38 MAPK and PI3K but not by U0126, a 
MEK 1/2 inhibitor. or by Y27632, a ROCK inhibitor. These data suggest that 
MAPK signaling regulates iNOS expression at the transcriptional level in 
BV2 cells mediated via both p38 MAPK and PI3K signaling pathways, but 
not via ERK MAPK and ROCK pathways. 
This is consistent with previous reports that P38 phosphorylation can 
increase the activity of the transcription factor NF-ǉ%:LOPVHWDO
which enhances the transcription of a wide range of pro-inflammatory 
genes including inducible nitric oxide synthase (iNOS) and COX-2 (Bauer et 
al., 1997; Iuvone et al., 2004). Moreover, the involvement of PI3K in the 
regulation of iNOS expression was previous reported (Jang et al., 2004). 
The major source of ROS during inflammation is NADPH oxidase (Qin et al., 
2004), although other sources may also contribute (Sastre et al., 2003). 
NADPH oxidase is expressed mainly by microglia in the brain and its 
activity is increased by LPS (Green et al., 2001; Mayer et al., 2011). In this 
study, we tested the hypothesis that iNOS induction by LPS is conditional 
upon microglial NADPH oxidase activation. The NADPH oxidase inhibitor 
apocynin significantly inhibited iNOS protein expression in BV-2 cells. 
Therefore, it is possible that CBD could reduce iNOS expression by 
interacting with ROS generation. CBD has been shown to be effective in 
attenuating oxidative and nitrosative stress in a number of disease models 
(Booz, 2011). 
It was previously demonstrated that application of LPS to cultured spinal 
microglia produced a profound increase in the activated form of p38 MAPK, 
phospho-p38 (Hua et al., 2005) suggesting that production of nitric oxide is 
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dependent on p38 activation. p38 may affect the activity of iNOS, or by 
acting on transcription factors such as nuclear factor-ǉ%1)-ǉ%:LOPVet 
al., 2003) and, recently, CBD was shown to inhibit LPS-stimulated, NF-ǉ%-
dependent pro-inflammatory cytokine release in BV-2 cells (Kozela et al., 
2010).  
Whilst these sequences of events could explain the consequent inhibitory 
effects of CBD on NO formation, the involvement of the GPR55 receptor, 
fully activated by a component of the cell culture system, is tenuous. 
Whether CBD is initially recognized by a cell surface receptor or has its 
effects on a downstream component of the signaling cascade is uncertain. 
Although its recognition site in relation to microglial modulation is unclear, 
CBD might have potential for delaying the development of 
neurodegenerative diseases and inflammatory pain. 
2.6. Conclusion 
The data presented demonstrate that CBD inhibits microglial cells activity, 
as judged by NO formation, and this appears to be mediated by reduction 
of NF-Nǃ30$3.-1.DQG526DFWLYLW\ 
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2.6.1 Summary of chapter 2 
 
 
Figure 2.61: The summary graph shows the mechanism of inhabition of LPS 
induced NO. Inhibition of p38, NF-KB and iNOS. Moreover, CBD attenuate ROS 
induced by LPS. 
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3.1 Introduction  
The immune system, in which microglia play a crucial central role, exists to 
detect and eliminate invading pathogens and to clear debris associated 
with damage (Janeway, 1992; Aderm and Underil, 1999). Several different 
functions have been identified for microglia, including migration into the 
site of infection or damage and phagocytosis. The stimuli for these 
functions are still to be fully characterized (Frank-Cannon et al., 2009). 
 Phagocytosis can be defined as a mechanism for internalizing and 
destroying particles that are more than 0.5 µm in diameter  ( Botelho and  
Grinstein, 2011). Microglia function as the primary phagocytotic cells in the 
brain, acting to engulf invading microbes and pathological proteins. For 
H[DPSOH LW KDV EHHQ VKRZQ WKDW WKH $O]KHLPHU¶V GLVHDVH DVVRFLDWHG
DFFXPXODWLRQRIDP\ORLGǃFDQEHHQJXOIHGE\PLFURJOLD%DUGet al., 2000). 
Microglia migrate to the site of injury in other pathological conditions 
including stroke, neurodegenerative disease and tumor invasion 
(Kettenmann et al., 2011). Phagocytosis has been reported in microglia 
studied in tissue culture where they have been shown to ingest foreign 
objects (latex beads), immunoglobulin-coated erythrocytes, dead cells and 
infectious agents such as bacteria and fungi (Giulian and Baker, 1986; 
Hassan et al., 1991; Rieske et al., 1989; Williams et al., 1992; Lee et al., 
1992). 
Phagocytosis is initiated by activation of receptors on the cell surface 
including Fc gamma receptors (FcǄR) which interact with antibody-
opsonised (coated) pathogens and facilitate phagocytosis through 
pathways affecting reorganization of the actin cytoskeleton and activation 
of NADPH oxidase resulting in ROS formation. The complement system 
facilitates phagocytosis by opsonising pathogens, and operates through 
134 
 
signaling pathways which are different from those of Fc receptor-mediated 
phagocytosis (Zhou and Brown, 1994; Caron and Hall, 1998; Pollard and 
Borisy, 2003).  
Ligated FcRs on macrophage plasma membranes induce phosphorylation of 
tyrosines within the immunoreceptor tyrosines-based activation motif 
(ITAM) of FcR, leading to intracellular signals required for phagocytosis 
such as Syk, phosphatidylinositol 3-kinase (PI3K) and protein kinaseCİ 
(PKCİ Cox and Greenberg, 2001; Srinivasan et al., 2003). The 
reorganization of the actin cytoskeleton and increased synthesis of PIP3, PI-
(4,5)-P2 and diacylglycerol also stimulate the tyrosine kinase receptor-
associated phospholipase CǄ. leading to increased intracellular calcium and 
Rho GTPase protein (Garcia-Garcia  and Rosales, 2002; Srinivasan et al., 
2003). However, morphological and signalling characteristics of 
phagocytosis may differ depending on the local environment, substrate, etc 
(Aderem and Underhill, 1999).  
In order to phagocytose target material, microglia must respond to 
appropriate physiological stimuli and migrate to the areas of brain injury or 
inflammation (Noda and Suzummura, 2012).  It has been recognized that 
injury to central nervous system (CNS) tissue results in the release of 
chemotactic factors that initiate microglial migration to the site of insult. 
These include the chemokines monocyte chemoattractant protein 1 (MCP-
 PDFURSKDJH LQIODPPDWRU\ SURWHLQ Į PDFURSKDJH LQIODPPDWRU\
SURWHLQǃUHJXODWHGXpon activation normal T cell expressed and secreted 
(RANTES), interleukin 8 and interferon gamma inducible protein-10 (IP-10) 
(Cross and Woodroofe, 1999) 7UDQVIRUPLQJ JURZWK IDFWRU ǃ DQG EUDLQ-
derived chemotactic factor are also chemoattractants. Gradients of these 
chemokines have been found to be responsible for migration in vitro and in 
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injury models of the developing CNS (Cartier et al., 2005; Cross and 
Woodroofe, 1999).  
ATP and ADP are released upon acute injury to the CNS and have been 
found to be chemoattractant for microglial cells (Honda et al., 2001; 
Davalos et al., 2005).  Purine receptors responsible for recognition of these 
chemoattractants and migration of microglial cells include P2Y12 (which 
controls chemotaxis of amoeboid microglia and motility of ramified 
microglia), and P2X4 and P2Y13(Ohsawa et al., 2010; Ohsawa et al., 2007; 
Parkhurst et al., 2010; Farber et al., 2005). Some matrix proteins, 
LQFOXGLQJWKHǃǦintegrin CD11b, have been shown to be necessary to allow 
normal migration in response to injury (Isaksson et al., 2009). 
Cannabinoids have been shown to engage neuroprotective mechanisms 
against acute brain damage and toxicity both in vivo and in vitro. These 
include decreases in pro-inflammatory cytokines, nitric oxide, antioxidant 
activity and reductions in calcium influx (Mechoulam et al., 2002). 
Cannabidiol (CBD) comprises up to 40% of  Cannabis sativa extracts and 
represents one of the most promising cannabinoid drugs in clinical 
development due to its lack of psychoactive effects and its high level of 
tolerability in humans (Mechoulam et al., 2002; Mechoulam et al., 2007). 
Recently, CBD has attracted much interest due to pharmacological effects 
such as anticonvulsant, hypnotic, anti-inflammatory, anxiolytic, 
antipsychotic and neuroprotective actions (Barichello et al., 2012).  
Furthermore, in preclinical research, administration of CBD has been shown 
to reduce neuroinflammation in mice injected with intracerebral amyORLGǃ
(Martin-Moreno  et al., 2001). Low doses of CBD protect oligodendrocyte 
progenitor cells during immune system insult (Mecha et al., 2012) and it 
has been found that CBD has anti-inflammatory effects by inhibiting iNOS 
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expression, COX-2, nitric oxide generation and by reducing pro-
inflammatory cytokine production induced by LPS (Kozela et al., 2010).  
CBD has very low affinity for either CB1 or CB2 receptors (Showalter et al., 
1996); however, the action of CBD could involve other non-CB1/CB2 
receptors including abnormal cannabidiol receptors, (GPR18) (McHugh et 
al., 2010) and CBD can activate vanilloid (TRPV1) as well as TRPV2 
receptors (Oka et al., 2007; Ryberg et al., 2007).  Agonist and antagonist 
actions of CBD at GPR55, an orphan protein coupled-receptor (see Chapter 
2), have been described (Oka et al., 2007; Ryberg et al., 2007).  In 
addition, it activates 5-HT1A receptors (Russo et al., 2005) and it also 
blocks the reuptake of anandamide (Bisogno et al., 2001) and adenosine 
(Carrier et al., 2006). 
An accumulation of studies has indicated that cannabinoids may modulate 
inflammation, by enhancing microglial phagocytosis and migration to the 
sites of inflammation (Martín-Moreno et al., 2011). However, previous 
studies have provided no insights into the mechanisms of action of CBD on 
phagocytosis. 
3.2 The aim of this study 
 To evaluate the effects of phytocannabinoids on microglial migration and 
phagocytosis and to gain insight into the mechanisms of drug action.  
3.3 Methods  
3.3.1 Materials   
All cell reagents were obtained from Sigma-Aldrich Co (UK).  All 
cannabinoids were from Tocris Cookson (Bristol, UK); unless otherwise 
137 
 
stated.  Mounting medium (VECTASHIELD) was purchased from Vector 
laboratories, Rhodamine phalloidin from (Cytoskeleton, Molecular Probes, 
Eugene, USA) and DAPI from (Vector Laboratories, Petersborough, U.K.). 
Ruthenium red and N-arachidonylglycine were from Tocris Cookson 
(Bristol, UK). 1400W (an iNOS inhibitor) was from Abcam Biochemicals® 
(Bristol, UK) oligomycin was from Acros Organics (Leicestershire, UK ) and 
dexamethasone was purchased from Organon (Cambridge, UK). All 
cannabinoid drugs were diluted in 100% ethanol to 10-2M stocks, then in 
assay buffer to give final ethanol concentrations less than 0.1%. PEA, OEA, 
AEA and SEA were synthesized in the School of Chemistry, University of 
Nottingham, by Dr S.P.H. Alexander. 
3.3.2 Cell culture conditions 
Please see Chapter 2 for details. 
3.3.2.1 Murine microglial (BV-2) cell line 
BV-2 cells, a mouse microglial cell line, (a gift from Prof. Nephi Stella, 
:DVKLQJWRQ 8QLYHUVLW\ 86$ ZHUH JURZQ LQ 'XOEHFFR¶V 0RGified Eagle 
Medium (DMEM) with Ham-F12 obtained sterile from Sigma, supplemented 
with penicillin (100 U/ml) / streptomycin (100 µg/ml) solution, HEPES (15 
mM), NaHCO3 (5 mM), L-glutamine (2 mM) and 10% fetal bovine serum 
(FBS) which was heat inactivated. All cell culture solutions were stored at 4 
ǎC and pre-warmed to 37 ǎC in a water bath prior to use. The cells were 
grown to 95% confluence in 75cm2 flasks at 37°C with 5% CO2 and 95% 
atmosphere.   
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3.3.2.2 HAPI cell line 
 HAPI cells, an aggressively proliferating rat microglial cell line employed as 
a model of activated microglia, were a gift from Dr J.R. Connor, 
3HQQV\OYDQLD 6WDWH 8QLYHUVLW\ 86$ &HOOV ZHUH H[SDQGHG LQ 'XOEHFFR¶V
Modified Eagle Medium (DMEM) with 5% heat inactivated FBS, L-glutamine 
(2 mM), penicillin (100 U/ml) / streptomycin  (100 µg/ml) solution and 
maintained in a humidified incubator with 5% CO2 at 37 
ǎC. 
3.3.2.3 Macrophage like cells (RAW-264.7) 
RAW-264.7 cells, a monocyte/macrophage-like line were expanded in 
'XOEHFFR¶V0RGLILHG(DJOH0HGLXP'0(0ZLWKKHDWLQDFWLYDWHG)%6
L-glutamine (2 mM), penicillin (100 U/ml) / streptomycin (100 µg/ml) 
solutions. The cells were maintained in a humidified incubator with 5% CO2 
at 37 ǎC.  
3.3.2.4 Primary mouse microglial cultures,  
Please see Chapter 2 for details. 
3.3.3 Cell counts 
Please see Chapter 2 for details. 
3.3.4 Assessment of cell membrane integrity 
 Staining of cells with Trypan blue, a derivative of toluidine, allows 
distinction between live/ necrotic cells. Live cells maintain membrane 
integrity and exclude compounds that can enter the intracellular 
compartments. In contrast, necrotic cells have disrupted membranes and 
the above-mentioned selectivity is lost. 
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 Thus, upon staining, Trypan blue can freely traverse the membrane and 
stain necrotic cells. Cells are then examined under the light microscope, 
counted and the percentage of necrotic cells can be evaluated.   In all 
experiments, where the viability of microglia in phagocytosis was assessed 
by this method, cells were first trypsinised and harvested to 1.5 ml 
Eppendorf tubes. Subsequently, an equal volume of 0.4% Trypan blue 
was added to 150 µl of cell suspension and incubated in room temperature 
for 5±15 minutes. Following incubation, 10 µl of cell suspension was placed 
on the haemocytometer and the number of both stained and unstained 
cells was assessed.   
3.3.5 Assessment of phagocytosis  
In this study, phagocytosis was assessed in BV-2, HAPI, and RAW 264.7 
cell lines and in primary microglial cells and two methods used for 
assessment of phagocytosis. 
3.3.5.1 Phagocytosis assay   
Latex (amino-modified polystyrene) beads with or without fluorescent 
tagging (1-0.8 µm diameter respectively; Sigma; excitation/emission 
470/540) were used as phagocytosis targets.  
3.3.5.1.1 Fluorescent BSA latex beads  
To observe the phagocytic activity of microglia, BV-2 (5x105 cells) were 
cultured on glass coverslips (19 mm) in 12 well plates, and treated with 
cannabinoids (as indicated in individual experiment descriptions) for 24 
hours after which the medium was removed and different volumes of 
fluorescent latex beads from original stocks were re-suspended in 0.1% 
bovine serum albumin with PBS without Ca2+ and Mg2+ for 2 hours at 37°C. 
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Each volume (addition of 0.25 µl, 0.5 µl and 1 µl) of beads was tested to 
determine the optimum bead concentration that the cells would 
phagocytose. Following the 2-hours incubation, the assay was stopped and 
non-phagocytosed beads removed by applying several rinses of 1ml cold 
PBS to each well. The cells were then fixed onto coverslips with 500 µl of 
warm paraformadehyde (4% paraformadehyde/400 mM sucrose in PBS) at 
room temperature for 30 minutes.  
The cells were then washed several times with warm PBS and 
permeabilized with 500 µl of 0.1% Triton X-100 in 1% bovine serum 
albumin-containing PBS for 15 min at room temperature. To visualize the 
phagocytosed beads, F-actin was detected by staining with rhodamine 
phalloidin (a high-affinity F-actin probe conjugated red fluorescent dye) 
was purchased from Molecular Probes® Life technology  which binds to the 
polymerised form of actin (F-actin) diluted in PBS for 15 min at room 
temperature. Coverslips were then incubated with DAPI (1:1000) for 
staining of cell nuclei. The coverslips were mounted on glass slides by one 
drop of warm mounting medium without DAPI. The cells were viewed by 
confocal microscopy under 20X magnification using an oil immersion lens.  
All images of the cells were recorded using the same microscope, objective 
lens, and exposure time to allow comparison of measurements. 
Fluorescence intensity in each channel was corrected for background noise 
and quantified using Velocity 6 Demo image analysis software. Fluorescent 
beads were quantified on consecutive images using Velocity 6 Demo 
software to measure pixel intensity along the line scans at the bead site. 
The number of ingested beads per cell and total cells was counted to 
determine the rate of phagocytic cells and the mean number of ingested 
beads per cell.  
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3.3.5.1.2 Non-fluorescent latex beads 
Phagocytosis was assessed in BV-2 and HAPI cells. Cells were cultured at 
5x105 cells per well in 12 well-plates for 24 hours until cells were 
approximately 70% confluent.  Cells were stimulated with LPS alone or 
with CBD for 24 hours then incubated with latex beads (0.8µm) for 2 
hours. The cells were washed with cold PBS 3 times then fixed with 
paraformaldehyde (4%) for 30 minutes at room temperature. Images were 
taken using inverted microscope. To analyse the amount of phagocytosis 
that occurred in this culture. 3 images per conditions were randomly 
captured and then analysed by manually counting the number of beads 
engulfing and number of total cells per filed. 
3.3.6 Migration  
We designed a cell migration assay using an in-house designed and built 
³&RPSDVV´ GHYLFH 8QLYHUVLW\ RI 1RWWLQJKDP 0HGLFDO (QJLQHHULQJ 8QLW
This system (details withheld subject to patent application) allows 
migration to be measured in a 96-well plate, where cell migration into a 
vacant space can be recorded by image capture at regular intervals over a 
48 hour period using an inverted microscope with an attached camera. 
Images were analyzed using PowerPoint to measure the degree of cellular 
incursion into the vacant space. 
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                Figure 3.1³&RPSDVV´ cell migration assay device 
3.3.7 Western blotting 
3.3.7.1 Whole Cell Protein Extraction 
Whole cell protein lysates of BV-2 cells were used in immunoblotting 
assays (see chapter 2).  
3.3.7.2 Membrane fractionation 
Procedures for fractionation were adapted from the method of Rockstroh et 
al., (2011). Cells were plated 24 hours before the experiment. On the day 
of the experiment, BV-2 cells (5 x 104) were centrifuged for 5 min at 250 x 
g and washed twice with 3 ml with 1.5 ml buffer A (250 mM sucrose, 50 
mM Tris-HCl, 5 mM MgCl2 and protease inhibitor).  
The cell pellet was re-suspended in 1.5 ml buffer B (1 M sucrose, 50 mM 
Tris-HCl, 5 mM MgCl2 and [protease inhibitor tablet; containing 1 tablet of 
protease inhibitor cocktail (4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF), Bestatin hydrochloride, Leupeptin, E-64, Aprotinin, 
Pepstatin A, and Phosphoramidon disodium salt; Sigma]) by vortexing. The 
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suspension was incubated for 10 minutes while continuously rocking. After 
15 minutes centrifugation at 16,000 x g and 4 °C, the supernatant (S1) 
contained the cytosolic proteins. The pellet (P1) was dissolved in 1 ml 
buffer C (20 mM Tris-HCl, 0.4 M NaCl, 15% glycerol, 1.5% Triton X-100 
and protease inhibitor) and the mixture was incubated for 30 minutes 
shaking. The suspension was centrifuged for 15 minutes at 16,000 x g and 
4 °C. The supernatant (S2) contained the solubilised membrane proteins, 
the cell debris containing pellet (P2) was discarded. The protein 
determination for both fractions was carried out using the Lowry method. 
3.3.7.3 Gel electrophoresis  
The 10% sodium dodecyl sulphate (SDS) polyacrylamide gels were 
transferred into an electrophoresis tank (Bio-Rad, USA). The combs were 
removed from the gels and 500 ml electrophoresis buffer 1x (30.3g Tris, 
144g glycine and the 10 g SDS in 1L distilled water) was added into the 
WDQNǋJRIGHQDWXUHGSURWHLQVDPSOHVZHUHORDGHGLQWRWKHZHOOVZLWK
µl of the All Blue standard molecular weight markers (Bio-Rad laboratories 
Ltd, UK); electrophoresis was run at 200 V for 45 minutes.   
1 membrane and 2 filter papers were placed in sequence in transfer buffer 
(30.3g Tris, 144g glycine dissolved in 8 litres distilled water, to which a 
another 2 litres of methanol was added)  and then the proteins were 
transferred at 100V for 60 minutes at 4 ǎC using Bio-Rad apparatus. The 
SURWHLQWUDQVIHUZDVFKHFNHGE\XVLQJDIHZGURSVRI3RQFHDX¶VVROXWLRQ 
The membranes were incubated with 5% fat-free dried milk powder in 
TBST (30.3g Tris, 73.12g NaCl, in 1L distilled water adjusted to pH 7.6 and 
then diluted to 10 litres with the addition of Tween 20 to a final 
concentration of 0.1%) on a shaker at room temperature for 60 minutes 
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and then washed with 0.1% TBS-Tween twice.  The indicated primary 
antibodies were diluted in 5% milk in TBST. The membranes with diluted 
primary antibodies were incubated in small plastic bags on a shaker at 4°C 
overnight.  
 The membranes were washed with TBS-Tween on a shaker at room 
temperature for 3 times of 10 minutes each and then incubated with 5% 
milk in TBST diluted secondary antibodies  ([IRDye infrared LI-COR, USA] -
1:2000, dilution) goat anti-rabbit IgG or goat anti-mouse IgG with shaking 
for 1 hour at 37 ǎC. The membranes were washed with TBS-Tween on a 
shaker at room temperature for 3 times of 10 minutes each. Then washed 
one time with Milli-Q-water and the blots were scanned using the Li-COR 
Odyssey Infrared Imaging system (Li-Cor Bioscience), in 700 and 800 nm 
channels, with a resolution of 42 µm, quality, an intensity of 5, and focal 
offset of 2mm. The data were analyzed by Odyssey application software. 
The membranes were kept at 4°C for future reference. 
3.3.7.3.1 The primary antibodies used  
Anti-TRPV2 (1:1000, Calbiochem; PC421), anti-TRPV1 (1:1000, Santa Cruz 
Biotechnology; sc-28759), Phospho-Akt (Thr308) (244F9) Rabbit mAb, 
(1:1000, Cell Signaling Technology; 4056), Akt (40D4) Mouse mAb 
(1:1000, Cell Signaling Technology; 2920) and anti-GAPDH (1:2000; 
Sigma). 
3.3.8 Immunocytochemistry  
BV-2 cells (5 x 105) were seeded on poly-L-lysine-coated 13 mm glass 
coverslips and allowed to attach overnight in the conditioned medium. The 
following day, cells were serum-starved for 24 hours in a medium 
containing no fetal bovine serum (FBS); when indicated, 10% FBS was 
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added to some cells. The cells were incubated with medium alone, with 
LPS, or with drug for indicated times.  
Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline 
(PBS) for 30 minutes at room temperature, washed with PBS and then 
permeabilized using 0.1% Triton X-100 for 30 minutes. Blocking of non-
specific binding sites was performed by incubating cells with PBS containing 
1% bovine serum albumin (BSA) for 1 hour at room temperature. Cells 
were incubated with indicated primary antibody overnight at 4 °C.  
 After 3 washes with PBS, FIT-C-conjugated goat anti-rabbit IgG (1:800) or 
FIT-C-conjugated goat anti-mouse IgG (1:500, both IgG from Jackson 
Immuno Research) was added and incubation proceeded for 1 hour at 37 
°C.  To visualize the cells present on coverslips, the cell nuclei were stained 
with 4, 6-diamidino-2-phenylindole (DAPI, Molecular Probes) dye (1:1000) 
for 5 minutes at room temperature. After extensive washing, coverslips 
were mounted with mounting medium without DAPI (Vectashield)  was 
from (Vector Laboratories, inc Burlingame) and viewed through a 63x 
glycerin immersion objective lens or 40x oil immersion lens with a Leica 
DMRA2 fluorescent microscope. Images were cropped and brightness and 
contrast were adjusted equally using the ImageJ Software. The intensity of 
immunoreactivity was defined as the product of relative optical density 
(ROD) and area of immunoreactivity was measured using the ImageJ 
Software and velocity Demo 6 software was used for confirmation. 
Negative controls without primary antibody were included to identify non-
specific staining. 
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3.3.8.1The primary antibodies used  
 TRPV2; 1:500, CalBiochem, TRPV1; 1:100, Santa Cruz Biotechnology, PKC 
alpha (H-7) AC, Monoclonal Antibody;1:250, Santa Cruz Biotechnology; sc-
8393-AC), PKCİ 3RO\FORQDO $QWLERG\  6DQWD &UX] Biotechnology; 
sc-638, PLC Gamma2 (Q-20), Polyclonal Antibody (1:250; Santa Cruz 
Biotechnology; sc-407) or (,%Į-1; 1:100, alpha laboratories; 019-19741, 
Hampshire, UK) 
3.3.9 Reverse transcription polymerase chain reaction (RT-
PCR) 
3.3.9.1  RNA extraction 
The cell pellets from confluent 24 well plates of BV-2 cells or mouse whole 
brain tissue were homogenized in 1 ml lysis reagent (Tri-reagent®, 
Ambion, UK). The homogenate was incubated for 5 minutes on ice to 
promote a complete dissociation of nucleoprotein complexes before 
addition of BCP (1-bromo-3-chloro-propane) and centrifugation (10 864 g 
for 15 minutes at 4oC) to separate the mixture into an aqueous RNA phase 
and an organic protein phase. The upper aqueous phase was used for RNA 
precipitation at 20oC for 30 minutes with sodium acetate (2 M pH 4) and 
isopropanol (500 µl, 700 µl/1 ml of aqueous phase respectively). The 
organic phase was kept at -80oC for further protein extraction. RNA was 
collected by centrifugation (10 864 g for 10 minutes at 4oC) and washed 
twice with 70 % ethanol. 50 µl of DEPC-treated water was added to 
dissolve pellets before measuring the concentration of total RNA obtained 
using a NanoDrop device (ND-1000 Spectrophotometer, NanoDrop 
Technologies, USA).   
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3.3.9.2  mRNA Preparation  
As the target gene is a single exon gene, Dynabeads® mRNA purification 
kit (Invitrogen, UK) was used to extract mRNA from total RNA to overcome 
WKH SUREOHP RI JHQRPLF '1$ FRQWDPLQDWLRQ 7KH PDQXIDFWXUHU¶V
instructions were followed using a magnet (Magna-Sep TM, Invitrogen, UK) 
to remove the suspending, binding and washing buffer from oligo (dT) 
coated Dynabeads. mRNA was eluted from Dynabeads usLQJ  ǋO RI 
mM Tris-HCl and heating for 2 min  in 65-80°C.  
3.3.9.3 Complementary DNA (cDNA) synthesis  
5 µl (1 µg/µl) purified RNA was used to synthesis cDNA with superscript III 
reverse transcriptase (Invitrogen, UK) and another 5 µl underwent the 
same reaction but with superscript III reverse transcriptase replaced by 
HPLC water to generate a non-reverse transcriptase control (NRTs). To 
each 5 µl of RNA, 1 µl of random primer and 1 µl of dNTP were added, 
made up to a volume of 13 µl with 6 µl of HPLC grade water; the mixture 
was incubated at 65 °C for 5 minutes and quickly chilled on ice followed by 
addition of the following to make up the final reaction volume of 20µl (4 µl 
first strand buffer X5; 1 µl 0.1 M DDT; 1 µl RNAse inhibitor and 1 µl 
superscript III for cDNA sample or 1 µl NRTs sample). Finally, the mixture 
underwent an incubation period of 20 minutes at 37°C, then 60 minutes at 
50 °C and at 70 °C for 15 minutes. cDNA and NRTs synthesized were 
stored at -20°C for future use. 
3.3.9.4 Designing the Primers and Probes 
Primers for the target gene were designed using Primer Express 2 (Applied 
%LRV\VWHPV 8. IROORZLQJ PDQXIDFWXUHU¶V LQVWUXFWLRQV DQG SXUFKDVHG
through Eurofins MGW Operon. Primers and probes were assessed using 
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the National Center for Biotechnology Information Basic Local Alignment 
Search Tool (NCBI BLAST) to ensure that the chosen sequence was specific 
for the gene of interest. Primer and probes were re-constituted and diluted 
to 10µM prior to use. 
Mouse beta actin (ACTB) endogenous control (FAMTM Dye/MGB probe, 
non-Primer limited) Part Number 4352933E from (Applied Biosystems, UK) 
was used as control. 
Gene Primers sequence 
Mouse 
Trpv2 
Forward Primer ACTAAGGTGGAGGGTGGACGAT-¶ 
Reverse Primer       CCAAGCCTAGCGGGACTCT-¶ 
 Probe CCAGCTACGGAGGCTTCCGCG-¶ 
3.3.9.5 Taqman Real-Time PCR 
A mixture of cDNA from different samples of positive control was used to 
form the standard curve and 2 fold dilutions (1:2, 1:4, 1:8 etc) of each 
cDNA and non-template control to quantify relative concentrations of the 
target and reference genes in the samples, cDNA samples were diluted. A 
master mix prepared for the reference and target gene was calculated 
according to the desired number of wells each containing a mix of Taqman 
master mix, forward primer, and reverse primer, probe and HPLC water. 10 
µl from this mix was added to each well of a 96 well reaction plate (Applied 
Bioscience, USA) then 3 µl from each cDNA sample or standard was added 
in triplicate. The StepOne plus real time PCR system (Applied Biosystem, 
UK) was used for assay. 
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3.3.10 Fura-2 AM Ca2+ imaging 
Experiments were typically conducted using BV-2 cultures at 5x105 cells 
seeded onto 19 mm glass coverslips coated with poly-L-lysine. Cultures 
were washed 3 times in buffer (NaCl 145mM, KCl 5Mm, CaCl, 2mM, MgSO4 
7H2O 1mM, HEPES 10mM, glucose 10mM and 2g BSA)  and loaded for 30 
minutes in the dark at  37ǎ&ZLWKǋ0cell-permeable fluorescent Ca2+ 
indicator, Fura-2-AM (Cambridge Bioscience, Cambridge, UK). Cells were 
then washed again with buffer and all experiments performed at room 
temperature in the dark. Cultures were suprafused at a rate of 2 ml/min. 
Using the laser scanning microscope, emission intensity was measured up 
to 20 min, every 200 - 400 ms using excitation at 430 nm and emission 
detection range from 480 to 536 nm. Stimulating drugs were added after 
10 to 30 seconds. 
3.3.11 Statistical analysis  
Data were collected from three or more independent experiments (using 
different passages of cells) and are expressed as mean ± S.E.M. Statistical 
analysis was performed, where indicated, using repeated measures one-
way and two-way ANOVA, with post-hoc. Comparison of more than two 
groups was done by ANOVA followed by Dunnett's multiple comparison 
WHVWV RU %RQIHURQQL¶V PXOWLSOH FRPSDULVRQ West as appropriate. Statistical 
analysis was performed using GraphPad Prism© version 5 software 
(GraphPad Software, La Jolla, CA). Statistical significance was considered 
for a p value less than 0.05. 
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3.4 Results 
3.4.1 Phagocytic response after non- fluorescent latex beads 
exposure 
The phagocytic response of BV-2 to 0.8 µm latex beads after 2 hours 
exposure was assessed. The total proportion of cells that could phagocyte 
latex beads and the total beads were recorded. A significant stimulation of 
phagocytosis after incubation with either 10 µM CBD or 100 ng/ml LPS in 
the BV-2 cells is shown in Figure 3.2. 
 
Figure 3.2:  Phagocytosis of non-fluorescent latex beads assessed using an 
inverted microscope. BV2 cells were treated with (A) C; control (B) CBD 10µM (C) 
LPS 100ng/ml for 24 hours and incubated with latex beads (0.8 µm in size; 
0.5u/ml) for 2 hours then washed with PBS, fixed with PFD (4%) and visualized 
with an inverted microscope. manually counting the number of beads engulfing and 
number of total cells per filed (D) Histogram of number of beads /number of total 
cells. Data were analysed using one-way ANOVA followed by post-hoc 'XQQHWW¶V
test; *P<0.05 CBD compare with (C) control; *P<0.05 LPS compare with (C) 
control. 
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3.4.2 Fluorescent BSA latex beads 
3.4.2.1 Optimization of protocol  
Microglial phagocytosis was monitored by assessing the ingestion of latex 
beads (Figure 3.3). The influence of bead concentration and time-course on 
phagocytosis was investigated (Figure 3.4). The number of fluorescent 
beads accumulated by BV-2 cells tended to increase with increasing bead-
load (0.25 µl/ml< 0.5 µl/ml< 1 µl/ml).  At a bead concentration of 0.5 
µl/ml, phagocytosis of beads increased over the period 0.5 to 2 hours 
(Figure 3.5).  We further tested the effects of temperature and ethanol (as 
drug vehicle) on microglial phagocytic activity. BV-2 cells were incubated 
with 0.5 µl/ml fluorescent latex beads for 2 hours in the presence of (1%) 
bovine serum albumin at 37°C (control) or 4°C and in the presence of 
0.1% ethanol. We found that low temperature inhibited phagocytosis but 
phagocytic activity was not significantly affected by 0.1% ethanol (the 
maximum amount used as vehicle in any experiment) (Figure 3.6).  
 
Figure 3.3: Images show the phagocytic cells in BV-2 cells and primary mouse 
primary microglia. BV-2 cells (5x105cells/well)  or  primary cells were loaded with 
%6$ IOXRUHVFHQW EHDGV IRU  KRXUV WKHQ LQFXEDWHG DW ň ZLWK PHGLXP WKHQ
stained with rhodamine phalloidin  (a high-affinity F-actin probe conjugated red 
fluorescent dye) (red) and DAPI (blue). (A) BV-2 phagocytic cells (40X) (B) in 
primary mouse phagocytic microglia (red ,%Į-1 microglial marker), arrow indicates 
yellow fluorescent beads (40X).   
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Figure 3.4: Histogram shows the effect of BSA latex bead concentration on 
phagocytic activity in BV-2 cells. BV-2 cells (5x105cells/well) were incubated with 
medium for 24 hours. Fluorescent BSA beads (1µm size) were then added at the 
concentrations indicated for 2 hrs. Data were analysed using one-way ANOVA 
followed by post-hoc Bonferroni; **P<0.01, 1µl/ml concentration compare with 
0.5µl/ml concentration;*P< 0.25µl/ml concentration compared with 0.5µl/ml 
concentration. 
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Figure 3.5: Histogram shows the effect of incubation time on phagocytosis in BV2 
cells. BV-2 cells (5x105cells/well); Cells were incubated with the fluorescent beads 
(1µm-size, 0.5 µl/ml concentrations) for the times indicated. Data were analysed 
using one-way ANOVA followed by post-hoc Bonferroni; *P<0.05, 2h compare with 
1 h. 
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Figure 3.6: Histogram shows the effect of temperature and ethanol on 
phagocytosis in BV-2 cells. BV-2 cells (5x105cells/well); were loaded with 
fluorescent BSA latex beads (1µm, 0.5µl/POIRUKRXUVWKHQLQFXEDWHGDWňRU
37°C with or without ethanol. The figure represents means ±SEM of triplicate 
determinations in three independent experiments. The data are presented as a 
percentage of control. Data were analysed using one-way ANOVA followed by post-
hoc 'XQQHWW¶VWHVW3&&FRPSDUHZLWK& 
3.4.2.2 The role of the cytoskeleton in phagocytosis 
To assess cytoskeletal involvement in phagocytic BV-2 phagocytosis, the 
effect of cytochalasin D, an inhibitor of actin polymerization, was assessed. 
This drug disrupts actin microfilaments and activates p53-dependent 
signaling pathways causing arrest of the cell cycle at the G1-S transition. 
Bead phagocytosis is expected to require pseudopod extension which is an 
actin-based movement of the microglial cells. Cytochalasin D (1 µM) was 
added to BV-2 cells for 1 hour before incubation with fluorescent BSA 
beads at 37°C for 2 hours, and the cultures were gently washed in PBS to 
eliminate uningested beads, fixed using 4% formaldehyde for 20 min and 
washed with PBS. Samples were analyzed by fluorescence microscopy. 
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Cytochalasin D completely inhibited phagocytosis, indicating the 
dependence of phagocytosis on actin polymerization (Figure 3.7).  
3.4.2.3 The role of mitochondria in phagocytosis 
In order to assess the requirement for mitochondrial activity, the effects of 
oligomycin (a mitochondrial ATPase inhibitor) and FCCP (a mitochondrial 
uncoupler that blocks oxidative phosphorylation) on BV-2 phagocytosis 
were monitored. BV-2 cells were incubated with oligomycin (1µM) or with 
FCCP (1µM) for 1 hour then 0.5µl/ml fluorescent BSA latex beads were 
added for 2 hours. 1 hour treatments with oligomycin or FCCP failed to 
affect the ability of BV-2 to phagocytose latex beads (Figure 3.7). 
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Figure 3.7: Histogram shows the effect of the cytochalasin D (a cytoskeleton 
inhibitor), oligomycin (a mitochondrial ATPase inhibitor) and FCCP (a mitochondrial 
uncoupler) on phagocytosis in BV-2 cells. (5x105cells/well); BV-2 were pre-
incubated with indicated drugs at (1µM) for 1hour. Control wells (C) were incubated 
with culture medium alone. BV-2 cells were loaded with 0.5 µl/ml fluorescent beads 
(0.5 µl/ml) for 2 hours. The figure represents means ±SEM of triplicates of three 
independent experiments. The data are presented as a percentage of control. Data 
were analysed using one-way ANOVA followed by post-hoc 'XQQHWW¶V WHVW
**P<0.01 cytochalasin compare with control. 
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3.4.2.4 The role of myosin II in BV-2 phagocytosis   
Non-muscle myosin II, an actin-based motor protein, plays an important 
role in actin cytoskeleton organization and cellular motility. We examined 
the localization of myosin II and whether myosin light chain II (MLCII) is 
involved in the BSA latex bead phagocytosis using antibodies against 
MLCII, incubated with BSA latex beads (1µm-0.5 µL/ml for 2 hours at 37 
ǎC). MLCII antibody was added overnight.  Myosin II accumulates at the 
edges of BV-2 cells to form tight filaments through the edge of the cells 
during phagocytosis (figure 3.8; B). It seems likely that myosin II 
contributes to some aspect of phagocytosis localized around the BSA latex 
beads. 
  
Figure 3.8: Images show The role of myosin light chain II protein on phagoytosis 
by immunocytochemistry (A) non-stimulated staining with MLCII antibody (green) 
and DAPI (blue) (B) BV-2 cells stimulated with fluorescent BSA latex beads (1 µm ±
0.5 µl/ml for 2 hours (arrow beads). The cells were visualized by confocal 
microscopy under 63X magnification glycerin immersion.  
3.4.2.5 Expression of CD11b in microglial cells 
Microglia were assessed for changes in the extent and intensity of CD11b 
expression during phagocytosis of latex beads as this protein is used as an 
indicator of microglial activation. The expression in phagocytic microglia 
(i.e. exposed to beads) was compared to that in non-phagocytic microglia. 
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As a positive control, BV-2 microglia were treated with bacterial 
lipopolysaccharide (LPS), which induces an inflammatory response and 
activates microglia. The expression of CD11b in BV-2 phagocytic microglia 
was similar to that of BV-2 (control) non-phagocytic cells (Figure 3.9; A, B) 
while a significant increase in average intensity of CD11b expression in 
LPS-treated cells was observed (Figure 3.9; C).  
 
Figure 3.9: Confocal images showing expression of CD11b receptor 
immunocytochemical analysis of BV-2 cells stained with CD11b antibody (green) 
and blue DAPI. (A) Control non-phagocyte cells (B) phagocytes, BV-2 incubated 
with fluorescent BSA latex beads (0.5 µl/ml; 1 µm) for 2 hours (C) BV-2 incubated 
with LPS for 1hour (D) Fluorescent CD11b RFU The cells were visualized by confocal 
microscopy under 63X magnification using a glycerin immersion objective lens. The 
figure represents means ±SEM of triplicate determinations in three independent 
experiments. Data were analysed using one-way ANOVA followed by post-hoc 
'XQQHWW¶VWHVW3/36FRPSDUHZLWK(C) Control. 
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3.4.2.6 The role of phospholipase C Ǆ2 (3/&Ǆ2) in BV-2 
phagocytosis  
3/&Ǆ LV DFWLYDWHG GXULQJ SKDJRF\WRVLV LQ SKDJRF\WLF FHOOV ZKHUH LW LV
essential for particle ingestion and bactericidal response (Scott et al., 
2005). :H ILUVW H[DPLQHG WKH H[SUHVVLRQ SDWWHUQ RI 3/&Ǆ2 in BV-2 cells.  
Next, ZHH[DPLQHGZKHWKHU3/&ǄFRXOGEHDFWLYDWHGE\phagocytosis of 
ODWH[EHDGV7KHLPDJHVFRQILUPWKDW3/&ǄLVVWURQJO\H[SUHVVHGLQ%9-2 
cells (Figure 3.10; A) and appeared to be translocated to areas around the 
beads during phagocytosis (Figure 3.10; B) and (C) cells in the presence of 
ODWH[ EHDGV SOXV &%' ZLWK 3/&Ǆ WUDQVORFDWHG DURXQG WKH EHDGV LQVLGH
vesicles. 
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Figure 3.10: Confocal images showing expression of 3/&Ǆ2 protein 
immunocytochemical analysis of BV-2 cells stained with PLC Ǆ 2 antibody (green) 
and blue DAPI. (A) Control BV-2 cells (40X) (B) Phagocytosing BV-2 cells incubated 
with fluorescent BSA latex beads 0.5µl/ml; 1 µm for 2 hours, arrows indicate 
expression of PLC Ǆ2 around the beads (63X). (C)  BV-2 cells pre-incubated with 
CBD 10µM for 24 hrs, then incubated with BSA latex beads 0.5µl/ml for 2hrs, 
arrows indicate beads with translocation of PLCǄ2 inside the vesicles (63X). 
3.4.2.7 The role of protein kinase C (PKC) in BV-2 phagocytosis  
3.&Į 
3URWHLQ NLQDVH & Į 3.&Į FRQWULbutes to F-actin remodeling during 
phagocytosis and phagosomal maturation in phagocytic cells. A previous 
UHSRUW LQGLFDWHV D UROH IRU 3.&Į LQ VLJQDOLQJ &50$&-1-mediated 
phagocytosis of iC3b opsonized particles (Fallman et al., 1992; Makranz et 
al., 2003). To examine the role and expression of in phagocytosis of latex 
beads in microglial cells, BV-2 cells were incubated with or without latex 
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beads overnight with PKCĮ DQWLERG\ 7KH UHVXOWV LQGLFDWH DSSDUHQW
WUDQVORFDWLRQRI3.&ĮWRWKHFHOOPHPEUDQHDQGVXJJHVWWKDW3.&ĮPLJKW
play a role in latex bead phagocytosis in these cells (Figure 3.11; A-B). 
 
 
Figure 3.11: Images show the expression of 3.&Į protein by 
immunocytochemical analysis. BV-2 cells stained with PKCĮantibody (green) and 
blue DAPI. (A) Control non-phagocytosing cells (B) BV-2 cells incubated with non-
fluorescent latex beads (0.5µl/ml) for 2 hours. The cells were visualized by confocal 
microscopy under 63X magnification using a glycerin immersion objective lens.  
3.4.2.7.2 PKCİ 
PKC (İ) have been reported to translocate to membranes during FcgR 
cross-linking or phagocytosis (Zheng et al., 1995). To investigate the role 
and expression of PKCİ in microglial cells during phagocytosis, BV-2 cells 
were incubated with or without latex beads overnight with PKC-ɸ antibody. 
The results show apparent up-regulation of PKCİ to the cell membrane and 
suggest that PKCİ might play a role in BSA latex bead phagocytosis 
according to immunocytochemistry (Figure 3.12; A-B). 
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Figure 3.12: Images show the expression of PKCİ protein in BV-2 by 
immunocytochemical analysis. BV-2 cells stained with PKC-İantibody (green) and 
blue DAPI. (A) Control cells without beads (B) BV-2 cells incubated with non-
fluorescent BSA latex beads (0.5µl/ml) for 2 hours. The cells were visualized by 
confocal microscopy under 63X magnification using a glycerin immersion objective 
lens.  
3.4.2.8 The role of P2Y or P2X receptors in phagocytosis 
ATP and UDP trigger a dynamic change in the motility of microglia in vitro 
and in vivo (Koizumi et al., 2007). To evaluate whether P2Y or P2X 
receptors are involved in microglial phagocytic activity the role of these 
purinoceptors in BV2 phagocytosis was investigated. BV-2 cells were 
incubated with UDP or ATP for 24 hours then loaded with 0.5 µl/ml BSA 
latex beads for 2 hours. UDP (10 µM) a P2Y6 receptor agonist, but not ATP, 
produced a significant increase in phagocytosis (Figure 3.13). 
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 Figure 3.13: Histogram shows the effect of UDP and ATP (10 µM) on 
phagocytosis in BV-2 cells. (5x105cells/well); BV-2 cells were incubated with 
indicated drugs for 24 hours and control wells (C, control) were incubated with 
culture medium alone. The cells were loaded with 0.5 µl/ml fluorescent BSA beads 
for 2 hours. The figure represents means ±SEM of triplicate determinations from 
three independent experiments. The data are presented as a percentage of control. 
Data were analysed using one-way ANOVA followed by post-hoc 'XQQHWW¶V WHVW
***P<0.001 UDP compare with (C) Control. 
3.4.2.9 The role of pro-inflammatory mediators in BV-phagocytosis  
In order to determine whether nitric oxide has a direct effect on 
phagocytosis in BV2 cells, the selective iNOS inhibitor 1400W (N-[3-
(aminomethyl) benzyl] acetamidine) was incubated with BV-2 cells 1 hour 
prior to CBD (10 µM) for 24 hours then with added latex beads. 1400W 
failed to affect phagocytosis in the basal BV-2 cells (Figure 3.14), providing 
no evidence of a controlling influence of NO in BV2 phagocytosis.  
We also investigated the effect on phagocytic activity in BV-2 cells 
activated with bacterial lipopolysaccharide (LPS, 100ng/ml) and interferon 
(50 U/ml). Figure 3.14; shows that, in the presence of BSA latex beads, 
LPS and interferon respectively led to an increase in phagocytosis after 24 
hours incubation.  
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Figure 3.14: Histogram shows the effect of 1400W (selective iNOS inhibitor 
1400W), interferon and LPS on phagocytosis in BV-2 cells (5x105cells/well); cells 
were pre-treated with 1400W (10µM), SNP (10 µM), interferon-Ǆ8PODQG/36
(100ng/ml). Control wells (C) were incubated with culture medium alone. The cells 
were loaded with fluorescent BSA beads (0.5 µl/ml) for 2 hours. The figure 
represents means ±SEM of triplicates of three independent experimentsl. Data 
presented as a percentage of control. Data were analysed using one-way ANOVA 
followed by post-hoc 'XQQHWW¶V WHVW 3 ,1)-Ǆ FRPSDUH ZLWK (C) control; 
**P<0.01, LPS compare with (C) control. 
3.4.2.10 The role of anti-inflammatory drugs on BV-2 phagocytosis  
To test the effects of anti-inflammatory agents on microglial phagocytosis, 
BV-2 cells were incubated with minocycline which has been shown to have 
anti-inflammatory and neuroprotective effects and to prevent microglial 
activation (Familian et al., 2007). Cells were incubated with minocycline 
(10 µM) 1 hour prior to CBD (10 µM) for 24 hours then incubated for 2 
hours with latex beads (0.5 µl/ml). The results show that minocycline failed 
to affect phagocytosis in BV-2 cells (Figure 3.15). 
Glucocorticoids, including the synthetic glucocorticoid, dexamethasone, are 
recognised for their anti-inflammatory properties and ability to inhibit 
production of pro-inflammatory mediators such as nitric oxide synthase 
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(iNOS) (Lieb et al., 2003; Golde et al., 2003). Furthermore, they are 
reported to increase phagocytosis of apoptotic cells (Hodrea et al., 2012; 
Giles et al., 2001). The phagocytosis of BSA latex beads was investigated 
after exposure of BV-2 cells to different concentrations of dexamethasone 
(DEX) for 24 hours. Dexamethasone, as expected, augmented 
phagocytosis in a concentration-dependent manner as indicated in Figure 
3.15. 
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Figure 3.15: Histogram shows the effect of the microglial inhibitor minocycline 
and dexamethasone on phagocytosis in BV-2 cells. BV-2 (5x105cells/well); were 
pre-treated with dexamethasone 1µM or 2.5 µM for 24 hrs. Control wells (C, 
control) were incubated with culture medium alone. The cells were loaded with 
fluorescent latex beads (1 µm-size, 0.5 µl/ml) for 2 hours. The figure represents 
means ±SEM of triplicates of three independent experiments. The data are shown 
as percentages of. The vertical Y axis represents the number of beads ingested 
/number of the cells. Data were analysed using one-way ANOVA followed by post-
hoc 'XQQHWW¶VWHVW3 0.05 DEX 1µM compare with (C) control; **P< 0.01, DEX 
2.5 µM compare with (C) control. 
3.4.2.11 Effects of cannabinoids and endocannabinoids on 
microglial and macrophage phagocytosis  
In this study we evaluated the effects of cannabinoids and 
endocannabinoids on phagocytosis in BV-2 cells; AM251 (a CB1 antagonist 
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and putative GPR55 agonist), the GPR55 agonist lysophosphatidylinositol 
(LPI), JWH133 (a CB2 receptor selective agonist), CP55,940, a group of 
phytocannabinoids (CBDA, CBDV, THC, CBN and THC) and the 
endocannabinoids anandamide (AEA) and 2-AG (DOO DW ǋ0 IDLOHG WR
significantly affect phagocytosis. In contrast, the phytocannabinoid 
cannabidiol (CBD) produced a significant enhancement of phagocytosis at 
10 µM (Figure 3.16-3.18). Win55-212-2, a CB1/CB2 agonist inhibited 
phagocytosis as shown in Figure 3.16. 
We also measured phagocytosis of latex beads by primary microglia from 
C57BL/6 mice, RAW 264.7 and HAPI cells. Primary mouse microglia 
phagocytosed beads with a time course of uptake and concentration 
dependency similar to BV-2 cells (Figure 3.18). Pretreatment of the 
different cells with CBD enhanced the uptake of beads by similar amounts.  
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Figure 3.16: Histogram shows the effect of cannabinoids and endocanabinoids on 
phagocytosis in BV-2 cells. BV-2 cells (5x105cells/well) were pre-treated with the 
indicated drugs (all 10 µM) for 24 hours then incubated with fluorescent BSA latex 
beads (0.5 µl/ml for 2 hours). The figure represents means ±SEM of triplicate 
determinations of three independent experiments. The data are presented as a 
percentage of control. Data were analysed using one-way ANOVA followed by post-
hoc 'XQQHWW¶VWHVW3:,1-2 compare with (C) Control.  
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Figure 3.17: Histogram shows the effects of phytocannabinoids (10 µM) on 
phagocytosis in BV-2 cells. BV-2 cells were incubated with the indicated drugs for 
24 hours then loaded with fluorescent BSA beads (1µm; 0.5 µl/ml) for 2 hours. The 
figure represents means ±SEM of triplicate determinations of three independent 
experiments. The data are presented as a percentage of control. Data were 
analysed using one-way ANOVA followed by post-hoc 'XQQHWW¶VWHVW3&%'
10 µM compare with (C) control. 
 
(B)  Primary mouse microglial cells 
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Figure 3.18: Histogram shows the effect of phytocannabinoids on phagocytosis in 
primary mouse microglial cells. Primary mouse microglial cells were pre-treated 
with the indicated drugs (all 10 µM) for 24 hours then incubated with fluorescent 
BSA latex beads (0.5 µl/ml for 2 hours). The figure represents means ±SEM of 
triplicate determinations of three independent experiments. The data are presented 
as a percentage of control. Data were analysed using one-way ANOVA followed by 
post-hoc 'XQQHWW¶VWHVW35 CBD 10 µM compare with (C) control. 
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Figure 3.19: Histogram shows the effect of CBD on phagocytosis in RAW 264.7 
cells. RAW 264.7 (5x105cells/well) were treated with CBD at the indicated 
concentrations for 24 hours then incubated with (0.5 µl/ml) fluorescent latex BSA 
beads for 2 hours. The figure represents means ±SEM of triplicates of three 
independent experiments. The data are presented as a percentage of control. Data 
were analysed using one-way ANOVA followed by post-hoc 'XQQHWW¶V WHVW
**P<0.01, CBD 10 µM compare with (C) Control. 
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Figure 3.20: Histogram shows the effect of CBD on phagocytosis in HAPI cells. 
HAPI cells (5x105cells/well) were treated with CBD at the indicated concentrations 
for 24 hours then incubated with (0.5 µl/ml) fluorescent latex BSA beads for 2 
hours. The figure represents means ±SEM of triplicates of three independent 
experiments. The data are presented as a percentage of control. Data were 
analysed using one-way ANOVA followed by post-hoc 'XQQHWW¶VWHVW3 0.05 CBD 
10 µM compare with (C) control. 
3.4.2.12 Role of GPR18/Abn-CBD receptors in CBD induced 
phagocytosis 
To examine whether GPR18 receptors were involved in phagocytosis 
previously reported its involvement in microglia migration (McHugh  et al., 
2010) and its enhancement by CBD, experiments were performed using N-
arachidonylglycine (NAGLY) a putative endogenous GPR18 agonist. 
NAGLY (10 µM) did not significantly affect phagocytosis in BV-2 cells; 
neither was the effect of CBD reversed by pre-treatment with O-1918 (10 
µM) an Abn-CBD antagonist (Franklin and Stella 2003), (Figure 3.21); O-
1918. These data rule out the involvement of GPR18 and Abn-CBD in CBD-
augmentation of phagocytosis. 
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Figure 3.21: Histogram shows the effect of N-arachidonylglycine (NAGLY; GPR18 
agonist) and O-1918 (an abn-CBD antagonist) on phagocytosis in BV-2 cells. BV-2 
cells (5x105cells/well) were pre-incubated with O-1918 for 1hour then with CBD for 
24 hours. Control wells (C) were incubated with culture medium alone or with 
NAGLY 10 µM. The cells were loaded with (0.5 µl/ml) fluorescent BSA beads for 2 
hours. The figure represents means ±SEM of triplicates of three independent 
experiments. The data are presented as a percentage of control. Data were 
analysed using one-way ANOVA followed by post-hoc Bonferroni multiple 
comparesion test; *P<0.05, CBD 10 µM compare with (C) control;*P< 0.05 
CBD+O-1918 compare with CBD. 
3.4.2.13 The effect of pertussis toxin on CBD-induced phagocytosis 
Cannabinoid receptors are Gi protein-coupled and Gi signalling is 
suppressed by pertussis toxin. To examine if CBD-induced phagocytosis is 
mediated via a Gi protein-coupled mechanism, BV-2 cells were pretreated 
with 50 ng/ml of pertussis toxin for 18 hours followed by CBD (10 µM) 
treatment for 24 hours, then incubated with latex beads for 2 hours. 
Pertussis toxin had no effect on the CBD-enhancement of phagocytosis 
(Figure 3.22). This finding suggests that Gi protein-coupled receptors are 
not involved in the CBD-induced phagocytosis.  
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Figure 3.22: Histogram shows the effect of pertussis toxin (PTX) on CBD-induced 
phagocytosis in BV-2 cells. BV-2 cells (5x105cells/well) were pre-incubated with or 
without 50 ng/ml PTX for 18 hours, then incubated in the presence or absence of 
CBD (10µM) for 24 hours. The cells were loaded with 0.5 µl/ml fluorescent BSA 
latex beads for 2 hours. The figure represents means ±SEM of triplicates of three 
independent experiments. The data are shown as percentages of control. Data were 
analysed using one-way ANOVA followed by post-hoc Bonferroni multiple 
comparesion test; *P<0.05 CBD 10 µM compare with (C) Control, ns (non-
significant) CBD+PTX compare with CBD. 
3.4.2.14 The roles of PI3K, Rho/Rock kinase and p38 MAPK in CBD-
enhancement of phagocytosis 
We tested the effects of pre-incubation (1hr) with various inhibitors of 
PI3K, Rho kinases and p38 MAPK on phagocytosis in BV-2 and HAPI cells in 
the presence and absence of CBD. Cells were then incubated with (0.5 
µl/ml) fluorescent latex beads for 2 hours. Y27632 (a Rho/RocK inhibitor) 
decreased basal phagocytosis but did not affect CBD-enhanced 
phagocytosis; in fact the enhancement was somewhat more marked 
(Figure 3.23). SB203580 a P38 inhibitor had no effect on basal or CBD-
enhanced phagocytosis (Figure 3.24). 
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The selective phosphoinositide 3-kinase (PI3K) inhibitor wortmannin (10 
µM) reversed basal phagocytosis but CBD still enhanced bead ingestion in 
the presence of wortmannin (Figure 3.25).   
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Figure 3.23: Histogram shows the effect of Y27632 (a Rho/ROCK signalling 
inhibitor) on phagocytosis in BV-2 cells. BV-2 (5x105cells/well) were pre-incubated 
with Y27632 (10 µM) for 1hour, then treated with CBD for 24 hours. Control wells 
(C) were incubated with culture medium alone. The cells were loaded with (0.5 
µl/ml) fluorescent BSA latex beads for 2 hours. The figure represents means ±SEM 
of triplicates of three independent experiments. The data are shown as percentages 
of control. Data were analysed using one-way ANOVA followed by post-hoc 
%RQIHURQQL¶V PXOWLSOH FRPSDULVRQ 3 &%' YV FRQWURO 3 <
compare with (C) control and *p<0.05 Y27632 compare with (C) Control; CBD+ 
Y27632 compare with CBD ns (not significant). 
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Figure 3.24: Histogram shows the effect of SB203580 (a P38 inhibitor) on CBD 
induced phagocytosis in BV-2. BV-2 (5x105cells/well) were incubated with CBD (10 
µM) with or without SB203580 (10 µM). The cells were loaded with fluorescent BSA 
latex beads (0.5 µl/ml) for 2 hours. The figure represents means ±SEM of 
triplicates in three independent experiments. Data were analysed using one-way 
ANOVA followed by post-hoc BonfeURQQL¶VPXOWLSOHFRPSDULVRQ3&%'YV 
(C) control. SB203580 compare with control; CBD+ SB203580 compare with CBD 
ns, (not significant). 
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Figure 3.25: Histogram shows the effect of wortmannin on CBD induced 
phagocytosis in BV-2 cells. BV-2 (5x105cells/well) were pre-incubated with 
wortmannin (10 µM) for 1hour, and then treated with CBD for 24 hours. (C) Control 
wells were incubated with culture medium alone. The cells were loaded with 
fluorescent BSA latex beads (0.5 µl/ml) for 2 hours. The data are shown as 
percentages of control. Data were analysed using one-way ANOVA followed by 
post-hoc %RQIHURQQL¶V PXOWLSOH FRPSDULVRQ 3&%' YV FRQWURO **p<0.01 
wortmannin compare with control and **p<0.01 CBD+ wortmannin compare with 
CBD.  
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3.4.2.15 The role of ROS in CBD induced phagocytosis 
In order to investigate the role of reactive oxygen species (ROS) in CBD 
enhancement of microglial phagocytosis BV-2 cells were incubated with 
apocynin, a NADPH oxidase inhibitor (25 µM) for 1 hour prior to CBD (10 
µM) exposure for 24 hours. The results show that apocynin inhibited basal 
phagocytosis but did not block the enhancement of phagocytosis in CBD-
treated BV-2 (Figure 3.26). 
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Figure 3.26: Histogram shows the effect of apocynin on CBD induced 
phagocytosis in BV-2 cells. BV-2 (5x105cells/well) pre-incubated 1 hour with 
apocynin (25 µM). Then treated with CBD 10 µM for 24 hours and control wells (C) 
were incubated with culture medium alone. The cells were loaded with 1 µm; 0.5 
µl/ml fluorescent BSA latex beads for 2 hours. The figure represents means ±SEM 
of triplicates of three independent experiments. The data are shown as percentages 
of control. Data were analysed using one-way ANOVA followed by post-hoc 
BonfeURQQL¶V PXOWLSOH FRPSDULVRQ 3 &%' FRPSDUH ZLWK (C) control; 
**p<0.01 apocynin compare with (C) control and CBD+ apocynin compare with 
CBD (ns) not significant. 
3.4.2.16 The role of intracellular calcium in microglial phagocytosis 
BV-2 cells were exposed to the intracellular Ca2+ chelator BAPTA-AM (50 
µM) 1 hour prior to CBD (10µM). 24 hours later, BV-2 cells were incubated 
for 2 hours with fluorescent latex beads. BAPTA-AM did not significantly 
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affect either basal or CBD-enhanced phagocytosis. However, pre-incubation 
with EGTA (4 mM) despite having no effect on basal phagocytosis, 
abolished the CBD-enhancement (Figure 3.27). 
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Figure 3.27: Histogram shows the effects of BAPTA-AM (an intracellular Ca2+ 
chelator) on CBD-induced phagocytosis in BV-2 cells. BV-2 cells were pre-treated 
with BAPTA-AM (50 µM) or with EGTA 4mM for 60 minutes prior to CBD (10µM) for 
24 hours. Control wells were incubated in culture medium alone. Cells were then 
loaded with fluorescent BSA latex beads (1µm; 0.5ul/ml) for 2 hours. The figure 
represents means ±SEM of triplicates of three independent experiments. The data 
are presented as percentage of control. Data were analysed using one-way ANOVA 
followed by post-hoc %RQIHURQQL¶V PXOWLSOH FRPSDULVRQ P<0.01CBD compare 
with control; (ns) not significant CBD+ BAPTAM compare with CBD; **p<0.01 
CBD+EGTA compare with CBD. 
3.4.2.17 Effect of CBD and ATP on intracellular calcium in BV-2 cells 
ǋ0$73UDSLGO\DQGWUDQVLHQWO\LQFUHDVHGFDOFLXPQHDUO\IROGIURP
the basal levels. In contrast, CBD (10 µM) produced a sustained response, 
albeit of a similar peak height. Given the reports of CBD acting as a TRPV2 
agonist (Qin et al., 2008), we examined the effects of a TRP channel 
blocker, ruthenium red 55 ZKLFK IXOO\ UHYHUVHG &%'¶V HIIHFW )LJXUH
3.28; C). 
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Figure 3.28: Histograms shows the effect of CBD on intracellular calcium in BV-2 
by fura-2 ratiometric calcium imaging. In panels (A), ATP was added to cells to 
show the induction of rapid and transient increase in [Ca2+]i. After a thorough wash 
with HBSS, buffer, second dose of ATP was added to the cells. (B) 10µM CBD was 
added after a thorough wash with HBSS, buffer and second dose was loaded (C) 
CBD was added with RR to cells. Changes in calcium were measured by converting 
the 340/380 ratio of Fura-2 florescence (D) A bar chart with pooled data and error 
bars (A, B and C), data obtained from at least three independent experiments (n = 
40 cells) were averaged and plotted. 
 
3.4.2.18 The role of transient receptor potential channels in CBD- 
enhancement of phagocytosis 
The concentration dependence of the TRP channel blocker ruthenium red 
(RR) was assessed by incubating BV2 cells at 100 nM, 1 µM and 10 µM for 
1 hour which were then treated with or without CBD (10 µM) for 24 hours. 
BV-2 cells were then incubated with fluorescent latex beads for 2 hours. 
RR, at the maximum concentration employed, had no effect on basal 
phagocytosis but blocked the enhancement due to CBD (Figure 3.29), while 
lower concentrations were less effective.  
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SKF-963651 -(beta-[3-(4-methoxy-phenyl) mpropoxy]-4-
methoxyphenethyl) 1H-imidazole hydrochloride), a blocker of TRPC, TRPV 
sub-family channels and of receptor-mediated and voltage-gated Ca2+ 
entry (Bomben and Sontheimer, 2008; Merritt et al., 1990; Kim et al., 
2003), also completely prevented the enhancement of phagocytosis due to 
CBD (Figure 3.30) indicating that the effect of CBD is dependent on the 
influx of extracellular Ca2+, probably via TRP channels. 
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Figure 3.29: Histogram shows the effect of ruthenium red on CBD induced 
phagocytosis in BV-2 cells. BV-2 (5x105cells/well) were pre-incubated with RR (100 
nM, 1µ M and 10 µM) for 1hour, and then treated with CBD alone or in combination 
with RR for 24 hours. Control wells (C) were incubated with culture medium alone. 
The cells were loaded with 0.5 µl/ml fluorescent BSA latex beads for 2 hours. The 
figure represents means ±SEM of triplicates of three independent experiments. The 
data are shown as percentages of control. Data were analysed using one-way 
ANOVA followed by post-hoc %RQIHURQQL¶V PXOWLSOH FRPSDULVRQ 3&%'
compare with control; **p<0.01 CBD+ RR compare with CBD. 
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Figure 3.30: Histogram shows the effects of SKF96365 (SK) on CBD induced 
phagocytosis in BV-2 cells. BV-2 (5x105cells/well) pre-incubated with SK at (10µM) 
for 1hour, and then treated with CBD alone or with SK for 24 hours. Control wells 
(C) were incubated with culture medium alone. The cells were loaded with 0.5 µl/ml 
fluorescent BSA latex beads for 2 hours. The figure represents means ±SEM of 
triplicates of three independent experiments. The data are shown as percentages of 
control. Data were analysed using one-way ANOVA followed by post-hoc 
%RQIHURQQL¶V PXOWLSOH FRPSDULVRQ 3&%' FRPSDUH ZLWK FRQWURO QRW
significant SK compare with control; ***p<0.001 CBD+ SK compare with CBD. 
3.4.2.19 Expression of TRPV2 in BV-2 cells. 
In BV-2 cells, intense TRPV2-like immunofluorescent staining was observed 
throughout control cells (Figure 3.31; A). 
3.4.2.19.1 Effect of CBD on TRPV2 expression. 
To monitor the expression of TRPV2 and to evaluate the effect of CBD BV-2 
cells were serum-starved 3 hours prior to treatment with CBD alone or in 
the presence of CBD plus the protein synthesis inhibitor cycloheximide or a 
PI3K inhibitor. In the cells treated with CBD for 1 hour, TRPV2 staining was 
clearly enhanced in the region of the cell membrane with apparently 
reduced staining in the cytoplasm, suggesting that CBD caused a 
translocation of TRPV2 to the membrane (Figure 3.30 ;B), this was 
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abolished in the presence of cycloheximide and with the PI3K inhibitor 
(Figure 3.31 ; C, E, F). 
3.4.2.19.2 The effect of latex bead phagocytosis on translocation of 
TRPV2 
In order to evaluate the significance of expression and translocation of 
TRPV2 to the cell membrane in phagocytosis, in BV-2 cells TRPV2 staining 
was present in the plasma membrane (Figure 3.31; D). 
3.4.2.19.3 Effect of serum on translocation of TRPV2 in BV-2 
To investigate other agents potentially causing changes of localization of 
TRPV2, BV-2 cells were incubated in 10% foetal bovine serum (FBS) at 5, 
15, 30 and 60 minutes. In most of the un-stimulated cells, diffuse TRPV2-
like immunofluoresence was observed in the cytoplasm. Addition of serum 
induced changes in the distribution of the TRPV2 towards the margin of the 
cells. The effect of serum was observed within 5 min (result not shown) 
and persisted for at least 60 minutes (data not shown).  
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Figure 3.31: Images show the localization of TRPV2 in BV-2 by 
immunocytochemical analysis. (A) Control (B) CBD 10µM incubated for 1 hour (C) 
CHX 1µM incubated 1 hour prior to treatment with 10µM CBD for 1 hour (D) BV-2 
incubated with non-fluorescent latex beads 0.5µl/ml for 2 hours (E) BV-2 incubated 
with wortamannin 10 µM 1 hour before 10 µM CBD for 1hour (F) RR 10µM 
incubated 1 hr prior to CBD for 1 hr (G) BV-2 cell without primary antibody stained 
with rhodamine phalloidin and secondary antibody. The cells were visualized by 
confocal microscopy under 63X magnification using a glycerin immersion objective 
lens.  
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3.4.2.19.4 Expression of TRPV2 in primary murine microglial cells 
To examine the expression of TRPV2 in murine brain microglia, double 
staining for TRPV2 and the microglial marker IBɲ-1was assessed. We 
observed overlap of TRPV2 and IBɲ-1 staining. In IBɲ-1-positive microglia, 
TRPV2 translocation to the cell membrane was observed during activation 
with CBD (10µM) for 24 hours, confirming the results with BV-2 cells 
(Figure 3.32; B). 
 
 
Figure 3.32: Images show the effect of CBD on colocalization of TRPV2 in 
primary mouse microglial cells by immunocytochemical analysis (A) control cell 
incubated with free serum media for 24 hours, (B) cell treated with CBD 10 µM for 
24 hours. Cells were fixed with formaldehyde, permeabilized with 0.1% Triton X-
100, incubated overnight with the TRPV2 antibody (green), microglia marker (,%Į-
1) (red) and 60 min with a fluorescent secondary antibody and a nucleus is stained 
with DAPI (blue) yellow (red+green). The cells were visualized by confocal 
microscopy under 63X magnification using a glycerin immersion objective lens.  
 
3.4.2.20 Effect of CBD on TRPV2 protein expression in BV-2 
cells 
The expression of TRPV2 protein in BV-2 cells was investigated and found 
to be positive by Western blotting (Figure 3.33) in whole cells and 
membrane fractions; BV-2 cells were then incubated with CBD (10µM) at 5, 
10, 15, 30, 60 minutes and 24 hours as shown in Figure 3.33. In addition, 
the effects of RR and wortmannin were examined.  
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BV-2 cells were incubated with RR or wortmannin 1 hour prior to CBD for 1 
hour.  CBD significantly enhanced whole cell TRPV2 expression after 30 and 
60 minutes of incubation but this had returned to control levels by 24 
hours at which time expression in the membrane fraction was much 
enhanced by CBD. Basal and CBD-enhanced TRPV2 expression were 
reduced in the presence of cycloheximide. Interestingly, TRP channel 
blockade (using ruthenium red) and PI3K inhibition somewhat reduced the 
enhanced expression due to CBD, while Rho/Rho kinase inhibition was 
ineffective (Figure 3.34).  
 
 
Figure 3.33: Western blot and histogram show increase of TRPV2 protein 
expression by CBD in whole lysis cells and membrane in BV-2. BV-2 were incubated 
with CBD (10 µM) for 5, 10, 15 and 60 minutes alone. Cycloheximide (CHX 1 µM) 
was incubated for 6 hours prior to CBD. Data shown are ratios of TRPV2: GAPDH 
expression and represent the means ± SEM of 3 independent experiments. Data 
were analysed using one-way ANOVA followed by post-hoc %RQIHURQQL¶V PXOWLSOH
FRPSDULVRQ3&%'´YVFRQWURO3&%'KYVFRQWURO3
CBD 24hrs (membrane) vs. control; **p<0.01 CBD+ &+; ´ YV &%' ´
***P<0.001 CBD+CHX 1h vs. CBD 1h. 
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Figure 3.34: Western blot and histogram shows the effect of MAPK inhibitors (a 
Rho and PI3K) and non selective TRPVs inhibitor on CBD 10 µM caused TRPV2 
activation at 1 hour in whole lysis of BV-2. RR (non selective TRPVs inhibitor) and 
wortmannin (a PI3K inhibitor) at 10 µM significantly inhibited TRPV2 stimulated by 
CBD after 1 hour, whereas Y27632 (a Rho inhibitor) did not block TRPV2 expression 
induced by CBD.  Data were analysed using one-way ANOVA followed by post-hoc 
%RQIHURQQL¶V PXltiple comparison; **P<0.01 CBD 1hr vs.  control; ***P< 0.001 
CBD+ RR vs. CBD 1hr;  **P<0.01 CBD+ wortmannin vs. CBD 1h. 
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3.4.2.21 The role of a protein synthesis inhibitor (cycloheximide) 
on CBD-enhanced phagocytosis 
To test the hypothesis that CBD was acting via up-regulation of TRPV2 
receptor protein, we assessed the effect of cycloheximide, a protein 
synthesis inhibitor (CHX). BV2 cells were incubated with 1µM CHX for 6 
hours then treated with or without CBD (10 µM) for 24 hours before 
incubation with fluorescent latex beads for 2 hours. The results show that 
CHX reversed the CBD enhancement without affecting basal phagocytosis 
(Figure 3.35). 
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Figure 3.35: Histogram shows the effect of cycloheximide (CHX) on phagocytosis 
in BV-2 cells (5x105cells/well); BV-2 cells were pre-incubated with CHX (1 µM) for 
6hour, then treated with CBD for 24 hours. Control wells (C) were incubated with 
culture medium alone. The cells were loaded with fluorescent BSA latex beads (1 
µm; 0.5 µl/ml) for 2 hours. The figure represents means ±SEM of triplicates of 
three independent experiments. The data are shown as percentages of control. 
Data were analysed using one-way ANOVA followed by post-hoc %RQIHURQQL¶V
multiple comparison; **P<0.01CBD vs. (C) control; ***p<0.001 CBD+ CHX vs. 
CBD.  
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3.4.2.22 TRPV2 receptor message  
Quantitative RT-PCR analysis indicated that TRPV2 mRNA was expressed at 
measurable levels in un-stimulated BV2 cells. There was a trend towards 
an increase, albeit non-significant, after 60 min incubation with CBD 
(10µM) and at 24 hours there was a considerable enhancement (Figure 
3.36). 
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Figure 3.36: Histogram shows expression of TRPV2 in BV-2 cells and the effect of 
CBD on activation of TRPV2 by RT-PCR. RNA was extracted using Trizole reagent 
and RNA samples were reverse transcribed using the superscript reverse 
transcription, using mouse actin as a normalizing gene.  Data are means ± SEM of 
triplicate determinations of TRPV2/mouse actin ratio conducted in three separate 
experiments. Data were analysed using one-way ANOVA followed by post-hoc 
comparison; ***P<0.001, CBD 24hours compare with control. 
3.4.2.23 Vanilloid receptor (TRPV1) protein expression in BV-2 
We also investigated the expression of TRPV1 channels in BV-2 cells 
(Figure 3.38; A). CBD enhanced TRPV1 expression significantly at 60 
minutes and this had returned approximately to control levels by 24hrs. 
TRPV1 (95-100 kDa) and GAPDH (36 kDa) was assessed in Western blots 
probed with specific antibodies. CBD enhancement of TRPV1 expression 
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was blocked by treatment with the channel blocker RR and by the PI3K 
inhibitor wortmannin (10 µM at 1 hour) (Figure 3.37).  
 
 
C
CB
D 1
0m
in
CB
D 1
5m
in
CB
D 3
0m
in
CB
D 1
h
CB
D (
24
h)
CB
D+
RR
(1h
)
CB
D+
w
or
tm
an
nin
 
(1h
)
0
1
2
3
**
*
*
*
*
TR
PV
1 
/G
AP
D
H
 
 
Figure 3.37: Western and histogram show the effect of CBD on TRPV1 protein 
expression of whole lysis cells in BV-2. BV-2 were incubated with CBD (10 µM) for 
10, 15, 30, 60 mins and 24 hrs alone. RR (non-selective TRPV channel blocker) and 
wortmannin (a PI3K inhibitor) at 10 µM significantly inhibited TRPV1 stimulated by 
CBD after 1 hour, whereas Y27632 (a Rho inhibitor) did not block TRPV1 expression 
induced by CBD. The data represent the mean of 3 experiments± SEM. Normalized 
to GAPDH from three independent cultures. Data were analysed using one-way 
ANOVA followed by post-hoc comparison;*P<0.05 CBD 30 (mins) vs. (C) control, 
*P<0.05 CBD 1hrs vs. control; *P< CBD24hrs vs. control; *P<0.05 
CBD+wortmannin 1hr compare with CBD 1hr; **P< 0.05 CBD+RR compare with 
CBD1hr. 
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Figure 3.38: (A) Images show the expression of TRPV1 protein in control BV-2 
cells by immunocytochemical analysis. (B) control cell without primary antibody 
stained with rhodamine phalloidin. BV-2 Cells were fixed with formaldehyde, 
permeabilized with 0.1% Triton X-100, incubated overnight with the TRPV1 
antibody and 1h with a fluorescent secondary antibody. The cells visualized by 
confocal microscopy under 63X magnification.  
 
3.4.2.24 The role of AKT (protein kinase B) in CBD-mediated 
phagocytosis 
AKT is involved in several cellular processes such as cytoskeleton 
rearrangements and macrophage activation (Chan et al., 1999). CBD was 
tested for its ability to activate (phosphorylate) AKT. Incubation of cultured 
BV-2 with CBD (10 µM) failed to activate phosphorylation of AKT, whereas 
LPS stimulated phospho-AKT at 30 minutes and 24 hours (Figure 3.39). 
This result was confirmed by immunocytochemical  analysis in which CBD 
also failed to alter AKT in BV-2 (Figure 3. 40; B). 
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Figure 3.39: Western and histogram shows ratio of p-AKT and total AKT and the 
effect of CBD on AKT protein in BV-2 cells.  BV-2 incubated with CBD 10 µM at 15, 
30, 60 minutes and 24 hours alone or with wortmannin (a PI3K inhibitor) at 10 µM, 
which failed to activate of AKT activation at any time. LPS 100ng alone at time 
indicated significantly stimulated AKT.  Data shown is the mean of 3 experiments± 
SEM. Data were analysed using one-way ANOVA followed by post-hoc 
comparison;**P<0.01 LPS (24hrs) vs. (C) control, **P<0.01 LPS (30mins) vs. (C) 
control. 
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Figure 3.40: Images show the expression of P-AKT (A) Control and (B) the effect 
of CBD 10µM (at 1 hr) on P-AKT protein in BV-2 by immunocytochemical analysis. 
BV-2 Cells were fixed with formaldehyde, permeabilized with 0.1% Triton X-100, 
incubated overnight with the AKT antibody and 1hr with a fluorescent secondary 
antibody. The cells visualized by confocal microscopy under 63X magnification.  
3.4.3 Migration  
3.4.3.1 Effect of UDP on cell migration in RAW 264.7 cells  
Using the migratory device developed in the School of Biomedical Sciences, 
University of Nottingham (see method) we tested the effect of UDP (a 
selective P2Y6 receptor agonist) on RAW 264.7 monocyte/macrophage cells 
migration as a positive control to validate the device. We found that UDP 
(10 µM) stimulated migration significantly at 24 and 72 hrs. 
 
 
188 
 
3 h 24
h
72
h
0
1
2
3
C UDP C CUDP UDP
**
**
R
at
e 
o
f M
ig
ra
tio
n
 
Figure 3.41: Histogram shows the effect of UDP (10µM) on RAW 264.7 cell 
migration at (3, 24 and 72 hs).  RAW 264.7 were incubated with 10% FSA medium 
only (control) or with 10 µM UDP. Data represent means±S.E.M of three 
independent experiments. **P<0.01, two way ANOVA compared with control.   
3.4.3.2 Effect of CBD on BV2 cell migration  
 CBD (10uM) significantly enhanced BV-2 migration to a degree equivalent 
to that of UDP after 24 and 72 hrs of exposure (Figure 3.42 and 3.43). 
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Figure 3.42: Histogram show the effect of CBD (10µM) on BV-2 cell migration 
(10 µM) at 3, 24 and 72 hrs. BV-2 cell migration induced by CBD 10 µM at the 
indicated times. BV-2 cells were incubated with 10% FSA medium only (control) or 
with 10 µM CBD. Data represent means ±S.E.M of three independent experiments. 
**P<0.01 CBD vs. control, two way ANOVA. The rate of migration represents of 
difference between indicating migration with the basal using power point (see 
below). 
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Figure 3.43: BV-2 cell migration induced by CBD (10 µM) at 3, 24 and 72 hrs. 
Images showing BV-2 cell migration induced by CBD 10µM. BV-2 cells were 
incubated with 10% FSA medium only (control) or with 10 µM CBD using inverted 
microscope attached with camera.  The rate of migration represents of difference 
between indicating migration with the basal using power point. 
 
 
 
 
190 
 
3. 5 Discussion  
3.5.1 Characterization of microglial phagocytosis 
0LFURJOLDWKHEUDLQ¶VPDFURSKDJHV6WUHLWHWDO&KHZHWDO
play a critical role in remodeling and regenerating cells as well as providing 
the first line of defense against infection and brain insult (Liu et al., 2001; 
Perry, 2004). The ability of these cells to remove apoptotic cells by 
phagocytosis is essential for normal development, tissue homeostasis, and 
responses to injury or diseases (Hanisch and Kettenmann, 2007; Streit, 
2001).  The phagocyte removal of dying cells is generally believed to be a 
beneficial process and failure to clear apoptotic cells and/or cellular debris 
can itself lead to neuroinflammation and neurodegeneration (Napoli and 
Neumann, 2009). Furthermore, the phagocyte removal of apoptotic 
leukocytes by microglia has been shown to contribute to the resolution of 
autoimmune processes (Chan et al., 2003; Noda and Suzumura, 2012). 
Recognition and engulfment of tissue debris is a very complex process 
involving multiple ligand receptor interactions.  Phagocytosis, therefore, 
represents a significant functional feature of microglial cells where the 
potential to influence the phenomenon by brain-penetrating ligands could 
result in therapeutic benefit. 
Phagocytosis in the present study was assessed by measuring the ingestion 
of BSA latex particles, essentially as described by others. The first part of 
the chapter describes the characterization of phagocytosis in BV2 and other 
microglial cells as measured by this method. We found that at least 2 hours 
incubation with beads was required to be able to measure significant 
phagocytosis. It was clear that microglia at lower temperatures have a 
much lower ability to phagocytose beads in comparison to phagocytosis at 
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37 °C, consistent with previous studies which have reported that in vitro 
hypothermia suppresses microglial activation (Si et al., 1997). 
We assessed the functioning of the actin cytoskeleton in phagocytosis, 
using cytochalasin D. Cytochalasin D retards actin assembly by binding to 
actin filament ends (Brown and Spudich, 1981) and binds with high affinity 
to F-actin (Flanagan and Lin, 1980). In the present study, cytochalasin D 
completely blocked the phagocytosis of latex beads by BV-2, in agreement 
with the observation by Ting-Beall et al. (1992). In contrast, neither the 
mitochondrial uncoupler FCCP nor the mitochondrial ATPase inhibitor 
oligomycin had an effect on phagocytosis of latex beads, indicating that 
mitochondrial energy production is not important, at least not in the short 
term, for BV2 phagocytosis to proceed. 
Myosin II plays an important role in the formation of phagosomes during 
FcR-mediated phagocytosis in macrophages and it has been shown to be 
localized around developing phagosomes (Diakonova et al., 2002; de 
Lanerolle et al., 1993). Previous reports indicated that myosin II was 
required for FcR-mediated phagocytosis but not actin recruitment (Olazabal 
et al., 2002). Fc Ǆ is the receptor for phagocytosis of immunoglobulin-
opsonized cells and particles (Aderem and Underhill, 1999). In this study, 
myosin II light chain expression was activated during latex beads 
phagocytosis and appeared to become localized around the beads when 
compared to the control (bead-free) cells. 
CD11b is widely expressed on both phagocytotically active cells and 
microglial cells in the CNS and is involved in the complement-mediated 
phagocytosis of pathogens (Stevens et al., 2007).   Our results suggested 
that CDIIb failed to activate during latex-bead phagocytosis when 
compared with LPS-treated BV2 cells used as positive control. Phagocytosis 
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itself did not appear to activate microglia in the same way as an 
inflammatory challenge, as judged by CDIIb expression, in contrast, to the 
widespread view that activation is a requirement for phagocytosis 
(Kettenmann, 2007). 
Activated PLC-Ǆ, for example, following activation of Fc receptors, 
translocates to the inside surface of the cell membrane and catalyzes the 
hydrolysis of membrane-associated phosphatidylinositol 4,5-bisphosphate 
to form diacylglycerol and inositol 1,4,5-trisphosphate, which are capable 
of activating protein kinase C (PKC) and mobilizing intracellular calcium 
([Ca2+]i), respectively (Newton, 1997).  :HLQYHVWLJDWHGWKHUROHRI3/&Ǆ
in latex beads mediated phagocytosis in BV-2 microglia. PLCǄ2 appeared to 
be translocated around the beads and cell membrane after ingestion. PLCǄ 
may influence actin rearrangement, and loss of function of PLC results in 
impaired membrane ruffling (Kurokawa et al, 2004).  
Several studies indicate that PKC activity is required for FcǄR-mediated 
particle uptake. Phagocytosis of IgG-opsonized particles induces PKC 
activation anGWUDQVORFDWLRQWRWKHPHPEUDQHIUDFWLRQ3.&ĮUHJXODWHVWKH
interaction of MARCKS with actin; its localization to the phagosome 
suggests a role in phagocytosis and phagosome maturation (Aderem and 
Underhill, 1999; Allen and Aderem, 1996). Consistent with these studies, 
we found that both 3.&Į DQG3.&İWUDQVORFDWHGWRWKH%9FHOOPHPEUDQH
indicating an involvement in phagocytosis of latex beads.   
3.5.2 Regulation of phagocytosis 
It has been shown that pharmacological or immunological intervention can 
modulate the ability of microglia or macrophages to phagocytose and an 
aim of this chapter was to determine whether cannabinoids could act as 
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modulators of the process in BV2 and HAPI cells and mouse microglia in 
primary culture. JWH133, (a selective CB2 agonist), AM251 (a CB1 
antagonist and putative GPR55 agonist), phytocannabinoid (THC, CBN, 
CBDA, CBDV, THCV), CP55, 940 (CB1/CB2 agonist), endocannabinoids (AEA 
and 2-AG) and the GPR55 endogenous ligand LPI, all failed to alter the 
phagoctosis activity in microglia or macrophages. WIN55-212-2 (a CB1/CB2 
agonist), however, inhibited phagocytosis of latex beads, albeit at a 
concentration well above that required to activate cannabinoid receptors.   
Given the lack of expression of cannabinoid receptors in the BV2 cells used 
in this study (discussed in Chapter 2) this is not surprising. However, the 
non-psychoactive phytocannabinoid cannabidiol did significantly enhance 
phagocytosis. Cannabinoids have been noted to interact with numerous 
µRII-WDUJHW¶ VLWHV RWKHU WKDQ CB1/CB2 receptors and to affect fundamental 
processes involved in microglial cell activation, with one prominent 
recently-identified target being GPR18 (McHugh et al., 2010). However, 
NAGLY, an agonist of the orphan GPCR GPR18, did not inhibit or stimulate 
latex bead phagocytosis in BV-2 cells, and 0-1918 (abn-CBD antagonist) 
did not reverse CBD activation of phagocytosis. These findings rule out the 
involvement of GPR18 and abn-CBD receptors in phagocytosis and 
specifically in the enhancement due to CBD. Indeed, the finding that 
pertussis toxin had no effect either on basal or CBD-enhanced phagocytosis 
excludes the involvement of any Gi/o-linked receptors in BV2 phagocytosis. 
The roles of the purine receptors P2Y and P2X were evaluated in latex bead 
phagocytosis using UDP and ATP. Koizumi et al., (2007) have reported that 
microglia express the P2Y6 receptor, where activation by the endogenous 
agonist UDP triggers microglia phagocytosis. The robust activation of 
phagocytosis by UDP in the BV2 cells is consistent with this. On the other 
hand, ATP failed to alter phagocytic activity. This does not agree with 
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recent findings reporting that extracellular ATP at millimolar (0.5-1 mM) 
concentrations inhibits phagocytosis in mouse macrophages (Fang et al., 
2009) and indicates that microglial and macrophage phagocytosis are 
differentially controlled. 
We then investigated the potential roles of pro-inflammatory activators in 
latex bead phagocytosis in BV-2. Having previously assessed bacterial LPS 
(see Chapter 2), the effects of LPS and IFN-ǄZKLFK UHSRUWHGO\DFWLYDWHV
phagocytosis through activation of FcǄ receptors (Corradin et al., 1991), 
were investigated. We found that both bacterial LPS and interferon 
stimulated latex bead phagocytosis. This observation is consistent with 
previous studies showing that microglia are stimulated by bacteria or 
bacterial products and can protect the brain by phagocytosis and killing of 
pathogens (Redlich et al., 2012).  
NO is reported to attenuate phagocytosis in microglia; the mechanism is 
not currently known, but modification of the cytoskeleton and inhibition of 
pseudopodia formation have been documented (Jun et al., 1996). Kopec 
and Carroll, (2000) recently reported that the excessive formation of NO 
from cells within areas of brain inflammation may lead to the loss of 
microglial phagocytosis in these regions resulting in the inability of 
microglia to clear debris, resulting in neurodegenerative diseases. 
However, results presented here provide no support for the involvement of 
nitric oxide in bead phagocytosis in BV2 cells; for example, the iNOS 
inhibitor 1400W failed to alter latex bead phagocytosis.  
Microglial activation may induce the rapid generation of ROS through 
NADPH oxidase (Sankarapandi et al., 1998) and (Bergend et al., 2003) 
suggested that ROS produced during phagocytosis are critical for the 
bactericidal action of phagocytes. We, therefore, investigated the role of 
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NADPH oxidase on phagocytosis using the NADPH oxidase inhibitor 
apocynin. Basal phagocytosis was attenuated by apocynin but CBD was still 
able to provide significant enhancement. It is interesting that even when 
ROS generation is compromised, the phagocytic action of microglia is still 
capable of amplification (in this case by CBD). 
Next, we performed some experiments in order to investigate if another 
class of anti-inflammatory drugs could modulate the microglial phagocytic 
activity, using minocycline and dexamethasone. Minocycline (a tetracycline 
derivative) has anti-inflammatory effects and is neuroprotective in models 
of traumatic brain injury (Bye et al  3DUNLQVRQ¶V GLVHDVH DQG
$O]KHLPHU¶V GLVHDVH &KRL HW DO  +RZHYHU PLQRF\FOLQH IDLOHG WR
alter phagocytosis in BV-2 cells and did not reverse the CBD-mediated 
phagocytosis. This observation is supported by previous studies which 
showed minocycline inhibiting the production of pro-inflammatory cytokines 
E\KXPDQPLFURJOLDZLWKRXWDIIHFWLQJWKHSKDJRF\WRVLVRIDP\ORLGǃILEULOV
(Familian et al., 2007). 
Dexamethasone, as expected, promoted phagocytosis in a concentration-
dependent manner with the most prominent effect at 1 µM. Liu et al. 1999 
have reported that the steroid augmentation of phagocytosis in 
macrophage cells was mediated through the glucocorticoid receptor (GR) 
and blocked by the GR antagonist RU38486. Steroids such as 
dexamethasone, are recognized for their anti-inflammatory properties and 
their ability to inhibit production of pro-inflammatory cytokines such as 
TNF-Į %DUQHV  )XUWKHUPRUH WKH\ DUH GRFXPHQWHG WR LQFUHDVH
phagocytosis of apoptotic cells (Heasman et al., 2004). This observation 
may explain, at least in part, the powerful anti-inflammatory properties of 
steroids and their attenuation of chronic inflammatory conditions.  These 
data are supported by a study by Giles et al., (2001), which reported 
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dexamethasone activation of a phagocytic phenotype in macrophages with 
changes in adhesion-dependent loss of phosphorylation of adhesion 
mediators (paxillin and pyk2), reorganization of cytoskeletal elements and 
increased amounts of Rac GTPase. 
+DYLQJ UXOHG RXW WKH LQYROYHPHQW RI&%'¶V HQKDQFHPHQW of phagocytosis 
by Gi-coupled receptors, including cannabinoid receptors, we evaluated 
potential signaling pathways associated with CBD-mediated latex-bead 
phagocytosis. First, we tested the role of phosphatidylinositol 3-kinase (PI-
3K). The PI-3K pathway has been shown to be essential for pseudopod 
extension, a necessary step in phagocytosis. Furthermore, PI-3K was 
UHTXLUHGIRUJHQHDFWLYDWLRQDIWHU)FǄ5HQJDJHPHQWKanzaki et al., 1991). 
However, we found that PI3K inhibition with wortmannin reduced basal 
phagocytosis but that CBD was still able to produce a marked enhancement 
in its presence.   
We then investigated the role of Rho/ROCK signaling in latex bead 
phagocytosis. ROCK promotes actin±myosin-mediated contractile force 
generation through the direct phosphorylation of the regulatory myosin 
light chain (MLCII) and the myosin-binding subunit (MYPT1) of MLC 
phosphatase to inhibit catalytic activity. ROCK also plays a role in cell 
motility, adhesion, neurite retraction, and phagocytosis (Riento and Ridley, 
2003). 
 Moreover, Rho/ROCK is involved in phagocytosis that is mediated by the 
complement receptor 3 (CR3 EXW QRW IRU SKDJRF\WRVLV WKURXJK WKH )FǄ
receptors (Caron and Hall, 1998; Olazabal et al., 2002). In the present 
study using Y27632 (a Rho/ROCK inhibitor) we found, as with wortmannin, 
that Y27632 suppressed basal levels, but did not prevent CBD 
enhancement, of phagocytosis.  
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We then extended our analysis to P38, another MAPK regulator of 
microglial activation. Previous studies have suggested that the involvement 
of P38 kinase in phagocytosis might be due to the ability of P38 to 
phosphorylate the small heat shock protein HSP27 (Krump et al., 1997). 
HSP27 plays an important role in modulation of actin microfilament (Lavoie 
et al., 1993). Our data showed that P38 kinase was required for maximum 
basal phagocytic activity but it was not necessary for CBD enhancement.  
Mobilization of intracellular calcium represents an important second 
messenger in cells and in microglia can be required for many 
inflammatory-mediated responses, affecting enzymes, ion channels, gene 
transcription and proliferation in all eukaryote cells. The actin cytoskeleton 
has been shown to play a role in the generation of calcium transients in 
some cells (May and Machesky, 2001). The involvement of intracellular 
calcium stores in CBD elevation of [Ca2+]i has also been demonstrated in 
hippocampal cells (neurons and glia) in culture (Drysdale et al., 2006).  
Decreasing internal [Ca2+] by an intracellular chelator of calcium ions 
(BAPTA-AM) did not inhibit phagocytosis of latex beads nor did it reverse 
CBD-enhanced phagocytosis.  
This is perhaps conflicted with previous published data showing that 
BAPTA-AM had reduced Zymosan Phagocytosis in macrophages. However, 
these results and other studies suggest that the regulation of calcium 
mobilization and its role in phagocytosis differs depending on the receptors 
involved in mediating particle uptake (Girotti et al., 2004). 
Although depletion of intracellular stores can trigger a capacitative Ca2+ 
entry (Roderick and Cook, 2008). Furthermore, there is growing evidence 
reported that Ca2+ chelation does not attenuate particle binding by 
macrophages (Link et al., 2010). However, when the transmembrane Ca2+ 
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gradient was reduced in the presence of EGTA, the effect of CBD was 
abolished, suggesting that Ca2+ influx is required. Stimulation of 
phagocytosis by CBD was reversed by subsequent addition of 4 mM 
external Ca2+ (data not shown) so that the result could not be explained by 
a cytotoxic effect of EGTA.  
Extracellular Ca2+ could represent a major source of mobilized [Ca2+]i as a 
result of binding to the FcR. Binding of the FcR results in a transient 
membrane depolarization of the intact macrophage (Roderick and Cook, 
2008). This depolarization effect could activate opening of voltage-
dependent Ca2+ channels on the plasma membrane of macrophages, 
increasing cytosolic Ca2+ levels. 
That Ca2+ entry underpins the effect of CBD is supported by the finding 
that CBD produced an increase in [Ca2+]i equivalent to that of ATP in BV2 
cells. A similar effect has been reported in a previous study in which CBD 
elevated intracellular Ca2+ ([Ca2+]i) above the basal levels (Drysdale et al., 
2006).  Furthermore, this increase was blocked by the non-selective TRP 
channel blocker ruthenium red strongly suggesting the involvement of one 
of the TRP family members as the mediator of CBD enhancement of 
phagocytosis. A prime candidate is TRPV2 receptor as previous work has 
shown CBD elevation of calcium via this receptor channel (Qin et al., 
2008). 
In support of this proposed mechanism, SKF96365, an inhibitor of 
receptor-mediated and voltage-gated Ca2+ entry also abolished the effect 
of CBD. Link et al. (2010) have reported TRPV2 involvement in early 
phagocytosis and it appears to be essential for innate immunity. TRPV2 
channels play an important role in particle binding, the first step of 
phagocytosis (Link et al., 2010). In addition to potentially activating TRPV2 
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channels, CBD appears to have an effect on TRPV2 protein expression and 
cell localization. CBD enhancement was reversed by the protein synthesis 
inhibitor cycloheximide (CHX) although this did not affect basal 
phagocytosis. This is further supported by recent reports that CBD 
increases TRPV2 expression, both at mRNA and protein levels in 
glioblastoma multiforme cells (Nabiss et al., 2012). 
In the present experiments, there was a rapid enhancement of TRPV2 
protein expression due to CBD and this appeared to involve translocation of 
TRPV2 to the cell membrane with marked localization there by 24 hours. 
TRPV2 mRNA was also markedly increased by 24 hours although increases 
were difficult to detect over the first hour during which whole cell protein 
expression peaked. The reasons for this apparent disparity are unclear, but 
might be due to methodological or assay sensitivity differences.  A further 
possibility exists that CBD influences protein translation without 
immediately altering gene transcription. 
Interestingly, the enhanced expression was abolished in the presence of 
the TRP channel blocker and calcium-induced calcium release blocker from 
the ryanodine-sensitive intracellular calcium stores (Phillippe and Basa, 
1996) aruthenium red, suggesting that the enhancement depends upon 
CBD activation of TRP channel activity with consequent Ca2+ entry and 
increases in gene transcription. TRPV2 channel activity is controlled by 
growth factors acting through a PI3-kinase-dependent signaling pathway 
(Kanzaki et al., 1999). These data suggest the PI3-kinase pathway, may 
encourage a constitutive activity of TRPV2 channels.  
TRPV2 translocation to the plasma membrane might be regulated by other 
mechanisms. It has been proposed that calcium could be involved in such a 
dynamic regulation of TRPV2 channels (Boels et al., 2001) by stimulating 
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TRPV2 channel activity and, therefore, calcium influx, PI3-kinase could 
indirectly promote channel trafficking to the plasma membrane. Moreover, 
a TRPV2 associate known as the recombinase gene activator (RGA) protein 
has been reported. The RGA protein is localized at the endoplasmic 
reticulum/Golgi apparatus and interacts with intracellular TRPV2 (Barnhill 
et al., 2004). Interaction of RGA with TRPV2 promotes the basal surface 
localization of TRPV2 and control of TRPV2 surface levels (Stokes et al., 
2005).  (Barnhill et al. (2004) have demonstrated that RGA may play an 
important role for TRPV2 during the maturation of the ion channel protein. 
Other TRP channels in addition to TRPV2 might be involved in the effect of 
CBD on microglial function and the cannabinoid also rapidly enhanced the 
expression of the vanilloid channel TRPV1. Interestingly this was inhibited 
by wortmannin and ruthenium red suggesting that enhancement of channel 
activity with activation of PI-3K underpins this effect. Previous studies have 
reported that CBD has very low affinity for CB1 and CB2 receptors, but that 
it activates TRPV1 channels (Bisogno et al., 2001). Accumulating evidence 
indicates that TRPV1-receptor-mediated increases of [Ca2+]i by CBD occurs 
in a variety of cell types (Ligresti et al., 2006), including hippocampal 
neurones (Drysdale et al., 2006).  
The cannabinoid ligands THC, CP55940, CBN and AEA all failed to alter 
phagocytosis either in microglia or macrophages. Anandamide is an 
endogenous activator of cannabinoid receptors, acting on CB1 receptors 
with potency similar to that described for its action of TRPV1 (Marzo et al., 
2001; Ross, 2003). The functional relevance of the channel up-regulation is 
still to be investigated. 
LPS activates both phagocytosis and AKT in a time dependent manner 
(Faisal et al., 2005) so we next addressed whether or not the effect of CBD 
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was mediated by AKT signaling. The results show that CBD induced 
phagocytosis independently of Akt.  
3.5.3 Migration of microglial cells 
Cannabinoids, whether phytocannabinoids or endocannabinoids, have been 
found to induce migration of BV-2 microglial cells (Walter et al., 2003). In 
the present work, CBD promoted migration at 10µM concentrations in the 
BV- DQG PDFURSKDJH FHOO OLQHV XVLQJ D QRYHO ³&RPSDVV´ GHYLFH  7KH
positive control UDP also evoked a similar level of migration in BV2 cells.  
Although the cells do not express cannabinoid receptors, TRPV2 activation 
has been found to be involved in macrophage cell migration (Nagasawa et 
al., 2007). The latter report documented that the chemotactic peptide 
fMetLeuPhe induces the migration of macrophages and that this migration 
is associated with the translocation of the TRPV2 channel through a PI3K 
pathway (Nagasawa et al., 2007). 
According to the report by Walter et al., (2003), CBD increases migration 
of BV-2 cells in a Boyden chamber assay and the cannabinoids effects were 
mediated by CB2 and abnormal cannabidiol receptors. However, CBD 
significantly inhibited migration of U87 glioma cells independently of 
cannabinoid and vanilloid receptors (Vaccani et al., 2005). 
3.6 Conclusion:  
Taken together the results in this chapter demonstrate that CBD, but not 
other cannabinoids, enhances microglial and monocyte/macrophages 
phagocytosis and migration. The effect appears to be mediated by TRPV2 
channel activation leading to elevated [Ca2+]i and translocation of TRPV2 to 
the cell membrane.  
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TRPV2 has been documented as a potential pain target and is activated by 
noxious heat greater than 52°C (Caterina et al., 1999), the non-selective 
agonists 2-APB, phenylborate, DPBA (Juvin et al., 2007) and by 
probenecid. Recently it has been reported that CBD is an agonist for TRPV2 
although, no selective endogenous activators or antagonists have been 
reported. 
Translocation is an important mechanism for TRPV2 functional activation 
and it is up-regulated by growth factors which enhance its movement from 
intracellular pools into the plasma membrane (Iwata et al., 2003). PI 3-
kinase also activates TRPV2 translocation to plasma membrane (Penna et 
al., 2006) but does not appear to be involved in the enhancement due to 
cannabidiol. Although the effects of cannabidiol were not potent, it is a 
possible chemical starting point for the development of more potent TRPV2 
agonists which could have a beneficial effect on neuroinflammatory 
conditions via enhancement of microglial phagocytosis. 
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3.6.1 Summary of chapter 3 
 
Figure 3.44: The graph represents the effect of CBD in enhancement of 
phagocytosis by increasing intracellular calcium and increases the expression of 
TRPV2. The involvement of MLCII, PKC, PLC, ROS in basal phagocytosis.  
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4. Overview  
The work presented in this thesis focused upon an in vitro investigation of 
the effects of cannabinoid compounds on microglial function in order to 
explore their potential to modulate neuro-inflammatory conditions. 
When viewed as a whole, microglial activation is beneficial to most acute 
CNS pathologies. The ultimate role of microglia is to create a barrier 
between the healthy cells in the CNS and damaged or infected cells 
(Garden and  Möller, 2006; Block et al., 2007) and they are the primary 
immune cells of the CNS, playing an important part in detecting and 
removing foreign bodies which invade the brain. This involves their 
transient activation involving the expression of receptors, the release of 
cytokines and phagocytosis of cell debris. Microglia cells are, therefore, an 
essential functional part of the CNS (Garden and  Möller, 2006; Neumann 
et al., 2009) and adapted to protect the more susceptible cells, particularly 
neurons from damage. Microglial dysfunction in the form of chronic 
activation may, however, be implicated in neuroinflammatory conditions. 
The aim of studies reported here was to investigate the possibility of 
modulating microglial functions (NO release, phagocytosis, calcium 
mobilisation and migration) with cannabinoids. Cannabinoids have been 
suggested to be potentially useful therapeutic agents in the management 
RI FKURQLF SDLQ ZLWK JURZLQJ GDWD VXSSRUWLQJ WKH &% UHFHSWRUV¶ UROH LQ
immune cells, particularly microglia, in the CNS (Zhang et al., 2003). 
Nitric oxide (NO) is a key immune cell effector molecule and in the present 
study (Chapter 2), it was used as an indicator of microglial cell activation. 
The main activation stimulus used in the in vitro model was the bacterial 
exotoxin lipopolysaccharide (LPS) and it was demonstrated that LPS was 
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able to induce, in a concentration-dependant fashion, NO release in BV-2 
cells, HAPI cells (a model of activated microglia) and in murine primary 
microglial cells. The BV-2 cell line, which was the most frequently used in 
the study, possesses functional and phenotypic properties common to 
primary microglia including phagocytic ability, secretion of pro-
inflammatory cytokines and expression of surface receptors and antigens 
(Blasi et al., 1990) and, as such, is a suitable in vitro model for 
investigation of microglial function. Moreover, these immortalized cells 
replicate readily and are easy to maintain in culture, allowing for 
convenient and cost-effective experimentation when compared with 
primary microglial cells for which such studies are time consuming; only a 
very limited quantity of purified microglia can be generated and there is no 
guarantee that even primary microglial cultures retain the same phenotype 
as the cells express in situ.  
Cannabinoids have previously been reported to have effects in BV-2 cells, 
including effects on cell migration by CBD (Walter et al., 2003).  THC and 
CBD modulate the activities of BV-2 cells in different signalling pathway 
(Juknat et al., 2012). On the basis of these prior reports,  it was somewhat 
surprising that none of the cannabinoid receptor agonists in concentrations 
expected to activate CB1 and/or CB2 receptors affected LPS-stimulated NO 
formation, but it is clear that, under the culture conditions employed, the 
BV-2 cells failed to express either CB1 or CB2 receptors significantly. It does 
seem that BV-2 cell expression of cannabinoid receptors is not well 
maintained with increasing passage number (discussed in Chapter 2). The 
inhibitory effect of the CB1/CB2 agonist CP55940 on NO formation, only in 
high concentration, may be explained by its acting through other potential 
cannabinoid-like receptors, for example, GPR55 (Chapter 2), which are 
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reported to be activated by CP55940 (Ryberg et al., 2007, Kapur et al., 
2009) or some other, as yet unidentified, receptors.   
However, one cannabinoid compound, cannabidiol (CBD) was found to 
significantly attenuate the effects of microglial cell activation by bacterial 
lipopolysaccharide (LPS). CBD is the major non-psychotropic constituent of 
marijuana and it has been shown to have both anti-inflammatory and anti-
apoptotic actions on microglia (Iuvone et al., 2004; Mechoulam et al., 
2007). The ability of CBD to decrease microglial activation has been 
proposed as a treatment for neurodegenerative diseases such as cerebral 
LVFKHPLD $O]KHLPHU¶V DQG 3DUNLQVRQ¶s diseases and multiple sclerosis 
(Lastres-Becker et al., 2005; Lakhan and Rowland, 2009). However, the 
mechanism(s) through which CBD alters microglia activation is not 
understood, and, in the present project, a deal of effort was spent in 
attempting to elucidate the molecular targets for CBD, using a variety of 
experimental techniques.  
There are a number of reports suggesting the orphan receptor GPR55 as a 
potential member of the cannabinoid receptor family which may represent 
a novel pharmaceutical target (Johns et al., 2007, Ryberg et al., 2007) 
and, given that CBD has been identified as a GPR55 ligand, the potential 
roles of these receptors in modulating microglial functions were 
investigated. In the present study, GPR55 receptors appeared to be 
expressed in the BV-2 cells (as assessed by RT-PCR definition of 
measurable amounts of mRNA) and to be functional since the putative 
endogenous agonist LPI (Oka et al., 2007) produced a concentration-
dependent elevation of intracellular Ca2+ which was attenuated by CBD 
(Eldeeb et al., 2009), in agreement with its designation as a GPR55 
antagonist. However, CBD also reduced the Ca2+ response to ATP, calling 
into question its selectivity in this regard. Neither LPI nor O1602, another 
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GPR55 agonist (Johns et al., 2007), affected LPS-stimulated NO formation 
lending little support to the possibility that the effect of CBD on NO 
formation is GPR55-mediated. Nevertheless, it is conceivable, given the 
effects of the novel GSK antagonist, that GPR55 receptors in the BV-2 cells 
are constitutively active and that CBD acts as a GPR55 antagonist/inverse 
agonist under the prevailing culture conditions. However, recently found 
that responses to activation of GPR55 are not seen in the presence of 
serum. Could this explain why there are no responses observed in the 
presence of serum in the microglia (oral discussion Dr Andy Irving 
(university of Dundee). 
Although the inhibitory effect of CBD on NO formation cannot be readily 
explained as being mediated by GPR55, it is interesting that the expression 
of GPR55 message and protein were reduced by CBD (Chapter 2). The 
functional significance of this is yet to be investigated, but since the 
receptor is implicated in the modulation of pro-inflammatory cytokine 
production, at least in peripheral cells, that promote neuropathic pain 
(Staton et al., 2008), and CBD reduces neuropathic pain (Costa et al., 
2007)  it is possible that reduced microglial GPR55 expression might play a 
SDUWLQ&%'¶VDQDOJHVLF mechanism, given the significance of the role of the 
microglia-neuronal interaction in neuropathic pain (Gao and Ji, 2010). 
 In this context, the inhibitory effect of CBD on microglial COX-2 generation 
(Chapter 2) with the expected reduction in pro-inflammatory eicosanoids 
could be of consequence. Also, there is evidence that reduction of COX-2 
activity and PGE2 synthesis depression can activate phagocytosis 
(Stachowska et al., 2007), which might contribute towards the CBD 
activation of phagocytosis reported in Chapter 3.    
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Recently, CBD was shown to inhibit LPS-VWLPXODWHG1)ǉ%-dependent pro-
inflammatory cytokine release in BV-2 cells (Kozela et al., 2010) although 
no cannabinoid nor cannabinoid-related receptor was implicated in the 
effect, indicating that control of NO release is not the only microglial 
effector mechanism impacted by CBD. 
CBD is remarkable in the diversity of its actions on receptor and non-
receptor targets when employed in the micromolar concentration range 
(Pertwee, 2004; 2008) and with regard to NO formation, whether CBD is 
initially recognized by a cell surface receptor or has its effects on a 
downstream component of a signalling cascade is uncertain. The lack of 
DQ\HIIHFWRISHUWXVVLV WR[LQRQ&%'¶VDFWLRQVRURIDQ\&%'DFWLYDWLRQRI
*73Ǆ6 ELQGLQJ FHUWDLQO\ DSSHDUV WR UXOH RXW WKH LQYROYHPHQW RI DQ\ *L-
protein coupled receptors. In Chapter 3, however, evidence for mediation 
of the effects of CBD on phagocytosis by the ligand-gated ion channel 
TRPV2 was gathered. CBD generated a sustained extracellular Ca2+-
dependent increase in intracellular Ca2+ concentration in BV-2 cells which 
was inhibited by the channel antagonists ruthenium red and SKF96365 and 
there was a marked enhancement of TRPV2-like immunoreactivity 
indicating TRPV2 up-regulation, particularly in the cell membrane. There 
was an accompanying increase in TRPV2 mRNA, at least after 24 hrs, 
although the lack of significant change in message at earlier time points 
needs further investigation.  
It is somewhat counter-intuitive to see receptor activation resulting in up-
regulation of that receptor; the opposite (i.e. down-regulation) response to 
a receptor agonist being the more common phenomenon, but activation 
accompanied by up-regulation of TRPV2 possibly indicates the functional 
importance of this amplified response to channel activation in the control of 
microglial phagocytosis. 
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In innate immune cells, TRPV2 is expressed in different types of phagocytic 
cells, including macrophages, in which it mediates fMet-Leu-Phe migration, 
zymosan-, immunoglobulin G-, and complement-mediated phagocytosis 
along with Ca2+ influx and depolarisation (Nagasawa et al., 2007; Santoni 
et al., 2013). Link et al., (2010) observed that activation of macrophage 
phagocytosis is accompanied by PI (3) kinase-dependent translocation of 
TRPV2 to the phagosomes and that this was impaired in TRPV2-KO 
macrophages. 
Unfortunately, at the present time, there are no selective antagonists or 
agonists of the TRPV2 channel that could be used to unequivocally 
implicate it in the effects of CBD, although the phytocannabinoid could 
perhaps serve as a chemical template for future drug development.  
In Chapter 3, evidence was produced that TRPV1 channels might also be 
involved in the effects of CBD since their expression was enhanced in BV-2. 
However, no evidence of functional modulation was produced and future 
experiments should include testing the effects of TRPV1 antagonists, such 
as capsazepine, on CBD-enhanced phagocytosis. 
Effects of CBD on post- or non-receptor-mediated mechanisms are possible 
and results in Chapter 2 demonstrated that CBD alone enhanced 
generation of reactive oxygen species (ROS) (although it did appear to 
reduce the effects of LPS). This is interesting as ROS are reported to 
activate microglial phagocytosis (Zhang et al., 2003) and they might have 
a mediating role in CBD-enhanced phagocytosis in BV-2 cells. CBD was 
found to have a remarkable protective effect against hydrogen peroxide-
mediated microglial toxicity (Chapter 2), but whether this is related to its 
effects on ROS generation remains to be determined. 
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There is evidence demonstrating in vitro that the microglial triggering 
receptor expressed on myeloid cells-2 (TREM2) stimulates phagocytosis 
and down-regulates inflammatory signals in microglia via the signaling 
adaptor molecule DAP12 (Takahashi et al., 2005). Microglial 
TREM2/DAP12-mediated phagocytosis appears to be an essential function 
for CNS tissue homoeostasis (Neumann and Takahashi, 2007). 
Furthermore, in BV2 microglia, deletion of TREM2 led to reduced 
phagocytosis of apoptotic cells, but did not have an effect on phagocytosis 
of microbeads, indicating that TREM2 does not non-specifically promote 
phagocytosis (Hsieh et al., 2009). It would be interesting, in future studies, 
to determine whether TREM2 is involved in CBD-enhancement of microglial 
phagocytosis. 
It was stated earlier that NO generation was measured as an index of 
microglial activation, and it might appear to be a contradiction that CBD 
reduced NO formation but enhanced a clear functional end-point in 
phagocytosis. However, as stated in Chapters 2 and 3 it is probable that 
the overproduction of NO from microglial cells in areas of the brain 
(mimicked in vitro by LPS exposure) may reduce microglial phagocytosis in 
these regions resulting in the inability of microglia to clear debris and this 
could contribute to the neurodegenerative effects observed in chronic 
QHXURLQIODPPDWRU\ GLVHDVHV VXFK DV $O]KHLPHU¶V GLVHDVH DQG LW PLJKW
therefore, be the case that CBD inhibition of excessive NO production, as 
with LPS, actually contributes towards an enhanced phagocytotic effect. 
It is important to consider, given the effects of CBD on microglial function, 
whether future developments should seek to enhance or inhibit such 
functions. Van Rossum and Hanisch (2004) suggest that modulation of 
excessive microglia activation should only be considered in three situations. 
First, it is only useful to inhibit microglial activation if the extracellular 
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signal that is activating the microglia has been eliminated from the CNS. 
Thus, therapies must be directly related to the channels and receptors that 
are involved in the disease, such as cannabinoid receptors in 
neurodegenerative disease. Second, the deactivation of microglia by 
cannabinoids needs to decrease all the products and signals of activation. 
The fine balance between various cytokines and chemokines highlights this 
situation because diminishing one harmful cytokine can increase the 
detrimental regulatory effects of other cytokines. Finally, the mechanisms 
of microglia activation in response to pathogenic stimuli can only be 
manipulated if they do not affect homeostatic functions of microglia. 
Inhibiting all microglial function in the brain during a disease would surely 
exacerbate other pathological processes. For example, decreasing the 
clearance of amyloid beta plaques during the initial phase of Alzheimer 
disease has been shown to have negative effects on disease morbidity 
(Martín-Moreno et al., 2011). Therefore, the resolution of whether 
microglia is harmful or beneficial is contained in a better understanding of 
the intracellular interactions between microglia and disease components. 
Removing microglia cells from the CNS in healthy states would also 
necessarily have negative effects because of their beneficial role in synaptic 
control (Graeber et al., 1993) The consequences of attempting to amplify 
microglial phagocytosis are unknown, given that, to date, no selective 
pharmacological enhancers of phagocytosis are available; CBD, or at least 
a more potent analogue, could provide the opportunity to test such a 
situation. 
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4.1 Future directions and Points to Consider 
In this PhD project a number of important observations have been made. 
It was found that CBD can affect microglial cell function in the absence of 
cannabinoid receptors. The absence of CB1/2 receptors in our BV-2 cells 
allowed this unequivocal conclusion, but the effects of CBD in the presence 
of all of the naturally expressed microglial receptors (as in situ) should be 
tested. This is only truly possible by means of in vivo experimentation with 
CBD in animal models of neuroinflammatory conditions with measurement 
of microglial numbers and activity (using markers such as DAP12).  
The protective effects of CBD against peroxide-mediated microglial cell 
death are intriguing and merit further mechanistic investigation by 
measuring the levels of gluathione and reduced glutathione. 
TRPV2 was identified as a probable mediator of CBD-enhanced 
phagocytosis but the lack of appropriate pharmacological tools to 
investigate this further is a barrier. In vitro investigations using genetic 
knock-down of TRPV2 with siRNAs would be informative. 
TRPV1 was also identified as a potential mediator of the effects of CBD and 
functional experiments using selective agonists such as capsaicin and 
antagonists such as AMG 9810 and capsazepine would be instructive. 
Investigation of the effects of CBD on the microglial expression of other 
members of the TRP channel family, particularly TRPV4 (given its proposed 
sensory role, activation by endocannabioids, etc (Nilius et al., 2007) would 
be interesting. 
In relation to the methods employed, ingestion of latex beads is a widely 
employed protocol for measuring phagocytosis, but additionally employing 
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more physiologically appropriate paradigms, such as ingestion of apoptotic 
neurones (Takahashi et al., 2005) for testing CBD effects would be 
interesting. 
4.2 Conclusions 
In summary, it is worth considering that modulation of microglial functions 
with cannabinoids might be a possible therapeutic approach for 
neuroinflammatory conditions such as AD. Indeed it is accepted that 
regulation of CNS inflammation is essential to prevent irreversible cellular 
damage that can occur in neurodegenerative diseases such as multiple 
sclerosis (Baker et al., 2007). 
The results in this thesis are compatible with the proposal that CBD 
enhances the function of microglial cells, as demonstrated by increased 
motility and phagocytosis, albeit in the face of reduced NO production. The 
putative receptor(s) and signalling mechanisms mediating the effects of 
CBD are still uncertain although there is a clear role for TRPV2.  
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